
<html lang="en"     class="pb-page"  data-request-id="ef2ed3e9-2cd8-418b-9e66-3e9c0d8a492c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b00976;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-19"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="A Novel Parkinson’s Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway" /></meta><meta name="dc.Creator" content="Ya-Dan  Wang" /></meta><meta name="dc.Creator" content="Xiu-Qi  Bao" /></meta><meta name="dc.Creator" content="Song  Xu" /></meta><meta name="dc.Creator" content="Wen-Wen  Yu" /></meta><meta name="dc.Creator" content="Sheng-Nan  Cao" /></meta><meta name="dc.Creator" content="Jin-Ping  Hu" /></meta><meta name="dc.Creator" content="Yan  Li" /></meta><meta name="dc.Creator" content="Xiao-Liang  Wang" /></meta><meta name="dc.Creator" content="Dan  Zhang" /></meta><meta name="dc.Creator" content="Shi-Shan  Yu" /></meta><meta name="dc.Description" content="Numerous drug treatments are available for Parkinson’s disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt..." /></meta><meta name="Description" content="Numerous drug treatments are available for Parkinson’s disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 27, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00976" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00976" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00976" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00976" /></link>
        
    
    

<title>A Novel Parkinson’s Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00976" /></meta><meta property="og:title" content="A Novel Parkinson’s Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0016.jpeg" /></meta><meta property="og:description" content="Numerous drug treatments are available for Parkinson’s disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood–brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) &gt;5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00976"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00976">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-31/acsodf.2021.6.issue-31/20210810/acsodf.2021.6.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-31/ancham.2021.93.issue-31/20210810/ancham.2021.93.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-31/bichaw.2021.60.issue-31/20210810/bichaw.2021.60.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-15/cmatex.2021.33.issue-15/20210810/cmatex.2021.33.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-8/estlcu.2021.8.issue-8/20210810/estlcu.2021.8.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-8/jceda8.2021.98.issue-8/20210810/jceda8.2021.98.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-8/jctcce.2021.17.issue-8/20210810/jctcce.2021.17.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-31/langd5.2021.37.issue-31/20210810/langd5.2021.37.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-15/mamobx.2021.54.issue-15/20210810/mamobx.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00976&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00976&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00976&amp;href=/doi/10.1021/acs.jmedchem.6b00976" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 9062-9079</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00981" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00995" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Novel Parkinson’s Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Dan++Wang">Ya-Dan Wang</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiu-Qi++Bao">Xiu-Qi Bao</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Song++Xu">Song Xu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Wen++Yu">Wen-Wen Yu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheng-Nan++Cao">Sheng-Nan Cao</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jin-Ping++Hu">Jin-Ping Hu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Li">Yan Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-Liang++Wang">Xiao-Liang Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Zhang">Dan Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shi-Shan++Yu">Shi-Shan Yu</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div><div class="corresp-info"><strong>*</strong>For S. Y.: phone, +86-10-63165326; fax, 86-10-63017757; E-mail, <a href="/cdn-cgi/l/email-protection#bfc6caccd7d6ccd7ded1ffd6d2d291dedc91dcd1"><span class="__cf_email__" data-cfemail="8df4f8fee5e4fee5ece3cde4e0e0a3eceea3eee3">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For D. Z.: phone, +86-10-63165203; fax, 86-10-63017757; E-mail, <a href="/cdn-cgi/l/email-protection#e581848b9f8d848b82a58c8888cb8486cb868b"><span class="__cf_email__" data-cfemail="bedadfd0c4d6dfd0d9fed7d3d390dfdd90ddd0">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00976&amp;href=/doi/10.1021%2Facs.jmedchem.6b00976" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 9062–9079</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 12, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 July 2016</li><li><span class="item_label"><b>Published</b> online</span>27 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00976" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00976</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9062%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYa-Dan%2BWang%252C%2BXiu-Qi%2BBao%252C%2BSong%2BXu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D19%26contentID%3Dacs.jmedchem.6b00976%26title%3DA%2BNovel%2BParkinson%25E2%2580%2599s%2BDisease%2BDrug%2BCandidate%2Bwith%2BPotent%2BAnti-neuroinflammatory%2BEffects%2Bthrough%2Bthe%2BSrc%2BSignaling%2BPathway%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9079%26publicationDate%3DOctober%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00976"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2460</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00976" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Novel Parkinson’s Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ya-Dan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xiu-Qi&quot;,&quot;last_name&quot;:&quot;Bao&quot;},{&quot;first_name&quot;:&quot;Song&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Wen-Wen&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Sheng-Nan&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Jin-Ping&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xiao-Liang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Shi-Shan&quot;,&quot;last_name&quot;:&quot;Yu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;9062-9079&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00976&quot;},&quot;abstract&quot;:&quot;Numerous drug treatments are available for Parkinson’s disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood–brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) &gt;5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00976&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00976" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00976&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00976" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00976&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00976" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00976&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00976&amp;href=/doi/10.1021/acs.jmedchem.6b00976" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00976" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00976" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00976%26sid%3Dliteratum%253Aachs%26pmid%3D27617803%26genre%3Darticle%26aulast%3DWang%26date%3D2016%26atitle%3DA%2BNovel%2BParkinson%25E2%2580%2599s%2BDisease%2BDrug%2BCandidate%2Bwith%2BPotent%2BAnti-neuroinflammatory%2BEffects%2Bthrough%2Bthe%2BSrc%2BSignaling%2BPathway%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D19%26spage%3D9062%26epage%3D9079%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a>,</li><li><a href="/action/doSearch?ConceptID=290729" title="Nervous system diseases">Nervous system diseases</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/jmcmar.2016.59.issue-19/20161013/jmcmar.2016.59.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Numerous drug treatments are available for Parkinson’s disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound <b>21</b>), that exhibited potent in vitro anti-neuroinflammatory effects, good blood–brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD<sub>50</sub>) >5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55736" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55736" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is an age-related, progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, which decreases the interstitial dopamine level and leads to bradykinesia, rigidity, and tremor.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Therefore, current treatment focuses on dopamine replacement, the inhibition of dopamine degradation using catechol-<i>O</i>-methyl-transferase (COMT) or monoamine oxidase type B (MAO-B) inhibitors, dopamine reuptake, and direct dopamine receptor agonists.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2-5)</a> The available PD medications offer valuable symptomatic relief, but they are often associated with significant and intolerable side effects. Furthermore, importantly, these drugs cannot slow PD progression. Therefore, the development of broader and more fundamental therapeutic approaches to PD is critical.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The “neuroprotective therapy” concept has emerged as a potential treatment for PD and may effectively slow down or stop the disease progression.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a></div><div class="NLM_p">Neuroinflammation, which is well recognized as a key pathophysiological event contributing to progressive nigral dopaminergic neuron loss in PD,<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> may be another target for neuroprotective therapy. Microglia and astrocytes are major mediators of neuroinflammation in PD. Several reports have demonstrated the activation of microglial and astroglial cells near damaged or dying dopaminergic neurons in the substantia nigra.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> Positron emission tomography (PET) imaging of PD patients shows increased microglial activation, and elevated levels of proinflammatory mediators are evident in the substantia nigra during post-mortem examinations.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Epidemiological studies have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) confer a decreased risk of PD.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Therefore, preventative and curative treatments for PD have focused on discovering active substances that attenuate excessive glial activation and protect dopaminergic neurons. Several agents that target inflammatory pathways are currently under investigation.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">In this article, we describe the discovery and optimization of a novel anti-PD series of phloroglucinol compounds with significant potential anti-neuroinflammatory effects and, more importantly, the drugability investigation that enabled the selection of a preclinical drug candidate with potent in vitro and in vivo anti-neuroinflammatory activities, desirable pharmacokinetic properties, and extremely low toxicity. Its underlying mechanisms were also investigated, and the results support investigating this novel agent as a potential PD therapy further.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Discovery of the Hit Compound</h3><div class="NLM_p">3-Methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one (<b>1</b>), a known phloroglucinol derivative, was previously isolated by our research group from <i>Lysidice rhodostegia</i> roots (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). It was identified as the initial hit compound by screening for biological activities, which revealed a moderate inhibitory effect on nitric oxide (NO) production in lipopolysaccharide (LPS)-induced BV2 cells, with a half-maximal inhibitory concentration (IC<sub>50</sub>) of 50.6 μM. Moreover, this compound showed certain “lead-like” properties, including low molecular weight and a combination of polar and nonpolar moieties. Furthermore, it provided multiple diversification points for robust optimization.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0001.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the hit compound.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit-to-Lead Medicinal Chemistry Optimization</h3><div class="NLM_p">With careful analysis, it was supposed that the three phenolic hydroxyl group contained in the hit compound might bring some negative effects as follows: (1) the polar of the molecule is strong, which may affect the absorption, (2) glucuronidation of multihydroxyl groups may shorten the acting time of the compound within the body, (3) the stability of the compound is poor because the phenolic hydroxyl group is sensitive to chemical environment. Besides, the hit compound was not potent enough and its activity should be improved markedly. Therefore, structural modifications were performed to increase the anti-neuroinflammatory activities of the hit compound as well as improve its physicochemical properties. According to the basic principles of medicinal chemistry, the following strategies were used to achieve these purposes: (1) The structural skeleton of the hit compound was retained, and minimal modifications were made to adjust the lipid–water partition coefficients and/or improve its stability, such as changing the number of hydroxyl groups, methylating the hydroxyl groups at different positions, and altering the length of the side chain. (2) Substantial changes were made by introducing various common nitrogen-containing activity-modifying pharmacophores into the molecule, such as amide, aminoketone, amino, propanolamine, and furoxan units, to enhance the pharmacological effects. In the latter case, the number and methylation of hydroxyl groups, as well as the length of the side chain can be modified simultaneously. As the hit compound was simple, slight change might lead to wide variation in the structure. Consequently, 43 phloroglucinol derivatives belonging to six series (<b>2</b>–<b>8</b>, <b>9</b>–<b>10</b>, <b>11</b>–<b>17</b>, <b>18</b>–<b>25</b>, <b>26</b>–<b>43</b>, and <b>44</b>) were synthesized, 30 of which were new (indicated by *).</div><div class="NLM_p">Compound <b>2</b> was synthesized from <b>1</b> by methylating the hydroxyl group at the ortho position of the carbonyl with Me<sub>2</sub>SO<sub>4</sub> after protecting the other two with methoxymethyl (MOM) groups (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), and <b>3</b>–<b>8</b> were prepared via Friedel–Crafts reactions, with BF<sub>3</sub>-Et<sub>2</sub>O as a catalyst (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>3</sub>OCH<sub>2</sub>Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (b) Me<sub>2</sub>SO<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 5 h; (c) 2 N HCl, reflux, 1 h.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>3</b>–<b>8</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isovaleryl chloride, BF<sub>3</sub>-Et<sub>2</sub>O, 80 °C, 2 h; (b) valeryl chloride, BF<sub>3</sub>-Et<sub>2</sub>O, 80 °C, 2 h; (c) acetyl chloride, BF<sub>3</sub>-Et<sub>2</sub>O, 80 °C, 2 h.</p></p></figure><div class="NLM_p">Amides <b>9</b> and <b>10</b> were synthesized as follows: 2,4,6-trihydroxybenzoic acid was reacted with oxalyl chloride to give acyl chloride, which reacted with amines to yield the corresponding amides (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>9</b> and <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) oxalyl chloride, DMSO, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h; (b) isopropylamine, THF, rt, 1 h; (c) butylamine, THF, rt, 1 h.</p></p></figure><div class="NLM_p">The aminoketone analogues <b>11</b>–<b>17</b> were prepared in two steps: acylation of 1,3,5-trimethoxybenzene or phloroglucinol with an ω-chloro alkyl nitril through Houben–Hoesch reactions catalyzed by HCl gas and introduction of amino groups by replacing the chloro group with various amines in the presence of K<sub>2</sub>CO<sub>3</sub> (<a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The order of the two steps could be reversed for the synthesis of <b>11</b>–<b>14</b>; however, the amines must first react with 4-chlorobutanenitrile for the synthesis of <b>15</b>–<b>17</b> because the hydroxyl groups of phloroglucinol were unstable in the alkaline environment created by K<sub>2</sub>CO<sub>3</sub>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>11</b>–<b>14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) chloroacetonitrile, HCl gas, PhCl, rt, 6 h; (b) H<sub>2</sub>O, reflux, 1 h; (c) piperidine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h; (d) morpholine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h; (e) 1-methylpiperazine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h; (f) 1-ethylpiperazine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h.</p></p></figure><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>15</b>–<b>17</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) piperidine, K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, rt, 20 h; (b) <i>N</i>-methylcyclohexanamine, K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, rt, 20 h; (c) 1-(3-chlorophenyl)piperazine, K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, rt, 20 h; (d) (i) phloroglucinol, HCl gas, PhNO<sub>2</sub>, rt, 12 h, (ii) H<sub>2</sub>O, reflux, 1 h.</p></p></figure><div class="NLM_p">Compounds <b>18</b>–<b>25</b> were obtained from 2,4,6-trimethoxybenzaldehyde by adding amines or alkyl (methyl or ethyl) ester of the amino acid hydrochloride salts, followed by treatment with NaBH<sub>3</sub>CN in anhydrous MeOH (pH ∼ 6, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>), and then hydrolysis of the ester, if necessary.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>18</b>–<b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isopropylamine, NaBH<sub>3</sub>CN, MeOH, HOAc, argon, rt, 3 h; (b) <span class="smallcaps smallerCapital">l</span>-GlyOEt-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (c) <span class="smallcaps smallerCapital">l</span>-AlaOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (d) <span class="smallcaps smallerCapital">l</span>-SerOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (e) <span class="smallcaps smallerCapital">l</span>-Asp(OMe)<sub>2</sub>-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (f) <span class="smallcaps smallerCapital">l</span>-Glu(OMe)<sub>2</sub>-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (g) <span class="smallcaps smallerCapital">l</span>-PheOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (h) <span class="smallcaps smallerCapital">l</span>-HisOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (i) KOH, EtOH-H<sub>2</sub>O (1:1), rt, 2 h, Amberlite 120 H<sup>+</sup> resin.</p></p></figure><div class="NLM_p">The synthesis of racemic aryloxypropanolamine hydrochloride salts <b>26</b>–<b>31</b> is outlined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Condensations of 2-(chloromethyl)oxirane with <b>3</b>, <b>5</b>, and <b>1a</b>, the <i>O</i>-benzyl-protected product of <b>1</b>,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> which was achieved through treatment with NaH in anhydrous DMF, provided the epoxides <b>3b</b>, <b>5b</b>, and <b>1b</b>, respectively. These subsequently reacted with various amines, resulting in the corresponding aryloxypropanolamines. The hydrochloride salts were obtained through treatment with ethereal HCl, followed by a deprotection step, if necessary.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0013.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>26</b>–<b>31</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) benzyl <i>p</i>-toluenesulfonate, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 3 h; (b) 2-(chloromethyl)oxirane, NaH, DMF, N<sub>2</sub>, 90 °C, 2 h; (c) (i) isopropylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (d) (i) <i>tert</i>-butylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (e) H<sub>2</sub>, 3 atm, Pd-C, MeOH, HCl, rt, 12 h.</p></p></figure><div class="NLM_p">The synthesis of chiral aryloxypropanolamine hydrochloride salts <b>32</b>–<b>43</b> is shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Condensation of (<i>R</i>)-or (<i>S</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane with <b>3</b>, <b>5</b>, and <b>1a</b>, followed by hydrolysis of 1,3-dioxolane to diols, <i>p</i>-toluenesulfonylation of the primary alcohol-OH, and amination with various amines, resulted in the corresponding chiral aryloxypropanolamine, which had the indicated configuration.</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0014.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>32</b>–<b>43</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, NaH, DMF, N<sub>2</sub>, 90 °C, 24 h; (b) (<i>R</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, NaH, DMF, N<sub>2</sub>, 90 °C, 24 h; (c) 4% H<sub>2</sub>SO<sub>4</sub>, THF, rt, 8 h; (d) TsCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 48 h; (e) (i) isopropylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (f) (i) <i>tert</i>-butylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (g) H<sub>2</sub>, 3 atm, Pd-C, MeOH, HCl, rt, 12 h.</p></p></figure><div class="NLM_p">Compound <b>44</b> was synthesized according to the sequence shown in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. The reaction of cinnamyl alcohol and NaNO<sub>2</sub> in HOAc resulted in 4-hydroxymethyl-3-phenyl furoxan (<b>44a</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> which was converted into 4-chloromethyl-3-phenyl furoxan (<b>44b</b>) through treatment with SOCl<sub>2</sub>. Condensation of the resulting chloride with <b>2a</b> in the presence of K<sub>2</sub>CO<sub>3</sub>, followed by deprotection using 2 N HCl, provided the desired product <b>44</b>.</div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compound <b>44</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaNO<sub>2</sub>, HOAc, H<sub>2</sub>O, rt, 24 h; (b) SOCl<sub>2</sub>, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h; (c) K<sub>2</sub>CO<sub>3</sub>, KI, acetone, reflux, 5 h; (d) 2 N HCl, reflux, 1 h.</p></p></figure><div class="NLM_p">All synthesized phloroglucinol derivatives were tested for anti-inflammatory activity using the same method as for the hit compound screen (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The activity profile exhibited varied results for each analogue, and their structure–activity relationships (SARs) were discussed by structural series. Series 1: Compared with the hit compound <b>1</b>, the results of <b>2</b>–<b>6</b> showed that the numbers and positions of the phenolic hydroxyl groups and their methyl ethers greatly influenced the inhibitory activity against NO production in the LPS-induced BV2 cells. It seemed that reducing the number of hydroxyl groups to two (<b>5</b>) or one (<b>6</b>) might cause a negative impact on the anti-inflammatory activity. While methylation of one (<b>2</b>) or all the three (<b>4</b>) rather than two (<b>3</b>) hydroxyl groups markedly increase the activity. Moreover, the results of <b>7</b> and <b>8</b> suggested that the length of the side chain were also important for the activity, and valeryl would be more appropriate than isovaleryl and isobutyryl groups. Series 2 and 3: Introducing an amide (<b>9</b> and <b>10</b>) or an aminoketone (<b>11</b>–<b>17</b>) group seemed to make little sense to improve the activity. However, among the aminoketone analogues, <b>11</b>–<b>14</b> with substitution of methoxyl in place of hydroxyl groups and shorter length of the side chain were slightly more effective. Series 4: Compounds <b>19</b>–<b>25</b>, which incorporated amino acid substituents, exhibited significantly different activities. Weak inhibition of NO release was observed for compound <b>19</b>, which had a Gly substituent, whereas <b>21</b>–<b>23</b>, contained Ser, Asp, and Glu substituents, respectively, showed high inhibition levels, suggesting that side chain substituents with a certain polarity and electrical properties might be necessary for activity. Furthermore, <b>24</b> and <b>25</b>, with Phe and His substituents, respectively, are mostly inactive, indicating that aromatic functional groups in the side chain are not desirable. Series 5: Compounds <b>26</b>–<b>43</b> differed from the hit compound by an additional propanolamine unit at 2′-hydroxyl position, most of which showed moderate or marginal anti-neuroinflammatory activity except for compound <b>34</b> (IC<sub>50</sub> 11.2 μM). The absolute configuration of the chiral carbon in propanolamine unit had certain influence on the activity, but no clear regularity could be concluded. Series 6: Introduction a furoxan substituent by formation of ether resulted in significant improvement in the activity, which may provide an effective way to get more potent anti-neuroinflammatory product. But unfortunately, only one compound was synthesized for a variety of reasons.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Activities of Compounds <b>1</b>–<b>44</b> against LPS-Induced NO Release in BV2 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">50.7</td><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="center">5.8</td><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">51.5</td><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char=".">84.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center">11.1</td><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">75.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="center">113.4</td><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="center">90.7</td><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">137.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center">11.2</td><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char=".">74.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="center">194.7</td><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">21.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="center">92.6</td><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char=".">138.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="center">37.1</td><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">41.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="center">24.9</td><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">11.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="center">32.4</td><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">95.3</td><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">25.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">22.7</td><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">40.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">182.2</td><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">53.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">54.8</td><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char=".">28.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char=".">24.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center">39.1</td><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">37.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center">6.6</td><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="center">14.4</td><td class="colsep0 rowsep0" align="left">curcumin<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center">8.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Half-maximal inhibitory concentration.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Inhibition rate was less than 50% at the maximal concentration of 0.01 M.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Positive control.</p></div></div></div><div class="NLM_p last">In a word, the SARs of the phloroglucinol derivatives are very complicated. Both minimal and substantial modification may influence the anti-neuroinflammatory effect. Finally, compounds <b>2</b>, <b>21</b>, <b>23</b>, and <b>44</b>, which had IC<sub>50</sub> values of 5.8, 6.6, 8.4, and 8.5 μM, respectively, were selected as target compounds for further investigations. It is noteworthy that, except for <b>2</b>, the other three proposed compounds are remarkably different from the hit compound in their structures, which may lead to a different mode of action.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vitro Efficacy of Lead Compounds in Primary Cultures</h3><div class="NLM_p">The four promising compounds were further examined for anti-neuroinflammatory effects in primary mixed mesencephalic neuronal/glial cultures. The microglia were activated by LPS stimulation, as indicated by the overexpression of membrane Iba-1, a marker of microglia activation, and they showed increased production of IL-1β and TNF-α. The neuroinflammatory response was greatly inhibited by compounds <b>2</b>, <b>21</b>, <b>23</b>, and <b>44</b> at 10 μM (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A–C). The LPS-induced neuroinflammation also induced dopaminergic neurotoxicity, as reflected by the reduced expression of tyrosine hydroxylase (TH), which was rescued by these compounds (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>D). These data suggested that the four compounds potentially suppressed neuroinflammation and protected dopaminergic neurons.</div><figure id="fig2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0002.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of compounds <b>2</b>, <b>21</b>, <b>23</b>, and <b>44</b> on neuroinflammation and TH expression in primary mixed midbrain neuronal/glial cultures stimulated with LPS. Control group: primary mixed mesencephalic neuronal/glial cultures with no treatment. LPS group: primary mixed neuronal/glial cultures stimulated with LPS (100 ng/mL). Other groups: 10 μM of <b>2</b>, <b>21</b>, <b>23</b>, and <b>44</b> incubated with cells for 1 h before LPS challenge and then incubated for 5 h to detect cytokines, 24 h to measure Iba-1 expression, and 7 days to measure TH expression. (A) Effects of the indicated compounds on Iba-1 expression in microglia (<i>n</i> = 4). A representative image is shown. Inhibitory effects of the indicated compounds on (B) IL-1β and (C) TNF-α production in medium measured by ELISA assay (<i>n</i> = 6). (D) Effects of the indicated compounds on TH expression measured by Western blot (<i>n</i> = 4). A representative immunoblot image is shown. Data are the mean ± standard deviation (SD), *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control cells; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus LPS-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacokinetic Properties and Safety Profiles</h3><div class="NLM_p">The in vivo preliminary pharmacokinetic properties of these four lead compounds were investigated in mice following the intragastric administration of each compound at a dose of 50 mg/kg (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). All compounds were detectable in the plasma 5 min after administration. However, only <b>2</b> and <b>21</b> efficiently passed through the blood–brain barrier, whereas the concentrations of <b>23</b> and <b>44</b> in the brain were low (just above the limit of detection) and undetected, respectively. Therefore, compounds <b>2</b> and <b>21</b> were selected for further safety studies.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pharmacokinetic Properties of the Lead Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">blood</th><th class="rowsep1 colsep0" colspan="3" align="center">brain</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–∞</sub> (μg·[L·h])<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μg/L)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">AUC<sub>0–∞</sub> (μg·[L·h])</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (μg/L)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">610.8 ± 42.2<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1361.6 ± 561.1</td><td class="colsep0 rowsep0" align="center">1981.2 ± 346.7</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.6</td><td class="colsep0 rowsep0" align="center">4668.0 ± 1624.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char="±">5733.0 ± 635.7</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">2590.0 ± 420.2</td><td class="colsep0 rowsep0" align="center">497.1 ± 72.2</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.4</td><td class="colsep0 rowsep0" align="center">192.0 ± 27.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char="±">3195.1 ± 891.1</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1645.0 ± 233.4</td><td class="colsep0 rowsep0" align="center">≈LOD<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center">≈LOD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char="±">37.6 ± 18.0</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">26.5 ± 8.4</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Area under the curve from 0 h to infinity.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Half-life.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Maximum concentration.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">The values are the mean ± SD (<i>n</i> = 6).</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Limit of detection.</p></div></div></div><div class="NLM_p last">The results of in vitro toxicity study indicated that neither of the two compounds had selectivity for hERG. In the in vivo toxicity study, both showed satisfactory maximum tolerated doses after being orally administered to mice, with median lethal dose (LD<sub>50</sub>) values of 2000 and >5000 mg/kg for compounds <b>2</b> and <b>21</b>, respectively. Nevertheless, the 14-day toxicity study showed that compound <b>2</b> exhibited hepatotoxicity and nephrotoxicity at a higher dose (1000 mg/kg), whereas compound <b>21</b> had no detectable adverse effects. Considering the long-term administration requirements for PD medications, compound <b>21</b> was chosen instead of compound <b>2</b> for further in vivo efficacy studies.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Efficacy of Compound <b>21</b> in PD Mouse Models</h3><div class="NLM_p">Compound <b>21</b> was successively evaluated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD mouse models, respectively, and in α-synuclein (syn) transgenic mice. Obvious dopaminergic neuron dysfunction and neuroinflammatory responses were observed in the three different PD models. Compound <b>21</b> greatly improved the motor behavior dysfunction of the mice by increasing their staying time on the rod in the rotarod tests and their performance scores in the pole tests. Furthermore, it increased the dopamine levels in the striatum, reversed the decline of TH-positive neurons in the substantia nigra, and decreased the productions of proinflammatory molecules, such as IL-1β and TNF-α, at doses of 10 and 20 mg/kg after short- (MPTP, 10-day) or long-term (MPTP/prob, 7-week and α-syn transgenic mice, 10-week) administration (<a class="ref internalNav" href="#fig3" aria-label="Figures 3">Figures 3</a>–<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The in vivo study demonstrated the potent neuroprotective effects of compound <b>21</b> on dopaminergic neurons, which were closely associated with its suppression of neuroinflammation in the brain.</div><figure id="fig3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0003.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of compound <b>21</b> on the MPTP-induced subacute PD mouse model. Control group: mice were treated with 0.5% sodium carboxymethylcellulose (CMC-Na). MPTP group: mice were injected with MPTP hydrochloride (30 mg/kg, ip) for 5 consecutive days. Other groups: mice were administered different doses of compound <b>21</b> (5, 10, 15 mg/kg) and L-DOPA (20 mg/kg) 30 min before each MPTP injection and continued administering for the next 7 days. Compound <b>21</b> improved motor behavior of mice, as measured by (A) rotarod test and (B) pole test (<i>n</i> = 15). (C) Effect of compound <b>21</b> on dopamine level (<i>n</i> = 8). (D) Effect of compound <b>21</b> on the TH-positive staining neurons. Representative sections of substantia nigra from five mice are shown. Inhibitory effect of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in the mouse midbrain measured by ELISA assay on the 12th day after the administration of compound <b>21</b> (<i>n</i> = 6). Data are the mean ± SD; *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control mice; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus MPTP injected mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0004.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compound <b>21</b> on the MPTP/prob-induced chronic PD mouse model. Control group: mice were treated with 0.5% CMC-Na. MPTP/prob group: mice were administered 10 doses of MPTP hydrochloride (25 mg/kg, subcutaneously, sc) in combination with probenecid (250 mg/kg, ip) on a 5-week schedule. Other groups: mice showing behavioral dysfunction after the last MPTP/prob injection were administered different doses of compound <b>21</b> (5, 10, 15 mg/kg) and L-DOPA (20 mg/kg) once a day for 7 weeks. Compound <b>21</b> improved motor behavior of mice, as measured by (A) rotarod test and (B) pole test (<i>n</i> = 15). (C) Effect of compound <b>21</b> on dopamine level (<i>n</i> = 8). (D) Effect of compound <b>21</b> on the TH-positive staining neurons. Representative sections of substantia nigra from five mice are shown. Inhibitory effect of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in the mouse midbrain measured by ELISA assay (<i>n</i> = 6). Data are the mean ± SD; *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control mice; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus MPTP/prob-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0005.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>21</b> on α-syn transgenic mice. WT group: mice were treated with 0.5% CMC-Na. α-Syn group: α-Syn (A53T) transgenic mice. Other groups: mice were administered different doses of compound <b>21</b> (5, 10, 15 mg/kg) and L-DOPA (20 mg/kg) once a day for 12 weeks. Compound <b>21</b> improved motor behavior of mice, as measured by (A) rotarod test and (B) pole test (<i>n</i> = 15). (C) Effect of compound <b>21</b> on dopamine level (<i>n</i> = 8). (D) Effect of compound <b>21</b> on the TH-positive staining neurons. Representative sections of substantia nigra from five mice are shown. Inhibitory effect of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in the mouse midbrain measured by ELISA assay (<i>n</i> = 6). Data are the mean ± SD; *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control mice; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus α-syn transgenic mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Mechanistic Studies of Neuroprotective Effects</h3><div class="NLM_p">To elucidate the molecular target of compound <b>21</b> in neuroinflammation, we performed isobaric tags for relative and absolute quantification (iTRAQ)-labeling proteomic studies in a MPTP/prob-induced chronic PD mouse model. We quantified 3508 proteins and applied a threshold of >1.5-fold to identify proteins that were differentially expressed, and 132 met the criteria (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_002.xlsx" class="ext-link">Proteomics Data</a>). Among these proteins, we selected those that were reportedly associated with neuroinflammation to validate the proteomic quantization. Finally, 20 proteins were analyzed, and eight were consistent with the proteomic analysis, as described in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. The Western blot analysis confirmed phosphatase and tensin homologue deleted on chromosome 10 (PTEN); Akt and NO synthase (NOS) were the most affected by compound <b>21</b>. Akt is reportedly the downstream effector of PTEN, and its phosphorylation may induce NOS activation.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> PTEN counteracts the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway and controls inflammatory responses.<a onclick="showRef(event, 'ref23 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref25">(23, 25)</a> The present results indicated that the PTEN/Akt pathway and downstream NOS might be involved in the anti-inflammatory activity of compound <b>21</b>.</div><figure id="fig6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0006.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>21</b> suppressed neuroinflammation by inhibiting Src signaling. Control group: primary microglia with no treatment. LPS group: primary microglia stimulated with LPS (100 ng/mL). LPS <i>+</i><b>21</b> group: the microglia was incubated with compound <b>21</b> (10 μM) for 1 h followed by LPS challenge. Negative control group: primary microglia or mixed mesencephalic neuronal/glial cultures were tranfected with empty vector. Negative control + LPS group: primary microglia or mixed mesencephalic neuronal/glial cultures were tranfected with empty vector followed by LPS challenge. Src siRNA group: microglia or mixed mesencephalic neuronal/glial cultures were tranfected with Src siRNA. Src siRNA <i>+</i> LPS/MPP<sup>+</sup>/α-Syn group: primary microglia or mixed mesencephalic neuronal/glial cultures were tranfected with Src siRNA, LPS (100 ng/mL), MPP<sup>+</sup> (30 μM), or α-syn (250 nM) was added 4 h later. Src siRNA + LPS/MPP<sup>+</sup>/α-Syn + <b>21</b> group: primary microglia or mixed neuronal/glial cultures were tranfected with Src siRNA, compound <b>21</b> (10 μM) was added 1 h before LPS, MPP<sup>+</sup> or α-Syn challenge. Effects of compound <b>21</b> on (A) p-PTEN, (B) p-Akt, and (C) p-Src expression in primary microglia cultures. (D) Regulation of Src on PTEN and Akt in primary microglia cultures (<i>n</i> = 4). Effects of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in LPS-stimulated primary microglia cultures (<i>n</i> = 6). Effects of compound <b>21</b> on TH expression in (G) LPS-, (H) MPP<sup>+</sup>-, and (I) α-syn-stimulated primary mixed mesencephalic neuronal/glial cultures (<i>n</i> = 4). Representative immunoblot images are shown. The results are shown as the mean ± SD; **<i>P</i> < 0.01 versus control cells; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus LPS-, MPP<sup>+</sup>- or α-syn-treated cells; Δ<i>P</i> < 0.05 versus Src siRNA-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">PTEN function is primarily regulated by phosphorylation through specific kinases, such as Src-tyrosine kinase, glycogen synthase kinase-3 (GSK3)-β, casein kinase 2 (CK2), liver kinase B1 (LKB1), Rho guanosine triphosphatases (GTPases) activating protein 21 (ARHGAP21), and Rho-associated protein kinase 1 (ROCK1), which is frequently associated with functionally inactive PTEN.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> Among these kinases, the expression levels of GSK3β, ARHGAP21, ROCK1, and Src were affected by compound <b>21</b> in the proteomic quantization. The four proteins were then validated, and Src-tyrosine kinase was the most obviously altered by compound <b>21</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_001.pdf" class="ext-link">Figures S1 and S2</a>). Src-tyrosine kinase is a major modulator in the proximal intracellular signaling pathways in innate cells and activates monocytes and macrophages.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Inhibition of Src reportedly suppresses neuroinflammation and protects mice from ischemia-induced brain damage.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Our present results revealed that in addition to PTEN and Akt phosphorylation, Src activation was also inhibited by compound <b>21</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A–C). Src primarily phosphorylates PTEN at Tyr240, inactivating it and phosphorylating Akt.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We knocked down the Src gene in primary microglia and midbrain mixed neuronal/glial cultures and stimulated the cells with LPS, 1-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>), or α-synuclein. We found that the phosphorylation of PTEN and Akt decreased (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>D), the inflammatory response was reduced, and the injury of dopaminergic neurons was alleviated (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>E). Most importantly, we found that the suppression of neuroinflammation (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>E and F) and the neuroprotective activity of compound <b>21</b> were mostly abrogated when Src was silenced (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>G–I). The above data proved that Src tyrosine kinase was the main target of compound <b>21</b> in its neuroinflammation regulation and associated neuroprotection.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this paper, we reported the discovery and optimization of a novel class of anti-neuroinflammatory compounds: phloroglucinol derivatives. The SARs of this series were complex, and changes in either the phenolic hydroxyl groups or the side chain of the hit compound significantly influenced the activities. Note that the introduction of various nitrogen-containing pharmacophores into the hit compound enhanced the potency more efficiently than minor modifications, such as changing the number of hydroxyl groups, methylating the hydroxyl groups at different positions, and altering the length of the side chain. These results might provide a new strategy for the structural modification of other similar compounds.</div><div class="NLM_p last">Our study provided evidence supporting compound <b>21</b> as a potential candidate for PD treatment because of its potent in vitro and in vivo anti-neuroinflammatory activities, novel mechanism, impressive penetration of the blood–brain barrier, and low toxicity. Moreover, our results yielded further proof that neuroinflammation suppression might become an effective disease-modifying therapy that could delay or slow the progression of PD and thereby open up a new strategy for the future treatment of PD patients. We believe that further structural modification based on compound <b>21</b> and its exact mechanisms would enable the development of more potent agents used for PD, and these studies are currently underway in our laboratory.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p">Reagents and solvents were of commercial quality and used without further purification. <sup>1</sup>H and <sup>13</sup>C NMR spectra were acquired on an INOVA-500, Mercury-400 or Mercury-300 spectrometer. HRESIMS data were obtained on an Agilent 6520 Accurate-Mass-Q-TOF LC/MS spectrometer. ESIMS data were recorded on an Agilent 1100 series LC/MSD Trap/SL spectrometer. Optical rotations were measured on a JASCO P-2000 automatic polarimeter. TLC was conducted with glass precoated with silica gel GF254 (Qingdao Marine Chemical Inc., China) to monitor the progression of the reactions. Silica gel (200–300 mesh, Qingdao Marine Chemical Inc., China) were used for column chromatography (CC). The purity of the test compounds was determined by HPLC analysis using an Agilent 1100 series instrument equipped with a DAD detector and a YMC-Pack ODS column (100 mm × 4.6 mm, 5 μm) at 210 nm and was generally ≥95% if not denoted. Preparative HPLC was performed on a Shimadzu LC-6AD instrument with a SPD-20A detector using a YMC-Pack ODS-A column (250 mm × 50 mm, 5 μm).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 1-(2,4-Dihydroxy-6-methoxyphenyl)-3-methylbutan-1-one (<b>2</b>)</h4><div class="NLM_p">To a stirred suspension of <b>1</b> (2.10 g, 10.0 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added DIPEA (2.71 g, 21.0 mmol) and the reaction mixture was stirred for 15 min at 0 °C, and then CH<sub>3</sub>OCH<sub>2</sub>Cl (2.00 g, 25.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added dropwise. The mixture was stirred for 1 h at room temperature and subsequently poured into cold water (20 mL) and extracted with chloroform (3 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 15:1 as eluent) afforded <b>2a</b> as a colorless oil (1.40 g, 47%).</div><div class="NLM_p">To a solution of <b>2a</b> (0.30 g, 1.0 mmol) in anhydrous acetone (20 mL) was added anhydrous K<sub>2</sub>CO<sub>3</sub> (0.27 g, 2.0 mmol), and the reaction mixture was refluxed for 15 min, followed by addition of Me<sub>2</sub>SO<sub>4</sub> (100 μL, 2.0 mmol). After refluxing for an additional 5 h, the solvent was removed in vacuo. Water (20 mL) was then added to the residue, and the aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 30:1 as eluent) afforded <b>2b</b> (0.25 g, 60%) as a yellow oil.</div><div class="NLM_p last">To a solution of <b>2b</b> (0.25g, 0.8 mmol) in MeOH (10 mL) was added 2 N HCl (2 mL), and the reaction mixture was refluxed for 1 h. Then the solvent was removed in vacuo, and the resulting residue was dissolved in EtOAc (50 mL) and washed with water. The organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 5:1 as eluent) afforded <b>2</b> as a white solid (0.18 g, 83%, mp 122–123 °C). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.71 (br s, OH-2′), 10.59 (br s, OH-4′), 5.94 (1H, s, H-5′), 5.85 (1H, s, H-3′), 3.80 (3H, s, OCH<sub>3</sub>), 2.77 (2H, d, <i>J</i> = 6.5 Hz, H-2), 2.07 (1H, m, H-3), 0.89 (6H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.0, 165.7, 164.4, 162.4, 104.2, 95.3, 90.9, 55.3, 51.9, 24.5, 22.2 (2C). HRESIMS <i>m</i>/<i>z</i> = 225.1126 [M + H]<sup>+</sup> (calcd for C<sub>12</sub>H<sub>17</sub>O<sub>4</sub>, 225.1121).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure for Acylation by Friedel–Crafts Reaction for Compounds <b>3</b>–<b>8</b> (GP1)</h4><div class="NLM_p">The phenolic precursor (10.0 mmol) was dissolved in BF<sub>3</sub>-Et<sub>2</sub>O (20 mL) and an amount of 1 equiv of acyl chloride was added, and the reaction mixture was stirred at 80 °C for 2 h. After cooling, the reaction mixture was poured into ice-cooled 5% KOAc solution (50 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The resulting product was obtained by column chromatography.</div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-methylbutan-1-one (<b>3</b>)</h5><div class="NLM_p last">This compound was prepared from 3,5-dimethoxyphenol and isovaleryl chloride by means of GP1 as a white solid (1.70 g, 71%, mp 54–55 °C). Eluent for column chromatography: petroleum ether/EtOAc (30:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.59 (1H, s, OH-2′), 6.09 (1H, s, H-5′), 6.07 (1H, s, H-3′), 3.84 (3H, s, OCH<sub>3</sub>-4′), 3.79 (3H, s, OCH<sub>3</sub>-6′), 2.78 (2H, d, <i>J</i> = 6.5 Hz, H-2), 2.08 (1H, m, H-3), 0.91 (6H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). ESIMS <i>m</i>/<i>z</i> = 237 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 1-(2,4,6-Trimethoxyphenyl)-3-methylbutan-1-one (<b>4</b>)</h5><div class="NLM_p last">This compound was prepared from 1,3,5-trimethoxybenzene and isovaleryl chloride by means of GP1 as a colorless oil (1.23 g, 49%). Eluent for column chromatography: petroleum ether/EtOAc (30:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.24 (2H, s, H-3′, H-5′), 3.79 (3H, s, OCH<sub>3</sub>-4′), 3.72 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 2.48 (2H, d, <i>J</i> = 7.0 Hz, H-2), 2.03 (1H, m, H-3), 0.87 (6H, d, <i>J</i> = 7.0 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). ESIMS <i>m</i>/<i>z</i> = 275 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 1-(2-Hydroxy-4-methoxyphenyl)-3-methylbutan-1-one (<b>5</b>)</h5><div class="NLM_p last">This compound was prepared from 3-methoxyphenol and isovaleryl chloride by means of GP1 as a colorless oil (1.95 g, 94%). Eluent for column chromatography: petroleum ether/EtOAc (25:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.81 (br s, OH- 2′), 7.82 (1H, d, <i>J</i> = 8.5 Hz, H-6′), 6.47 (1H, dd, <i>J</i> = 8.5, 2.0 Hz, H-5′), 6.44 (1H, d, <i>J</i> = 2.0 Hz, H-3′), 3.79 (3H, s, OCH<sub>3</sub>), 2.79 (2H, d, <i>J</i> = 6.5 Hz, H-2), 2.12 (1H, m, H-3), 0.91 (6H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). ESIMS <i>m</i>/<i>z</i> = 209 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 1-(4-Hydroxyphenyl)-3-methylbutan-1-one (<b>6</b>)</h5><div class="NLM_p last">This compound was prepared from phenol and isovaleryl chloride by means of GP1 as a white solid (1.00 g, 56%, mp 90–92 °C). Eluent for column chromatography: petroleum ether/EtOAc (20:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.80 (2H, d, <i>J</i> = 8.0 Hz, H-2′, 6′), 6.81 (2H, d, <i>J</i> = 8.0 Hz, H-3′, 5′), 2.73 (2H, d, <i>J</i> = 6.5 Hz, H-2), 2.10 (1H, m, H-3), 0.90 (6H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). ESIMS <i>m</i>/<i>z</i> = 179 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 1-(2,4,6-Trihydroxyphenyl)pentan-1-one (<b>7</b>)</h5><div class="NLM_p last">This compound was prepared from phloroglucinol and valeryl chloride by means of GP1 as a white solid (1.19 g, 57%, mp 130–131 °C). Eluent for column chromatography: CH<sub>2</sub>Cl<sub>2</sub>/MeOH (30:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.21 (2H, s, OH-2′, OH-6′), 10.30 (1H, s, OH-4′), 5.78 (2H, s, H-3′, H-5′), 2.96 (2H, t, <i>J</i> = 7.5 Hz, H-2), 1.55 (2H, m, H-3), 1.31 (2H, m, H-4), 0.87 (3H, t, <i>J</i> = 7.5 Hz, CH<sub>3</sub>-5). ESIMS <i>m</i>/<i>z</i> = 211 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 1-(2,4,6-Trihydroxyphenyl)ethanone (<b>8</b>)</h5><div class="NLM_p last">This compound was prepared from phloroglucinol and acetyl chloride by means of GP1 as a white solid (0.70 g, 42%, mp 224 °C). Eluent for column chromatography: CH<sub>2</sub>Cl<sub>2</sub>/MeOH (30:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.21 (br s, OH-2′, OH-6′), 10.30 (br s, OH-4′), 5.78 (2H, s, H-3′, H-5′), 2.53 (3H, s, CH<sub>3</sub>-2). ESIMS <i>m</i>/<i>z</i> = 169 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure for Amidation for Compounds <b>9</b> and <b>10</b> (GP2)</h4><div class="NLM_p">To a stirred suspension of 2,4,6-trihydroxybenzoic acid (0.34 g, 2.0 mmol) and DMF (0.1 mL) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added dropwise oxalyl chloride (0.51 g, 4.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The reaction mixture was stirred at room temperature for 1 h and then evaporated in vacuo to give a clear oil. This crude oil was dissolved in anhydrous THF (5 mL), and amine (5.0 mmol) in THF (5 mL) was added dropwise in an ice-bath. After stirring at room temperature for 1 h, the mixture was filtered and the filtrate was concentrated in vacuo to dryness. The resulting product was obtained by column chromatography.</div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> <i>N</i>-Isopropyl-2,4,6-trihydroxybenzamide (<b>9</b>)</h5><div class="NLM_p last">This compound was prepared using isopropylamine by means of GP2 as a white solid (0.31 g, 80%, mp 100–102 °C). Eluent for column chromatography: CH<sub>2</sub>Cl<sub>2</sub>/MeOH (25:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (1H, d, <i>J</i> = 7.5 Hz, NH), 5.77 (2H, s, H-3′, H- 5′), 4.03 (1H, m, H-3), 1.15 (6H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). ESIMS <i>m</i>/<i>z</i> = 212 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> <i>N</i>-Butyl-2,4,6-trihydroxybenzamide (<b>10</b>)</h5><div class="NLM_p last">This compound was prepared using butylamine by means of GP2 as a white solid (0.32 g, 73%, mp 73–75 °C). Eluent for column chromatography: CH<sub>2</sub>Cl<sub>2</sub>/MeOH (25:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.62 (2H, s, OH-2′, OH-6′), 9.87 (1H, s, OH-4′), 8.60 (1H, t, <i>J</i> = 5.5 Hz, NH), 5.77 (2H, s, H-3′, H-5′), 3.26 (2H, dd, <i>J</i> = 13.0, 6.5 Hz, H-3), 1.47 (1H, m, H-4), 1.30 (1H, m, H-5), 0.89 (3H, t, <i>J</i> = 7.0 Hz, CH<sub>3</sub>-6). LC-ESI-MS (<i>m</i>/<i>z</i>): ESIMS <i>m</i>/<i>z</i> = 226 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure for Introduction of Aminoketone Unit for Compounds <b>11</b>–<b>14</b> (GP3)</h4><div class="NLM_p">To a stirred solution of 1,3,5-trimethoxybenzene (2.00 g, 12.0 mmol) in chlorobenzene (50 mL) was added chloroacetonitrile (0.90 g, 12.0 mmol), and the reaction mixture was stirred at room temperature with HCl gas bubbled in for 6 h, followed by filtration. A solution of the precipitate in water (20 mL) was refluxed for 1 h and then cooled to 0 °C. The key intermediate <b>11b</b> was obtained by filtration as a white solid (2.75g, 94%). To a suspension of <b>11b</b> (0.50 g, 2.0 mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub> (0.34 g, 4.0 mmol) in anhydrous acetone (20 mL) was added an amount of 1 equiv of amines (2.0 mmol), and the mixture was refluxed for 24 h and then filtered. The filtrate was concentrated in vacuo, and the residue was recrystallized in EtOH/H<sub>2</sub>O (4:1) to provide the resulting product.</div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 2-(Piperidin-1-yl)-1-(2,4,6-trimethoxyphenyl)ethanone (<b>11</b>)</h5><div class="NLM_p last">This compound was prepared from <b>11b</b> and piperidine by means of GP3 as a white solid (0.48 g, 84%, mp 66–67 °C). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.23 (2H, s, H-3′, H-5′), 3.78 (3H, s, OCH<sub>3</sub>-4′), 3.71 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.31 (2H, s, H-2), 2.37 (4H, t, <i>J</i> = 4.5 Hz, H-2″, H-6″), 1.43 (4H, m, H-3″, H-5″), 1.33 (2H, m, H-4″). ESIMS <i>m</i>/<i>z</i> = 294 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 2-Morpholino-1-(2,4,6-trimethoxyphenyl)ethanone (<b>12</b>)</h5><div class="NLM_p last">This compound was prepared from <b>11b</b> and morpholine by means of GP3 as a white solid (0.41 g, 69%, mp 94–96 °C). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.24 (2H, s, H-3′, H-5′), 3.79 (3H, s, OCH<sub>3</sub>-4′), 3.72 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.53 (4H, t, <i>J</i> = 4.5 Hz, H-3″, H-5″), 3.38 (2H, s, H-2), 2.43 (4H, br s, H-2″, H-6″). ESIMS <i>m</i>/<i>z</i> = 296 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 2-(4-Methylpiperazin-1-yl)-1-(2,4,6-trimethoxyphenyl)ethanone (<b>13</b>)</h5><div class="NLM_p last">This compound was prepared from <b>11b</b> and <i>N</i>-methylpiperazine by means of GP3 as a white solid (0.41 g, 57%, mp 130–131 °C). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.23 (2H, s, H-3′, H-5′), 3.79 (3H, s, OCH<sub>3</sub>-4′), 3.72 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.36 (2H, s, H-2), 2.43 (4H, br s, H-2″, H-6″), 2.27 (4H, br s, H-3″, H-5″), 2.13 (3H, s, CH<sub>3</sub>-1‴). ESIMS <i>m</i>/<i>z</i> = 309 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 2-(4-Ethylpiperazin-1-yl)-1-(2,4,6-trimethoxyphenyl)ethanone (<b>14</b>)</h5><div class="NLM_p last">This compound was prepared from <b>11b</b> and <i>N</i>-ethylpiperazine by means of GP3 as a white solid (0.47 g, 70%, mp 95–97 °C). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.23 (2H, s, H-3′, H-5′), 3.78 (3H, s, OCH<sub>3</sub>-4′), 3.71 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.35 (2H, s, H-2), 2.43 (4H, br s, H-2″, H-6″), 2.30 (4H, br s, H-3″, H-5″), 2.26 (2H, q, <i>J</i> = 7.0 Hz, H-1‴), 0.95 (3H, t, <i>J</i> = 7.0 Hz, H-2‴). ESIMS <i>m</i>/<i>z</i> = 323 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> General Procedure for Introduction of Aminoketone Unit for Compounds <b>15</b>–<b>17</b> (GP4)</h4><div class="NLM_p">To a suspension of 4-chlorobutanenitrile (1.03 g, 10.0 mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub> (1.40 g, 25.0 mmol) in anhydrous acetonitrile (20 mL) was added an amount of 1 equiv of amines (10.0 mmol), and the mixture was stirred at room temperature for 20 h and then concentrated in vacuo. To the residue was added water (25 mL) and extracted with EtOAc (3 × 15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to give a clear oil. To a solution of the crude oil in nitrobenzene (20 mL) was added phloroglucinol (1.26 g, 10.0 mmol), and the reaction mixture was stirred at room temperature with HCl gas bubbled in for 12 h. Then water (15 mL) was added to the mixture until the precipitate was dissolved. The organic layer was decanted and washed with water (20 mL), and the washing added to the aqueous layer, which was refluxed for 1 h subsequently. The mixture was cooled to 0 °C and a precipitate appeared. The precipitate was filtered off and recrystallized in EtOH/H<sub>2</sub>O to afford the resulting product.</div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 4-(Piperidin-1-yl)-1-(2,4,6-trihydroxyphenyl)butan-1-one Hydrochlorate (<b>15</b>)</h5><div class="NLM_p last">This compound was prepared from piperidine by means of GP4 as a white solid (0.67 g, 21%, mp 204–205 °C). Solvent for recrystallization: EtOH/H<sub>2</sub>O (5:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.23 (2H, s, OH-2′, OH-6′), 10.45 (1H, s, OH-4′), 5.81 (2H, s, H-3′, H-5′), 3.43 (2H, br d, <i>J</i> = 11.5 Hz, H-2″a, H-6″a), 3.08 (2H, t, <i>J</i> = 6.5 Hz, H-2), 3.05 (2H, overlap, H-4), 2.86 (2H, m, H-2″b, H-6″b), 1.94 (2H, m, H-3), 1.79 (2H, br d, <i>J</i> = 14.0 Hz, H-3″a, H-5″a), 1.65 (2H, overlap, H-3″b, H-5″b), 1.60 (1H, m, H-4″a,), 1.38 (1H, m, H-4″b). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.8, 164.5, 163.9, 163.9, 103.4, 94.3, 94.3, 55.2, 51.8, 51.8, 38.7, 22.3, 22.3, 21.0, 17.9. HRESIMS <i>m</i>/<i>z</i> = 280.1534 [M + H]<sup>+</sup> (calcd for C<sub>15</sub>H<sub>22</sub>NO<sub>4</sub>, 225.1543).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 4-(Cyclohexyl(methyl)amino)-1-(2,4,6-trihydroxyphenyl)butan-1-one Hydrochlorate (<b>16</b>)</h5><div class="NLM_p last">This compound was prepared from <i>N</i>-methylcyclohexanamine by means of GP4 as a white solid (0.38 g, 11%, mp 160–162 °C). Solvent for recrystallization: EtOH/H<sub>2</sub>O (10:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.73 (2H, s, H-3′, H-5′), 2.98 (2H, t, <i>J</i> = 7.0 Hz, H-2), 2.44 (2H, t, <i>J</i> = 7.0 Hz, H-4), 2.35 (1H, m, H-1″), 2.18 (3H, s, NCH<sub>3</sub>), 1.74 (2H, overlap, H-3), 1.73 (2H, overlap, H-2″a, H-6″a), 1.71 (2H, m, H-2″b, H-6″b), 1.54 (1H, br d, <i>J</i> = 12.5 Hz, H-4″a), 1.16 (2H, m, H-3″a, H-5″a), 1.12 (2H, m, H-3″b, H-5″b), 1.04 (1H, m, H-4″b). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.9, 164.8, 164.8, 164.7, 104.4, 94.7, 94.7, 62.1, 52.3, 40.3, 37.0, 27.8, 27.8, 25.9, 25.4, 25.4, 22.6. HRESIMS <i>m</i>/<i>z</i> = 308.1858 [M + H]<sup>+</sup> (calcd for C<sub>17</sub>H<sub>26</sub>NO<sub>4</sub>, 308.1856).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 4-(4-(3-Chlorophenyl)piperazin-1-yl)-1-(2,4,6-trihydroxyphenyl)butan-1-one Hydrochlorate (<b>17</b>)</h5><div class="NLM_p last">This compound was prepared from 1-(3-chlorophenyl)piperazine by means of GP4 as a white solid (0.60 g, 13%, mp 169–171 °C). Solvent for recrystallization: EtOH/H<sub>2</sub>O (10:1). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.21 (2H, s, OH-2′, OH-6′), 10.43 (1H, s, OH-4′), 7.26 (1H, t, <i>J</i> = 8.0 Hz, H-5‴), 7.05 (1H, br s, H-2‴), 6.96 (1H, br d, <i>J</i> = 8.0 Hz, H- H-4‴), 6.87 (1H, br d, <i>J</i> = 8.0 Hz, H-6‴), 5.82 (2H, s, H-3′, H-5′), 3.90 (2H, br d, <i>J</i> = 12.5 Hz, H-2″a, H-6″a), 3.59 (2H, br d, <i>J</i> = 11.5 Hz, H-3″a, H-5″a), 3.19 (2H, overlap, H-2″b, H-6″b), 3.16 (2H, overlap, H-3″b, H-5″b), 3.10 (2H, t, <i>J</i> = 6.5 Hz, H-2), 3.03 (2H, t, <i>J</i> = 11.5 Hz, H-4), 1.99 (2H, m, H-3). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 203.0, 164.8, 164.1, 164.1,150.7, 133.9, 130.6, 119.2, 115.2, 114.1, 103.6, 94.6, 94.6, 55.1, 50.5, 50.5, 44.9, 44.9, 38.9, 18.2. HRESIMS <i>m</i>/<i>z</i> = 391.1420 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>Cl, 391.1419).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <i>N</i>-(2,4,6-Trimethoxybenzyl)propan-2-amine (<b>18</b>)</h5><div class="NLM_p last">To a stirred solution of 2,4,6-trimethoxybenzaldehyde (196 mg, 1.0 mmol) in anhydrous MeOH (5 mL) was added isopropylamine (120 mg, 2.0 mmol) and NaBH<sub>3</sub>CN (76 mg, 1.2 mmol), followed by adjustment of the pH to ∼6.0 with HOAc. The reaction mixture was stirred at room temperature for 3 h under an argon atmosphere and quenched with H<sub>2</sub>O (20 mL). The solution was extracted with EtOAc (3 × 15 mL), and the combined organic layers were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 5:1 as eluent) afforded <b>18</b> as a white solid (110 mg, 47%, mp 177 °C). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.28 (2H, s, H-3′, H-5′), 3.93 (2H, s, H-1), 3.80 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.79 (3H, s, OCH<sub>3</sub>-4′), 3.32 (1H, m, H-3), 3.18 (1H, br s, NH), 1.25 (6H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). ESIMS <i>m</i>/<i>z</i> = 240 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> General Procedure for Reductive Amination for Compounds <b>19</b>–<b>25</b> (GP5)</h4><div class="NLM_p">To a stirred solution of 2,4,6-trimethoxybenzaldehyde (196 mg, 1.0 mmol) in anhydrous MeOH (5 mL) was added an amount of 2 equiv of <span class="smallcaps smallerCapital">l</span>-amino acid methyl (ethyl) ester hydrochloride (2.0 mmol), followed by the addition of NaBH<sub>3</sub>CN (76 mg, 1.2 mmol). The reaction mixture was stirred at room temperature for 3 h under an argon atmosphere and quenched with H<sub>2</sub>O (20 mL). The solution was extracted with EtOAc (3 × 15 mL), and the combined organic layers were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue obtained on column purification afforded the corresponding intermediate. A solution of the intermediate in 5% KOH in EtOH/H<sub>2</sub>O (1:1, 10 mL) was stirred at room temperature for 1 h. The reaction mixture was then neutralized with ion-exchange resin (Amberlite IR-120 H<sup>+</sup>), and the filtrate was concentrated in vacuo to yield a residue, which was subjected to prepared HPLC to afford the resulting product.</div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 2-((2,4,6-Trimethoxybenzyl)amino)acetic Acid (<b>19</b>)</h5><div class="NLM_p last">This compound was prepared from glycine ethyl ester hydrochloride by means of GP5 as a white solid (110 mg, 43%, mp 160–161 °C). Eluent for column chromatography: petroleum ether/EtOAc (5:1). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (18:82:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 32 min). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (2H, s, H-3′, H-5′), 4.05 (2H, br s, H-1), 3.79 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.78 (3H, s, OCH<sub>3</sub>-4′), 3.57 (2H, s, H-3). ESIMS <i>m</i>/<i>z</i> = 278 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (<i>S</i>)-2-((2,4,6-Trimethoxybenzyl)amino)propanoic Acid (<b>20</b>)</h5><div class="NLM_p last">This compound was prepared from <span class="smallcaps smallerCapital">l</span>-alanine methyl ester hydrochloride by means of GP5 as a white solid (102 mg, 38%, mp 174–175 °C). Eluent for column chromatography: petroleum ether/EtOAc (4:1). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (20:80:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 28 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −10.1° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (2H, s, H-3′, H-5′), 4.07 (2H, br s, H-1), 3.80 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.79 (3H, s, OCH<sub>3</sub>-4′), 3.36 (1H, m, H-3), 1.44 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.8, 162.5, 159.7, 159.7, 99.3, 90.7, 90.7, 55.9, 55.9, 55.6, 54.0, 37.7, 15.2. HRESIMS <i>m</i>/<i>z</i> = 292.1155 [M + Na]<sup>+</sup> (calcd for C<sub>13</sub>H<sub>19</sub>NO<sub>5</sub>Na, 292.1155).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (<i>S</i>)-3-Hydroxy-2-((2,4,6-trimethoxybenzyl)amino)propanoic Acid (<b>21</b>)</h5><div class="NLM_p last">This compound was prepared from <span class="smallcaps smallerCapital">l</span>-serine methyl ester hydrochloride by means of GP5 as a white solid (108 mg, 39%, mp 220–221 °C). Eluent for column chromatography: petroleum ether/EtOAc (1:1). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (13:87:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 35 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −6.5° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.26 (2H, s, H-3′, H-5′), 4.10 (2H, br s, H-1), 3.85 (1H, overlap, H-5a), 3.75 (1H, overlap, H-5b), 3.79 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.78 (3H, s, OCH<sub>3</sub>-4′), 3.48 (1H, br s, H-3). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.5, 162.4, 159.7, 159.7, 99.5, 90.9, 90.9, 60.9, 59.3, 56.0, 56.0, 55.6, 38.7. HRESIMS <i>m</i>/<i>z</i> = 284.1136 [M – H]<sup>−</sup> (calcd for C<sub>13</sub>H<sub>18</sub>NO<sub>6</sub>, 284.1140).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (<i>S</i>)-2-((2,4,6-Trimethoxybenzyl)amino)succinic Acid (<b>22</b>)</h5><div class="NLM_p last">This compound was prepared from <span class="smallcaps smallerCapital">l</span>-aspartic acid dimethyl ester hydrochloride by means of GP5 as a white solid (138 mg, 44%, mp 138–139 °C). Eluent for column chromatography: petroleum ether/EtOAc (5:1). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (10:90:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 41 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −7.3° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.28 (2H, s, H-3′, H-5′), 4.17 (1H, d, <i>J</i> = 13.0 Hz, H-1a), 4.13 (1H, d, <i>J</i> = 13.0 Hz, H-1b), 3.99 (1H, t, <i>J</i> = 6.0 Hz, H-3), 3.80 (3H, s, OCH<sub>3</sub>-4′), 3.79 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 2.84 (2H, br s, H-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.1, 169.2, 162.5, 159.6, 159.6, 99.2, 90.8, 90.8, 56.0, 56.0, 55.5, 54.7, 39.0, 34.0. HRESIMS <i>m</i>/<i>z</i> = 312.1092 [M – H]<sup>−</sup> (calcd for C<sub>14</sub>H<sub>18</sub>NO<sub>7</sub>, 312.1089).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>S</i>)-2-((2,4,6-Trimethoxybenzyl)amino)pentanedioic Acid (<b>23</b>)</h5><div class="NLM_p last">This compound was prepared from <span class="smallcaps smallerCapital">l</span>-glutamic acid dimethyl esters hydrochloride by means of GP5 as a white solid (155 mg, 48%, mp 121–123 °C). Eluent for column chromatography: petroleum ether/EtOAc (5:1). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (13:87:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 29 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +10.8° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.26 (2H, s, H-3′, H-5′), 4.03 (1H, d, <i>J</i> = 13.0 Hz, H-1a), 3.97 (1H, d, <i>J</i> = 13.0 Hz, H-1b), 3.79 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.78 (3H, s, OCH<sub>3</sub>-4′), 3.44 (1H, t, <i>J</i> = 6.5 Hz, H-3), 2.41 (1H, m, H-5a), 2.32(1H, m, H-5b), 2.01 (1H, m, H-6a), 1.94 (1H, m, H-6b). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.7, 169.9, 162.3, 159.6, 159.6, 99.9, 90.7, 90.7, 58.8, 55.9, 55.9, 55.5, 38.5, 30.3, 24.9. HRESIMS <i>m</i>/<i>z</i> = 326.1247 [M – H]<sup>−</sup> (calcd for C<sub>15</sub>H<sub>20</sub>NO<sub>7</sub>, 326.1245).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>S</i>)-3-Phenyl-2-((2,4,6-trimethoxybenzyl)amino)propanoic Acid (<b>24</b>)</h5><div class="NLM_p last">This compound was prepared from <span class="smallcaps smallerCapital">l</span>-phenylalanine methyl ester hydrochloride by means of GP5 as a white solid (115 mg, 33%, mp 102 °C). Eluent for column chromatography: petroleum ether/EtOAc (10:1). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (30:70:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 47 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +6.5° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.32 (2H, t, <i>J</i> = 7.5 Hz, H-3″, H-5″), 7.26 (1H, t, <i>J</i> = 7.5 Hz, H-4″), 7.22 (2H, d, <i>J</i> = 7.5 Hz, H-2″, H-6″), 6.27 (2H, s, H-3′, H-5′), 4.07 (2H, br s, H-1), 3.91 (1H, br s, H-3), 3.80 (3H, s, OCH<sub>3</sub>-4′), 3.78 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.32 (1H, dd, <i>J</i> = 13.5, 4.5 Hz, H-5a), 3.09 (1H, dd, <i>J</i> = 13.5, 8.0 Hz, H-5b). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.2, 162.4, 159.6, 159.6, 134.8, 129.3, 129.3, 128.4, 128.4, 127.1, 98.8, 90.6, 90.6, 59.3, 55.8, 55.8, 55.4, 38.3, 34.9. HRESIMS <i>m</i>/<i>z</i> = 346.1653 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>24</sub>NO<sub>5</sub>, 346.1649).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>S</i>)-3-(1<i>H</i>-Imidazol-5-yl)-2-((2,4,6-trimethoxybenzyl)amino)propanoic Acid (<b>25</b>)</h5><div class="NLM_p last">This compound was prepared from <span class="smallcaps smallerCapital">l</span>-histidine methyl ester hydrochloride by means of GP5 as a white solid (70 mg, 21%, mp 110–112 °C). Eluent for column chromatography: petroleum ether/EtOAc (5:1). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (10:90:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 54 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +7.5° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (1H, s, H-3″), 7.47 (1H, s, H-5″), 6.26 (2H, s, H-3′, H-5′), 4.13 (1H, d, <i>J</i> = 13.5 Hz, H-1a), 4.07 (1H, d, <i>J</i> = 13.5 Hz, H-1b), 4.07 (1H, br s, H-3), 3.79 (3H, s, OCH<sub>3</sub>-4′), 3.77 (6H, s, OCH<sub>3</sub>-2′, OCH<sub>3</sub>-6′), 3.34 (1H, dd, <i>J</i> = 15.5, 6.0 Hz, H-5a), 3.24 (1H, dd, <i>J</i> = 15.5, 8.0 Hz, H-5b). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.9, 162.6, 159.8, 159.8, 134.5, 127.6, 117.8, 99.1, 90.8, 90.8, 57.4, 55.9, 55.9, 55.6, 38.5, 24.8. HRESIMS <i>m</i>/<i>z</i> = 336.1556 [M + H]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub>, 335.1554).</div></div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Procedure for Introduction of Propanolamine Unit for Compounds <b>26</b>–<b>31</b> (GP6)</h4><div class="NLM_p">To a solution of the phenolic precursor (<b>3</b>, <b>5</b>, or <b>1a</b>, 5.0 mmol) in anhydrous DMF (60 mL) was added NaH (0.12 g, 5.0 mmol), and the reaction mixture was stirred at room temperature for 20 min under an argon atmosphere, followed by the addition of (±)2-(chloromethyl)oxirane (2.31 g, 25.0 mmol), and then stirred at 90 °C for 2 h. After cooling, the mixture was poured into ice-cooled water (100 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue obtained on column purification using petroleum ether/EtOAc (30:1–10:1) as eluent afforded the corresponding epoxide. The epoxide (1.0 mmol) was dissolved in amine (3 mL), and the solution was allowed to stand at 80 °C for 3 h in a sealed tube and then evaporated in vacuo. To a sirred solution of the residue in absolute diethyl ether (15 mL) was added dropwise a saturated HCl–diethyl ether solution (1 mL) and a precipitate appeared, which was filtered off to afford the resulting hydrochlorate.</div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 1-(2-(2-Hydroxy-3-(isopropylamino)propoxy)-4,6-dimethoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>26</b>)</h5><div class="NLM_p last">This compound was prepared using <b>3</b> and isopropylamine by means of GP6 as a white solid (110 mg, 19%, mp 128–130 °C). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (1H, br s, H-5′), 6.26 (1H, d, <i>J</i> = 1.5 Hz, H-3′), 4.14 (1H, m, H-2″), 4.01 (1H, dd, <i>J</i> = 10.4, 4.8 Hz, H-1″a), 3.96 (1H, dd, <i>J</i> = 10.4, 5.6 Hz, H-1″b), 3.79 (3H, s, OCH<sub>3</sub>), 3.72 (3H, s, OCH<sub>3</sub>), 3.29 (1H, m, H-5″), 3.02 (1H, m, H-3″a), 2.88 (1H, m, H-3″b), 2.54 (2H, br d, <i>J</i> = 5.6 Hz, H-2), 2.02 (1H, m, H-3), 1.25 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-6″), 1.17 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.88 (6H, d, <i>J</i> = 6.4 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.7, 161.8, 157.7, 156.5, 113.4, 91.9, 91.5, 70.4, 65.0, 55.9, 55.6, 53.5, 49.9, 46.7, 24.3, 22.6, 22.6, 18.6, 18.2. HRESIMS <i>m</i>/<i>z</i> = 354.2277 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>NO<sub>5</sub>, 354.2275).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 1-(2-(2-Hydroxy-3-(<i>tert</i>-butylamino)propoxy)-4,6-dimethoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>27</b>)</h5><div class="NLM_p last">This compound was prepared using <b>3</b> and tertbutylamine by means of GP6 as a white solid (200 mg, 34%, mp 114–115 °C). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (1H, br s, H-5′), 6.25 (1H, br s, H-3′), 4.14 (1H, m, H-2″), 4.04 (1H, dd, <i>J</i> = 10.4, 4.8 Hz, H-1″a), 3.98 (1H, dd, <i>J</i> = 10.0, 5.6 Hz, H-1″b), 3.92 (3H, s, OCH<sub>3</sub>), 3.72 (3H, s, OCH<sub>3</sub>), 3.04 (1H, m, H-3″a), 2.84 (1H, m, H-3″b), 2.54 (2H, d, <i>J</i> = 6.8 Hz, H-2), 2.02 (1H, m, H-3), 1.29 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.87 (6H, d, <i>J</i> = 6.4 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.7, 161.8, 157.7, 156.4, 113.4, 91.9, 91.5, 70.3, 65.4, 56.4, 55.9, 55.7, 53.5, 44.3, 24.9, 24.9, 24.9, 24.4, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 368.2437 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>34</sub>NO<sub>5</sub>, 368.2431).</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 1-(2-(2-Hydroxy-3-(isopropylamino)propoxy)-4-methoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>28</b>)</h5><div class="NLM_p last">This compound was prepared using <b>5</b> and isopropylamine by means of GP6 as a white solid (70 mg, 12%, mp 94–95 °C). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59 (1H, d, <i>J</i> = 8.4 Hz, H-6′), 6.64 (1H, br s, H-3′), 6.59 (1H, dd, <i>J</i> = 8.4, 1.6 Hz, H-5′), 4.31 (1H, m, H-2″), 4.14 (2H, br s, H-1″), 3.82 (3H, s, OCH<sub>3</sub>), 3.32 (1H, m, H-5″), 3.15 (1H, m, H-3″a), 3.01 (1H, m, H-3″b), 2.85 (1H, dd, <i>J</i> = 16.0, 6.8 Hz, H-2a), 2.79 (1H, dd, <i>J</i> = 16.0, 6.8 Hz, H-2b), 2.08 (1H, m, H-3), 1.27 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-6″), 1.25 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.87 (6H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 199.7, 163.8, 159.2, 131.8, 121.1, 106.3, 99.3, 70.7, 65.1, 55.7, 52.0, 49.9, 47.0, 24.6, 22.6, 22.6, 18.6, 18.3. HRESIMS <i>m</i>/<i>z</i> = 324.2173 [M + H]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>30</sub>NO<sub>4</sub>, 324.2169).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 1-(2-(2-Hydroxy-3-(<i>tert</i>-butylamino)propoxy)-4-methoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>29</b>)</h5><div class="NLM_p last">This compound was prepared from <b>5</b> and <i>tert</i>-butylamine by means of GP6 as a white solid (82 mg, 13%, mp 135–137 °C). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.60 (1H, d, <i>J</i> = 8.4 Hz, H-6′), 6.64 (1H, d, <i>J</i> = 2.0 Hz, H-3′), 6.60 (1H, dd, <i>J</i> = 8.4, 2.0 Hz, H-5′), 4.29 (1H, m, H-2″), 4.15 (2H, br s, H-1″), 3.82 (3H, s, OCH<sub>3</sub>), 3.17 (1H, m, H-3″a), 2.95 (1H, m, H-3″b), 2.85 (1H, dd, <i>J</i> = 16.0, 6.8 Hz, H-2a), 2.80 (1H, dd, <i>J</i> = 16.0, 6.8 Hz, H-2b), 2.09 (1H, m, H-3), 1.32 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.87 (6H, d, <i>J</i> = 6.4 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 199.7, 163.8, 159.2, 131.8, 121.2, 106.3, 99.3, 70.6, 65.4, 56.4, 55.7, 51.9, 44.5, 25.0, 25.0, 25.0, 24.6, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 338.2331 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>NO<sub>4</sub>, 338.2326).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 1-(2,4-Dihydroxy-6-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)-3-methylbutan-1-one Hydrochlorate (<b>30</b>)</h5><div class="NLM_p last">To a solution of <b>1</b> (3.00 g, 14.3 mmol) in acetone (200 mL) were added anhydrous K<sub>2</sub>CO<sub>3</sub> (25.00 g, 181.0 mmol) and benzyl <i>p</i>-toluenesulfonate (7.86 g, 30.0 mmol), which was synthesized according to the method by Dewick, and the reaction mixture was refluxed for 3 h. After cooling, the solvent was removed in vacuo. The residue was dissolved in water (150 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 30:1 as eluent) afforded <b>1a</b> as a white solid (2.98 g, 53%). <b>30a</b> was prepared from <b>1a</b> and isopropylamine by means of GP6 as a white solid (400 mg, 60%). To a solution of <b>30a</b> (170 mg, 0.3 mmol) in MeOH (30 mL) was added a catalytic amount of Pd-C, and the reaction mixture was stirred at room temperature for 12 h under H<sub>2</sub> at 3 atm. After filtration, the filtrate was concentrated in vacuo, and the residue obtained on prepared HPLC purification afforded <b>30</b> as a white solid (50 mg, 49%, mp 186–187 °C). Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (22:78:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 35 min). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.90 (1H, s, H-3′), 5.89 (1H, s, H-5′), 4.00 (1H, dd, <i>J</i> = 8.0, 3.5 Hz, H-1″a), 3.92 (1H, overlap, H-1″b), 3.88 (1H, m, H-2″), 2.93 (1H, dd, <i>J</i> = 16.0, 7.0 Hz, H-3″a), 2.84 (1H, dd, <i>J</i> = 16.0, 6.5 Hz, H-3″b), 2.77 (1H, m, H-5″), 2.72 (1H, dd, <i>J</i> = 13.5, 6.5 Hz, H-2a), 2.60 (1H, dd, <i>J</i> = 13.5, 7.0 Hz, H-2b), 2.13 (1H, m, H-3), 1.00 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-6″), 0.99 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.90 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4), 0.88 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.7, 166.2, 165.5, 162.3, 104.7, 95.9, 92.2, 71.6, 68.2, 52.3, 49.9, 48.5, 24.5, 22.7, 22.7, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 326.1968 [M + H]<sup>+</sup> (calcd for C<sub>17</sub>H<sub>28</sub>NO<sub>5</sub>, 326.1962).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 1-(2,4-Dihydroxy-6-(2-hydroxy-3-(<i>tert</i>-butylamino)propoxy)phenyl)-3-methylbutan-1-one Hydrochlorate (<b>31</b>)</h5><div class="NLM_p last">The intermediate <b>31a</b> was prepared from <b>1a</b> and <i>tert</i>-butylamine by means of GP6 as a white solid (450 mg, 66%), and the end product <b>31</b> was obtained from <b>31a</b> (150 mg, 0.3 mmol) as a white solid (59 mg, 64%, mp 205–206 °C) by catalytic hydrogenation as described in synthesis of <b>30</b>. Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (22:78:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 39 min). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.90 (1H, br s, H-3′), 5.81 (1H, br s, H-5′), 4.01 (1H, dd, <i>J</i> = 9.5, 4.0 Hz, H-1″a), 3.89 (1H, overlap, H-1″b), 3.84 (1H, m, H-2″), 2.94 (1H, dd, <i>J</i> = 16.0, 7.0 Hz, H-3″a), 2.85 (1H, dd, <i>J</i> = 16.0, 6.5 Hz, H-3″b), 2.64 (1H, dd, <i>J</i> = 12.0, 5.0 Hz, H-2a), 2.62 (1H, dd, <i>J</i> = 12.0, 6.0 Hz, H-2b), 2.13 (1H, m, H-3), 1.03 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.90 (3H, d, <i>J</i> = 7.0 Hz, CH<sub>3</sub>-4), 0.89 (3H, d, <i>J</i> = 7.0 Hz, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.4, 166.3, 166.2, 162.3, 104.6, 95.9, 92.3, 71.5, 68.7, 52.3, 50.2, 45.4, 28.6, 28.6, 28.6, 24.6, 22.7, 22.6. HRESIMS <i>m</i>/<i>z</i> = 340.2123 [M + H]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>30</sub>NO<sub>5</sub>, 340.2118).</div></div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> General Procedure for Introduction of Chiral Propanolamine Unit for Compounds <b>32</b>–<b>43</b> (GP7)</h4><div class="NLM_p">To a solution of the phenolic precursor (<b>3</b>, <b>5</b>, or <b>1a</b>, 20.0 mmol) in anhydrous DMF (60 mL) was added NaH (0.48 g, 20.0 mmol), and the mixture was stirred at room temperature for 20 min under an argon atmosphere, followed by the addition of an amount of 1.25 equiv of (<i>R</i>)- or (<i>S</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane (25.0 mmol), and then stirred at 90 °C for 12 h. After cooling, the reaction mixture was poured into ice-cooled water (100 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue obtained on column purification using petroleum ether/EtOAc (30:1–20:1) as eluent afforded the corresponding intermediate with a 2,2-dimethyl-1,3-dioxolane moiety. To a stirred solution of the intermediate (4.0 mmol) in THF (30 mL) was added dropwise 4% H<sub>2</sub>SO<sub>4</sub> (30 mL), and the mixture was stirred at room temperature for 8 h. Then the organic solvent was removed in vacuo and the residue was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to provide the corresponding 1,2-diols. bThe diols (3.0 mmol) was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (40 mL), and a catalytic amount of pyridine was added, followed by the addition of TsCl (573 mg, 3.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The reaction mixture was stirred at room temperature for 48 h and concentrated in vacuo. The residue obtained on column purification using petroleum ether/EtOAc (25:1–15:1) as eluent afforded the ester of the primary hydroxyl group.bThe ester (0.50 mmol) was dissolved in amine (3 mL), and the solution was allowed to stand at 80 °C for 3 h in a sealed tube and then evaporated in vacuo. The residue was dissolved in absolute ether, and a saturated HCl–diethyl ether solution was added. The precipitate was filtered off to afford the resulting hydrochlorate.</div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (<i>S</i>)-1-(2-(2-Hydroxy-3-(isopropylamino)propoxy)-4,6-dimethoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>32</b>)</h5><div class="NLM_p last">This compound was prepared using <b>3</b>, (<i>S</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane and isopropylamine by means of GP7 as a white solid (55 mg, 2%, mp 130–132 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −22.5° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (1H, br s, H-5′), 6.25 (1H, br s, H-3′), 4.16 (1H, m, H-2″), 4.01 (1H, m, H-1″a), 3.96 (1H, m, H-1″b), 3.79 (3H, s, OCH<sub>3</sub>), 3.72 (3H, s, OCH<sub>3</sub>), 3.29 (1H, m, H-5″), 3.02 (1H, br d, <i>J</i> = 11.1 Hz, H-3″a), 2.90 (1H, m, H-3″b), 2.54 (2H, br d, <i>J</i> = 6.9 Hz, H-2), 2.02 (1H, m, H-3), 1.25 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-6″), 1.23 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.88 (6H, d, <i>J</i> = 6.6 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.7, 161.8, 157.7, 156.5, 113.4, 91.9, 91.5, 70.4, 65.0, 55.9, 55.6, 53.5, 49.9, 46.7, 24.3, 22.6, 22.6, 18.6, 18.2. HRESIMS <i>m</i>/<i>z</i> = 354.2282 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>NO<sub>5</sub>, 354.2275).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (<i>R</i>)-1-(2-(2-Hydroxy-3-(isopropylamino)propoxy)-4,6-dimethoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>33</b>)</h5><div class="NLM_p last">This compound was prepared using <b>3</b>, (<i>R</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and isopropylamine by means of GP7 as a white solid (68 mg, 4%, mp 136–137 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +22.6° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (1H, br s, H-5′), 6.26 (1H, br s, H-3′), 4.10 (1H, m, H-2″), 4.01 (1H, m, H-1″a), 3.96 (1H, m, H-1″b), 3.79 (3H, s, OCH<sub>3</sub>), 3.72 (3H, s, OCH<sub>3</sub>), 3.29 (1H, m, H-5″), 3.02 (1H, br d, <i>J</i> = 11.1 Hz, H-3″a), 2.96 (1H, m, H-3″b), 2.54 (2H, br d, <i>J</i> = 6.9 Hz, H-2), 2.02 (1H, m, H-3), 1.25 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-6″), 1.23 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.88 (6H, d, <i>J</i> = 6.6 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.7, 161.8, 157.7, 156.5, 113.4, 91.9, 91.5, 70.4, 65.0, 55.9, 55.6, 53.5, 49.9, 46.7, 24.3, 22.6, 22.6, 18.6, 18.2. HRESIMS <i>m</i>/<i>z</i> = 354.2279 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>NO<sub>5</sub>, 354.2275).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (<i>S</i>)-1-(2-(2-Hydroxy-3-(<i>tert</i>-butylamino)propoxy)-4,6-dimethoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>34</b>)</h5><div class="NLM_p last">This compound was prepared using <b>3</b>, (<i>S</i>)- 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and <i>tert</i>-butylamine by means of GP7 as a white solid (86 mg, 3%, mp 116–117 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −23.9° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (1H, d, <i>J</i> = 1.5 Hz, H-5′), 6.25 (1H, d, <i>J</i> = 1.5 Hz, H-3′), 4.16 (1H, m, H-2″), 4.06 (1H, m, H-1″a), 3.97 (1H, m, H-1″b), 3.79 (3H, s, OCH<sub>3</sub>), 3.72 (3H, s, OCH<sub>3</sub>), 3.04 (1H, m, H-3″a), 2.86 (1H, m, H-3″b), 2.54 (2H, d, <i>J</i> = 6.9 Hz, H-2), 2.02 (1H, m, H-3), 1.29 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.87 (6H, d, <i>J</i> = 6.9 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.7, 161.8, 157.7, 156.5, 113.4, 91.9, 91.5, 70.3, 65.4, 56.4, 55.9, 55.6, 53.5, 44.3, 24.9, 24.9, 24.9, 24.4, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 368.2437 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>34</sub>NO<sub>5</sub>, 368.2431).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> (<i>R</i>)-1-(2-(2-Hydroxy-3-(<i>tert</i>-butylamino)propoxy)-4,6-dimethoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>35</b>)</h5><div class="NLM_p last">This compound was prepared using <b>3</b>, (<i>R</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and <i>tert</i>-butylamine by means of GP7 as a white solid (75 mg, 5%, mp 113–114 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +23.9° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.27 (1H, d, <i>J</i> = 1.8 Hz, H-5′), 6.25 (1H, d, <i>J</i> = 1.8 Hz, H-3′), 4.15 (1H, m, H-2″), 4.06 (1H, m, H-1″a), 3.97 (1H, m, H-1″b), 3.79 (3H, s, OCH<sub>3</sub>), 3.72 (3H, s, OCH<sub>3</sub>), 3.04 (1H, m, H-3″a), 2.86 (1H, m, H-3″b), 2.54 (2H, d, <i>J</i> = 6.9 Hz, H-2), 2.02 (1H, m, H-3), 1.29 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.87 (6H, d, <i>J</i> = 6.6 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 202.7, 161.8, 157.7, 156.5, 113.4, 91.9, 91.5, 70.3, 65.4, 56.4, 55.9, 55.6, 53.5, 44.3, 24.9, 24.9, 24.9, 24.4, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 368.2433 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>34</sub>NO<sub>5</sub>, 368.2431).</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (<i>S</i>)-1-(2-(2-Hydroxy-3-(isopropylamino)propoxy)-4-methoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>36</b>)</h5><div class="NLM_p last">This compound was prepared using <b>5</b>, (<i>S</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane and isopropylamine by means of GP7 as a white solid (93 mg, 7%, mp 98–99 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −1.4° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59 (1H, d, <i>J</i> = 8.7 Hz, H-6′), 6.64 (1H, d, <i>J</i> = 1.8 Hz, H-3′), 6.60 (1H, br d, <i>J</i> = 8.7 Hz, H-5′), 4.30 (1H, m, H-2″), 4.13 (2H, br s, H-1″), 3.82 (3H, s, OCH<sub>3</sub>), 3.34 (1H, m, H-5″), 3.15 (1H, m, H-3″a), 3.00 (1H, m, H-3″b), 2.85 (1H, dd, <i>J</i> = 16.2, 6.9 Hz, H-2a), 2.79 (1H, dd, <i>J</i> = 16.2, 6.9 Hz, H-2b), 2.08 (1H, m, H-3), 1.27 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-6″), 1.26 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.87 (6H, d, <i>J</i> = 6.6 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 199.7, 163.8, 159.2, 131.8, 121.1, 106.3, 99.3, 70.7, 65.1, 55.7, 51.9, 49.9, 47.0, 24.6, 22.6, 22.6, 18.6, 18.3. HRESIMS <i>m</i>/<i>z</i> = 324.2178 [M + H]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>30</sub>NO<sub>4</sub>, 324.2169).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> (<i>R</i>)-1-(2-(2-Hydroxy-3-(isopropylamino)propoxy)-4-methoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>37</b>)</h5><div class="NLM_p last">This compound was prepared using <b>5</b>, (<i>R</i>)- 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and isopropylamine by means of GP7 as a white solid (65 mg, 3%, mp 97–98 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +1.4° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59 (1H, d, <i>J</i> = 8.7 Hz, H-6′), 6.64 (1H, d, <i>J</i> = 1.8 Hz, H-3′), 6.60 (1H, dd, <i>J</i> = 8.7, 1.8 Hz, H-5′), 4.31 (1H, m, H-2″), 4.14 (2H, br s, H-1″), 3.82 (3H, s, OCH<sub>3</sub>), 3.32 (1H, m, H-5″), 3.15 (1H, m, H-3″a), 3.00 (1H, m, H-3″b), 2.85 (1H, dd, <i>J</i> = 16.2, 6.9 Hz, H-2a), 2.79 (1H, dd, <i>J</i> = 16.2, 6.9 Hz, H-2b), 2.08 (1H, m, H-3), 1.27 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-6″), 1.26 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.87 (6H, d, <i>J</i> = 6.6 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 199.7, 163.8, 159.2, 131.8, 121.1, 106.3, 99.3, 70.7, 65.1, 55.7, 51.9, 49.9, 47.0, 24.6, 22.6, 22.6, 18.6, 18.3. HRESIMS <i>m</i>/<i>z</i> = 324.2180 [M + H]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>30</sub>NO<sub>4</sub>, 324.2169).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (<i>S</i>)-1-(2-(2-Hydroxy-3-(<i>tert</i>-butylamino)propoxy)-4-methoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>38</b>)</h5><div class="NLM_p last">This compound was prepared using <b>5</b>, (<i>S</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and <i>tert</i>-butylamine by means of GP7 as a white solid (37 mg, 3%, mp 148–149 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −3.4° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59 (1H, d, <i>J</i> = 8.4 Hz, H-6′), 6.64 (1H, d, <i>J</i> = 2.1 Hz, H-3′), 6.60 (1H, dd, <i>J</i> = 8.4, 2.1 Hz, H-5′), 4.30 (1H, m, H-2″), 4.16 (2H, br s, H-1″), 3.82 (3H, s, OCH<sub>3</sub>), 3.17 (1H, m, H-3″a), 2.97 (1H, m, H-3″b), 2.85 (1H, dd, <i>J</i> = 16.2, 6.6 Hz, H-2a), 2.80 (1H, dd, <i>J</i> = 16.2, 6.6 Hz, H-2b), 2.07 (1H, m, H-3), 1.32 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.87 (6H, d, <i>J</i> = 6.6 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 199.7, 163.8, 159.2, 131.8, 121.2, 106.3, 99.3, 70.6, 65.4, 56.4, 55.7, 51.9, 44.5, 25.0, 25.0, 25.0, 24.6, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 324.2326 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>NO<sub>4</sub>, 338.2334).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> (<i>R</i>)-1-(2-(2-Hydroxy-3-(<i>tert</i>-butylamino)propoxy)-4-methoxyphenyl)-3-methylbutan-1-one Hydrochlorate (<b>39</b>)</h5><div class="NLM_p last">This compound was prepared using <b>5</b>, (<i>R</i>)- 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and <i>tert</i>-butylamine by means of GP7 as a white solid (75 mg, 4%, mp 151–153 °C); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +3.4° (<i>c</i> = 0.333, CH<sub>3</sub>OH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59 (1H, d, <i>J</i> = 8.4 Hz, H-6′), 6.64 (1H, d, <i>J</i> = 2.1 Hz, H-3′), 6.60 (1H, dd, <i>J</i> = 8.4, 2.1 Hz, H-5′), 4.29 (1H, m, H-2″), 4.17 (2H, br s, H-1″), 3.82 (3H, s, OCH<sub>3</sub>), 3.17 (1H, m, H-3″a), 2.97 (1H, m, H-3″b), 2.85 (1H, dd, <i>J</i> = 16.2, 6.6 Hz, H-2a), 2.80 (1H, dd, <i>J</i> = 16.2, 6.6 Hz, H-2b), 2.09 (1H, m, H-3), 1.32 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.87 (6H, d, <i>J</i> = 6.9 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 199.7, 163.8, 159.2, 131.8, 121.2, 106.3, 99.3, 70.6, 65.4, 56.4, 55.7, 51.9, 44.5, 25.0, 25.0, 25.0, 24.6, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 324.2332 [M + H]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>NO<sub>4</sub>, 338.2334).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> (<i>S</i>)-1-(2,4-Dihydroxy-6-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)-3-methylbutan-1-one Hydrochlorate (<b>40</b>)</h5><div class="NLM_p last">The intermediate <b>40a</b> was prepared using <b>1a</b>, (<i>S</i>)- 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and isopropylamine by means of GP7 as a white solid (168 mg, 7%). The end product <b>40</b> was obtained from <b>40a</b> (168 mg, 0.3 mmol) as a white solid (58 mg, 52%, mp 207–209 °C) by catalytic hydrogenation as described in synthesis of <b>30</b>. Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (22:78:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 35 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −4.2° (<i>c</i> = 0.067, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.90 (1H, d, <i>J</i> = 1.5 Hz, H-3′), 5.81 (1H, d, <i>J</i> = 1.5 Hz, H-5′), 3.99 (1H, dd, <i>J</i> = 8.5, 3.0 Hz, H-1″a), 3.92 (1H, overlap, H-1″b), 3.88 (1H, m, H-2″), 2.93 (1H, dd, <i>J</i> = 16.0, 7.0 Hz, H-3″a), 2.84 (1H, dd, <i>J</i> = 16.0, 6.5 Hz, H-3″a), 2.77 (1H, m, H-5″), 2.72 (1H, m, H-2a), 2.62 (1H, dd, <i>J</i> = 11.5, 6.5 Hz, H-2b), 2.13 (1H, m, H-3), 1.00 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-6″), 0.99 (3H, d, <i>J</i> = 6.0 Hz, CH<sub>3</sub>-7″), 0.90 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4), 0.88 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.7, 166.2, 165.5, 162.3, 104.6, 95.9, 92.3, 71.6, 68.1, 52.3, 49.9, 48.5, 24.5, 22.7, 22.7, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 326.1972 [M + H]<sup>+</sup> (calcd for C<sub>17</sub>H<sub>28</sub>NO<sub>5</sub>, 326.1962).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> (<i>R</i>)-1-(2,4-Dihydroxy-6-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)-3-methylbutan-1-one Hydrochlorate (<b>41</b>)</h5><div class="NLM_p last">The intermediate <b>41a</b> was prepared using <b>1a</b>, (<i>R</i>)- 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and isopropylamine by means of GP7 as a white solid (129 mg, 4%). The end product <b>41</b> was obtained from <b>41a</b> (129 mg, 0.2 mmol) as a white solid (45 mg, 70%, mp 210–212 °C) by catalytic hydrogenation as described in synthesis of <b>30</b>. Conditions for prepared HPLC were the same as those for <b>40</b>; [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +4.2° (<i>c</i> = 0.067, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.92 (1H, d, <i>J</i> = 1.5 Hz, H-3′), 5.84 (1H, d, <i>J</i> = 1.5 Hz, H-5′), 3.99 (1H, br d, <i>J</i> = 5.5 Hz, H-1″a), 3.91 (1H, overlap, H-1″b), 3.89 (1H, m, H-2″), 2.94 (1H, dd, <i>J</i> = 16.0, 6.5 Hz, H-3″a), 2.84 (1H, dd, <i>J</i> = 16.0, 6.5 Hz, H-3″b), 2.76 (1H, m, H-5″), 2.72 (1H, m, H-2a), 2.63 (1H, dd, <i>J</i> = 11.0, 6.0 Hz, H-2b), 2.13 (1H, m, H-3), 1.00 (3H, d, <i>J</i> = 5.5 Hz, CH<sub>3</sub>-6″), 0.99 (3H, d, <i>J</i> = 5.5 Hz, CH<sub>3</sub>-7″), 0.90 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4), 0.88 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.6, 166.1, 165.0, 162.3, 104.7, 95.8, 1, 71.6, 68.1, 52.3, 49.9, 48.5, 24.5, 22.7, 22.7, 22.6, 22.6. HRESIMS <i>m</i>/<i>z</i> = 326.1967 [M + H]<sup>+</sup> (calcd for C<sub>17</sub>H<sub>28</sub>NO<sub>5</sub>, 326.1962).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (<i>S</i>)-1-(2,4-Dihydroxy-6-(2-hydroxy-3-(<i>tert</i>-butylamino)propoxy)phenyl)-3-methylbutan-1-one Hydrochlorate (<b>42</b>)</h5><div class="NLM_p last">The intermediate <b>42a</b> was prepared using <b>1a</b>, (<i>S</i>)- 4-(chloromethyl)-2,2- dimethyl-1,3-dioxolane, and <i>tert</i>-butylamine by means of GP7 as a white solid (95 mg, 4%). The end product <b>42</b> was obtained from <b>42a</b> (95 mg, 0.2 mmol) as a white solid (34 mg, 54%, mp 218–219 °C) by catalytic hydrogenation as described in synthesis of <b>30</b>. Conditions for prepared HPLC: CH<sub>3</sub>CN/H<sub>2</sub>O/TFA (22:78:0.03, 5 mL/min, <i>t</i><sub>R</sub> = 39 min); [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −10.6° (<i>c</i> = 0.067, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.89 (1H, d, <i>J</i> = 2.0 Hz, H-3′), 5.81 (1H, d, <i>J</i> = 2.0 Hz, H-5′), 4.01 (1H, dd, <i>J</i> = 9.0, 3.5 Hz, H-1″a), 3.90 (1H, overlap, H-1″b), 3.84 (1H, m, H-2″), 2.93 (1H, dd, <i>J</i> = 16.0, 7.0 Hz, H-3″a), 2.85 (1H, dd, <i>J</i> = 16.0, 7.0 Hz, H-3″b), 2.67 (1H, dd, <i>J</i> = 11.5, 5.0 Hz, H-2a), 2.62 (1H, dd, <i>J</i> = 11.5, 6.5 Hz, H-2b), 2.13 (1H, m, H-3), 1.04 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.90 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4), 0.89 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.4, 166.3, 166.2, 162.3, 104.6, 95.9, 92.3, 71.5, 68.7, 52.3, 50.2, 45.4, 28.6, 28.6, 28.6, 24.6, 22.7, 22.6. HRESIMS <i>m</i>/<i>z</i> = 340.2117 [M + H]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>30</sub>NO<sub>5</sub>, 326.2118).</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (<i>R</i>)-1-(2,4-Dihydroxy-6-(2-hydroxy-3-(<i>tert</i>-butylamino)propoxy)phenyl)-3-methylbutan-1-one Hydrochlorate (<b>43</b>)</h5><div class="NLM_p last">The intermediate <b>43a</b> was prepared using <b>1a</b>, (<i>R</i>)- 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, and <i>tert</i>-butylamine by means of GP7 as a white solid (186 mg, 5%). The end product <b>43</b> was obtained from <b>43a</b> (186 mg, 0.4 mmol) as a white solid (51 mg, 41%, mp 222–224 °C) by catalytic hydrogenation as described in synthesis of <b>30</b>. Conditions for prepared HPLC were the same as those for <b>42</b>; [α]<sub class="stack">D</sub><sup class="stack">20</sup> = +10.6° (<i>c</i> = 0.067, CH<sub>3</sub>OH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.92 (1H, d, <i>J</i> = 1.5 Hz, H-3′), 5.82 (1H, d, <i>J</i> = 1.5 Hz, H-5′), 4.01 (1H, dd, <i>J</i> = 9.0, 3.5 Hz, H-1″a), 3.90 (1H, overlap, H-1″b), 3.88 (1H, m, H-2″), 2.94 (1H, dd, <i>J</i> = 16.0, 7.0 Hz, H-3″a), 2.85 (1H, dd, <i>J</i> = 16.0, 7.0 Hz, H-3″b), 2.69 (1H, dd, <i>J</i> = 11.0, 6.0 Hz, H-2a), 2.62 (1H, dd, <i>J</i> = 11.5, 6.5 Hz, H-2b), 2.13 (1H, m, H-3), 1.04 (9H, s, CH<sub>3</sub>-6″, CH<sub>3</sub>-7″, CH<sub>3</sub>-8″), 0.90 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4), 0.89 (3H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.6, 166.2, 165.3, 162.3, 104.8, 95.9, 92.2, 71.6, 68.6, 52.3, 50.2, 45.3, 28.5, 28.5, 28.5, 24.6, 22.7, 22.6. HRESIMS <i>m</i>/<i>z</i> = 340.2115 [M + H]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>30</sub>NO<sub>5</sub>, 326.2118).</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 4-((3,5-Dihydroxy-2-(3-methylbutanoyl)phenoxy)methyl)-3-phenyl-furoxan (<b>44</b>)</h5><div class="NLM_p last">To a stirred solution of NaNO<sub>2</sub> (3.00g, 72.0 mmol) in water (50 mL) was added dropwise cinnamyl alcohol (2.00 g, 15.0 mmol) in HOAc (5 mL). The reaction mixture was stirred at room temperature for 4 h and then neutralized with NaHCO<sub>3</sub>, followed by the extraction with EtOAc (3 × 20 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 7:1 as eluent) afforded the furoxan alcohol <b>44a</b> (0.86 g, 30%). To a stirred solution of <b>44a</b> (192 mg, 1.0 mmol) and pyridine (0.32 mL, 4 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added SOCl<sub>2</sub> (0.35 mL) in an ice-bath. The mixture was stirred at room temperature for 3 h and then washed with ice water, saturated NaHCO<sub>3</sub> solution, and brine successively. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to give a clear oil. To a solution of the crude oil and <b>2a</b> (220 mg, 1.0 mmol) in acetone (20 mL) was added anhydrous K<sub>2</sub>CO<sub>3</sub> (210 mg, 1.5 mmol). After refluxing for 5 h, the reaction mixture was concentrated in vacuo. Water (20 mL) was then added to the residue, and the aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 15:1 as eluent) afforded <b>44b</b> as a yellow oil (200 mg, 42%). To a solution of <b>44b</b> (200 mg, 0.42 mmol) in MeOH (10 mL) was added 2 N HCl (2 mL) and the mixture was refluxed for 1 h, and then the solvent was removed in vacuo. The resulting residue was dissolved in EtOAc (50 mL) and was washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue obtained on column purification (silica, petroleum ether/EtOAc, 5:1 as eluent) afforded <b>44</b> as a white solid (150 mg, 90%, mp 125–127 °C). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.43 (1H, s, OH-6′), 10.73 (1H, s, OH-4′), 7.79 (2H, d, <i>J</i> = 7.5 Hz, H-2‴, H-6‴), 7.63 (2H, t, <i>J</i> = 7.5 Hz, H-3‴, H-5‴), 7.59 (1H, t, <i>J</i> = 7.5 Hz, H-4‴), 6.08 (1H, d, <i>J</i> = 1.5 Hz, H-3′), 5.96 (1H, d, <i>J</i> = 1.5 Hz, H-5′), 5.24 (2H, s, H-1″), 2.44 (2H, d, <i>J</i> = 7.0 Hz, H-2), 1.91 (1H, m, H-3), 0.66 (6H, d, <i>J</i> = 6.5 Hz, CH<sub>3</sub>-4, CH<sub>3</sub>-5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 204.1, 165.7, 164.5, 160.2, 156.9, 131.8, 129.7, 129.7, 127.6, 127.6, 125.6, 112.3, 105.2, 96.9, 92.6, 59.1, 52.2, 24.5, 22.3, 22.3. HRESIMS <i>m</i>/<i>z</i> = 385.1395 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>6</sub>, 385.1394).</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> BV-2 Cell Culture and Treatment</h3><div class="NLM_p last">BV-2 cells were cultured at 37 °C in an atmosphere of 5% CO<sub>2</sub> in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. For the compound screening experiments, the cells were plated in 96-well plates at a density of 5 × 10<sup>3</sup> cell/well and 24 h later were treated with compounds <b>1</b>–<b>44</b> at six different concentrations (100, 50, 10 5, 1, and 0.1 μM, respectively). Then, 1 h later the cells were treated with LPS (300 ng/mL) and incubated for another 24 h, and the culture media were collected for the detection of the NO concentration.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Primary Mixed Mesencephalic Neuronal/Glial Culture and Treatment</h3><div class="NLM_p last">Neuronal-glial cultures were prepared from the ventral mesencephalic tissue of embryonic day-14 Sprague–Dawley rats (Beijing Vital River Animal Center). Briefly, the whole brain was removed, mesencephalon was dissected, blood vessels and meninges were removed, and then pooled mesencephalic tissues were dissociated using mild mechanical trituration in ice-cold phosphate-buffered saline (PBS, pH 7.4). After pelleting and centrifugation, the cells were resuspended and plated (5 × 10<sup>5</sup>/well) into 24-well cell culture plates precoated with 10 mg/mL poly-<span class="smallcaps smallerCapital">d</span>-lysine. The cells were maintained at 37 °C in a humidified atmosphere of 95% air/5% CO<sub>2</sub> in minimal essential medium (MEM) containing 10% FBS, 10% horse serum, 1 μg/mL glucose, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 1 mM sodium pyruvate, 100 μM nonessential amino acids, 100 U/mL penicillin, and 100 μg/mL streptomycin. Seven-day-old cultures were used for the experiments, and the cells were treated with LPS (100 ng/mL) in the presence or absence of the indicated compounds at different concentrations (added 1 h before LPS stimulation) and then incubated for 5 h, 24 h, and 7 days to determine cytokine, Iba-1, or TH expressions, respectively.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Primary Microglia Culture and Treatment</h3><div class="NLM_p last">Primary microglia-enriched cultures were prepared from the whole brains of 1-day-old Sprague–Dawley rats (Beijing Vital River Animal Center). The brain tissue was cleared of the meninges and blood vessels, dissociated using mechanical trituration, and then placed in ice-cold PBS. The tissue was subsequently digested with 0.25 mg/mL trypsin, triturated in DMEM by pipetting, and filtered to remove large debris. The isolated cells (5 × 10<sup>7</sup>) were seeded into 150 cm<sup>2</sup> culture flasks coated with 10 mg/mL poly-<span class="smallcaps smallerCapital">d</span>-lysine in DMEM/F12 supplemented with 10% FBS, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamic acid, 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified incubator with 95% air/5% CO<sub>2</sub> at 37 °C. Following their attainment of confluence (12–14 days), the microglia were separated from the astroglia by shaking the flasks at 180 rpm for 1 h. The purity of the microglia-enriched cultures was >98%, as determined by immunocytochemical staining. The isolated microglia were plated on six-well plates, the cells were treated with LPS (100 ng/mL) in the presence or absence of compound <b>21</b> at 10 μM (added 1 h before LPS challenge) and then incubated for 3 h followed by the measurement of phosphorylated (p)-PTEN, p-Akt, and p-Src expression.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> RNAi</h3><div class="NLM_p last">To silence the <i>Src</i> gene using RNAi, the primary microglia or mixed mesencephalic neuronal/glial cultures were transfected with optimized concentrations of Src siRNA (Invitrogen, CA, USA). The transfections were performed using the lipofectamine RNAi MAX reagent (Invitrogen, CA, USA) and 25 nM of the appropriate siRNA according to the manufacturer’s instructions. The transfection medium was replaced with fresh DMEM/F-12 complete medium 4 h later. The microglia culture was incubated with compound <b>21</b>, followed by LPS (100 ng/mL), and then p-PTEN and p-Akt expression was measured 3 h later while IL-1β and TNF-α expressions were assayed 5 h later. The primary mixed midbrain neuronal/glial cultures were incubated with compound <b>21</b> and then treated with LPS (100 ng/mL), MPP<sup>+</sup> (30 μM), or α-syn (250 nM) 4 h later. The TH expression was measured 7 days later.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> In Vitro NO Production Assay</h3><div class="NLM_p last">The NO accumulation in the medium was assayed by measuring the production of nitrite (NO<sup>2–</sup>) using the Griess assay as described previously.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Enzyme-Linked Immunosorbent Assay (ELISA) of Cytokines</h3><div class="NLM_p last">Following the predetermined treatments, the cell culture media were collected and the IL-1β and TNF-α levels were detected. For cytokine assay of the brain tissue, the midbrain samples were homogenized with nondenaturing lysis buffer containing a protease inhibitor tease. IL-1β and TNF-α levels were subsequently measured using commercially available ELISA kits (R&D System, MN, USA) following the manufacturer’s instructions.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Western Blot Analysis</h3><div class="NLM_p last">The cells and midbrain were lysed in nondenaturing lysis buffer and the immunoblotting was performed as described previously.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The blot was developed using the LAS3000 chemiluminescence system (Fujifilm, Tokyo, Japan), and the densities of the bands were determined using the Gel-Pro Analyzer 4.0 software.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Pharmacokinetic Analysis</h3><div class="NLM_p last">Male ICR mice weighing 22–25 g (Animal Center of the Chinese Academy of Medical Sciences) were intragastrically administered compounds <b>2</b>, <b>21</b>, <b>23</b>, and <b>44</b>, each at a single dose of 50 mg/kg after a 16 h fast. Then blood samples and brain tissue were collected at 5, 15, and 30 min, and 1, 2, 4, and 8 h after dosing, following decapitation of the animal. All experimental procedures were performed in accordance with the guidelines of the Beijing Municipal Ethics Committee for the Care and Use of Laboratory Animals. The plasma was prepared by centrifuging the blood at 4000 rpm for 5 min. The brains were homogenized with saline, centrifuged at 12000 rpm for 25 min, and then a 5 μL aliquot of the plasma or brain extract was injected into the liquid chromatography/tandem mass spectrometry (LC/MS/MS) system on an Agilent 6890 gas chromatography (GC) apparatus (Agilent Corp., CA, USA). For the detection of compounds <b>21</b> and <b>23</b>, an isocratic chromatographic procedure was used with a mobile phase of 70% acetonitrile (1% trifluoroacetic acid) and 30% water (H<sub>2</sub>O) at a flow rate of 0.2 mL/min. The chromatographic procedure was performed using the CAPCELL PAK C18 column (2.1 mm × 100 mm, 5 μm) at 30 °C. Compounds <b>2</b> and <b>44</b> were detected using the Zorbax C18 column (2.1 mm × 50 mm, 3.5 μm) at 30 °C, and the mobile phase was 70% acetonitrile (1% trifluoroacetic acid) and 30% H<sub>2</sub>O at a flow rate of 0.2 mL/min.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> hERG Safety Assay</h3><div class="NLM_p last">The whole-cell voltage clamp analysis was performed using an internal solution of potassium chloride (KCl) 130 mM, magnesium chloride (MgCl<sub>2</sub>) 1 mM, ethylene glycol tetraacetic acid (EGTA) 5 mM, adenosine triphosphate (ATP)-Mg 5 mM, and HEPES 10 mM (pH 7.2). The external bath solution consisted of sodium chloride (NaCl) 137 mM, calcium chloride (CaCl<sub>2</sub>) 1.8 mM, KCl 4 mM, MgCl<sub>2</sub> 1 mM, glucose 5 mM, and HEPES 10 mM (pH 7.4). The potassium current (<i>I</i><sub>K</sub>) was elicited from a holding potential of −70 mV using 2 s long depolarizing steps to 50 mV applied in 10 mV increments every 15 s, while the tail current (Itail) was recorded using a step to −40 from +50 mV for 2 s using an EPC10 amplifier (Heka Instruments). The current signals were filtered at 2 kHz and digitized using an AD-DA converter for subsequent analysis with the PulseFit software ver. 8.74. The <i>I</i><sub>K</sub> and <i>I</i><sub>tail</sub> were measured at the end of and the beginning of the depolarizing and repolarizing pulses, respectively.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> In Vivo Toxicity Assessment</h3><div class="NLM_p last">ICR mice (Animal Center of the Chinese Academy of Medical Sciences) weighing 22–25 g were used. The mice were treated with compounds <b>2</b> and <b>21</b> via oral gavage each at 250, 500, and 1000 mg/kg for 14 consecutive days. In addition to regular monitoring of the animal’s general condition, the clinical chemistry of the liver and kidney were assessed. The experimental procedures were performed in accordance with the guidelines of the Beijing Municipal Ethics Committee for the Care and Use of Laboratory Animals.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Establishment of PD Mouse Models and Drug Administrations</h3><div class="NLM_p last">Male C57/BL mice (Animal Center of the Chinese Academy of Medical Sciences) weighing 22–25 g were used to establish the MPTP- and MPTP/prob-induced PD models. Male B6; C3H mice overexpressing mutant α-syn (A53T) were supplied by the Model Animal Research Center of Nanjing University and were maintained on a 12 h light/dark cycle at 24 °C in a room with a relative humidity of 60%. Furthermore, the animals were provided with food and water ad libitum and allowed to adapt to the conditions described above for 1 week before the experimentation. In the subacute PD model, MPTP (30 mg/kg of MPTP hydrochloride, intraperitoneally, ip) was injected into the mice consecutively for 5 days. Compound <b>21</b> (5, 10, and 20 mg/kg) and L-DOPA (20 mg/kg) suspended in 0.5% CMC-Na were administered 30 min before each MPTP injection, and after the last injection of MPTP, the compounds were continually administered to the mice for the next 7 days. In the chronic study, the mice were administered 10 doses of MPTP hydrochloride (25 mg/kg in saline, sc) in combination with probenecid (250 mg/kg in DMSO, ip). The 10 doses were administered on a 5-week schedule. After the last MPTP/prob injection, the mice were subjected to the rotarod behavioral test. Only those showing behavioral dysfunction were used in the subsequent experiments. Then, the mice were randomly divided into the MPTP/prob-, compound <b>21</b>- (5, 10, and 20 mg/kg), and L-DOPA-treated groups. Compound <b>21</b> and L-DOPA were administered to mice once a day for 7 weeks. In the α-syn (A53T) transgenic mice, compound <b>21</b> and L-DOPA were administered once a day for 12 consecutive weeks, which commenced when they were 4 months old. All experiments were performed in accordance with the guidelines of the Beijing Municipal Ethics Committee for the Care and Use of Laboratory Animals.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Rotarod Test</h3><div class="NLM_p last">The rotarod test, which requires animals to balance and walk on a rotating cylinder, is used to measure coordinated motor skills. The mice were positioned on the rotarod, which was then set to revolve at 14 rpm for up to 120 s. The rotarod automatically recorded the time when the animals first fell off the rod, which was designated as the latency. The mice were tested thrice, and the latency was recorded each time. The animals were allowed to rest for 1 h between each trial.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Pole Test</h3><div class="NLM_p last">The pole test was originally used to evaluate bradykinesia in PD mice. The pole used in this study was constructed of wood with height and diameter of 50 and 3 cm, respectively, and wrapped in gauze to prevent slipping while the base was positioned in the home cage. A wooden ball was glued to the top of the pole to prevent animals from sitting there and to help position the animals on the pole. The performance of the mice while they descended the pole was then scored, with 5 and 1 as the highest and lowest scores, respectively. If the mouse did not descend within 60 s, it was guided down. The mice were pretrained before the experimentation, and they each performed two successive trials, with a 1 h interval between the trials.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Histochemical Analysis</h3><div class="NLM_p last">The TH immunohistochemical analysis was performed as previously described.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Briefly, the brains of the mice were fixed and cut into 40 μm sections using a freezing microtome and the coronal sections through the substantia nigra were processed. The sections were incubated with primary antibodies against TH (Abcam, MA, USA) and the labeled proteins were visualized using 0.04% hydrogen peroxidase and 0.05% 3,3′-diaminobenzidine. The sections were observed using a light microscope (NIKON E600, Japan), and the number of positively stained cells in each group was recorded. All quantifications were performed blindly.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Striatal Dopamine Analysis</h3><div class="NLM_p last">The mouse striatal dopamine was analyzed using HPLC as described previously.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Briefly, the striatum was suspended in 0.6N perchloric acid, sonicated, and then centrifuged. Potassium dihydrogen phosphate solution consisting of potassium citrate 20 mM, potassium dihydrogen phosphate 300 mM, and ethylenediaminetetraacetic acid (EDTA)·Na<sub>2</sub> (2 mmol) were added to the supernatant and centrifuged. An aliquot of the supernatant was subsequently analyzed using an HPLC system (Waters, MA, USA).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Statistical Analysis</h3><div class="NLM_p last">The data were expressed as mean ± SD and were analyzed using a one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test. <i>P</i> < 0.05 was considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00976">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27851" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27851" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00976" class="ext-link">10.1021/acs.jmedchem.6b00976</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR (<sup>1</sup>H and <sup>13</sup>C) spectra of all target compounds, HPLC analysis of compounds, proteomics studies (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Proteomics data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_002.xlsx" class="ext-link">XLSX</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_001.pdf">jm6b00976_si_001.pdf (1.89 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_002.xlsx">jm6b00976_si_002.xlsx (521.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_003.csv">jm6b00976_si_003.csv (5.27 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00976" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Zhang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d3b7b2bda9bbb2bdb493babebefdb2b0fdb0bd"><span class="__cf_email__" data-cfemail="7b1f1a1501131a151c3b121616551a18551815">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shi-Shan Yu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#621b17110a0b110a030c220b0f0f4c03014c010c"><span class="__cf_email__" data-cfemail="8af3fff9e2e3f9e2ebe4cae3e7e7a4ebe9a4e9e4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Dan Wang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiu-Qi Bao</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Song Xu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Wen Yu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng-Nan Cao</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin-Ping Hu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Li</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-Liang Wang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia
Medica, Chinese Academy of Medical Sciences
and Peking Union Medical College, No. 1 Xian Nong Tan Street, Beijing 100050, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.W. and X.B. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d104e6278-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge financial support from the Natural Science Foundation of China (no. 201072234 and no. 21132009), and the National Science and Technology Project of China (grant no. 2012ZX09301002-002).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i92" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i92"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i93" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i93"> Abbreviations Used</h2><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">MPTP</td><td class="NLM_def"><p class="first last">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p></td></tr><tr><td class="NLM_term">LD<sub>50</sub></td><td class="NLM_def"><p class="first last">median lethal dose</p></td></tr><tr><td class="NLM_term">COMT</td><td class="NLM_def"><p class="first last">catechol-<i>O</i>-methyl-transferase</p></td></tr><tr><td class="NLM_term">MAO-B</td><td class="NLM_def"><p class="first last">monoamine oxidase type B</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">NSAIDs</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">MOM</td><td class="NLM_def"><p class="first last">methoxymethyl</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">Gly</td><td class="NLM_def"><p class="first last">glycine</p></td></tr><tr><td class="NLM_term">Ala</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">Ser</td><td class="NLM_def"><p class="first last">serine</p></td></tr><tr><td class="NLM_term">Asp</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">Glu</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">Phe</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term">His</td><td class="NLM_def"><p class="first last">histidine</p></td></tr><tr><td class="NLM_term">IL-1β</td><td class="NLM_def"><p class="first last">interleukin-1β</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor-α</p></td></tr><tr><td class="NLM_term">GAPDH</td><td class="NLM_def"><p class="first last">glyceraldehyde 3-phosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">TH</td><td class="NLM_def"><p class="first last">tyrosine hydroxylase</p></td></tr><tr><td class="NLM_term">CMC-Na</td><td class="NLM_def"><p class="first last">sodium carboxymethylcellulose</p></td></tr><tr><td class="NLM_term">prob</td><td class="NLM_def"><p class="first last">probenecid</p></td></tr><tr><td class="NLM_term">syn</td><td class="NLM_def"><p class="first last">synuclein</p></td></tr><tr><td class="NLM_term">iTRAQ</td><td class="NLM_def"><p class="first last">isobaric tags for relative and absolute quantification</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue deleted on chromosome 10</p></td></tr><tr><td class="NLM_term">NOS</td><td class="NLM_def"><p class="first last">NO synthase</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">GSK3</td><td class="NLM_def"><p class="first last">glycogen synthase kinase-3</p></td></tr><tr><td class="NLM_term">CK2</td><td class="NLM_def"><p class="first last">casein kinase 2</p></td></tr><tr><td class="NLM_term">LKB1</td><td class="NLM_def"><p class="first last">liver kinase B1</p></td></tr><tr><td class="NLM_term">GTPases</td><td class="NLM_def"><p class="first last">guanosine triphosphatases</p></td></tr><tr><td class="NLM_term">ROCK1</td><td class="NLM_def"><p class="first last">Rho-associated protein kinase 1</p></td></tr><tr><td class="NLM_term">ARHGAP21</td><td class="NLM_def"><p class="first last">Rho guanosine triphosphatases activating protein 21</p></td></tr><tr><td class="NLM_term">MPP+</td><td class="NLM_def"><p class="first last">1-methyl-4-phenylpyridinium ion</p></td></tr><tr><td class="NLM_term">CC</td><td class="NLM_def"><p class="first last">column chromatography</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s Modified Eagle Medium</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">MEM</td><td class="NLM_def"><p class="first last">minimal essential medium</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethylene glycol tetraacetic acid</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">SARs</td><td class="NLM_def"><p class="first last">structure−activity relationships</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lozano, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostrovsky, J. O.</span><span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson’s disease and in its treatment</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span><span class="refDoi"> DOI: 10.1016/S0959-4388(98)80122-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2FS0959-4388%2898%2980122-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%E2%80%99s+disease+and+in+its+treatment&doi=10.1016%2FS0959-4388%2898%2980122-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2898%2980122-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252898%252980122-0%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790%26doi%3D10.1016%2FS0959-4388%2898%2980122-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ferreira, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares-da-Silva, P.</span><span> </span><span class="NLM_article-title">Effect of opicapone on levodopa pharmacokinetics, catechol-<i>O</i>-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease</span> <span class="citation_source-journal">Eur. J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">825</span><span class="refDoi"> DOI: 10.1111/ene.12666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1111%2Fene.12666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=25649051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=815-825&author=J.+J.+Ferreiraauthor=J.+F.+Rochaauthor=A.+Falcaoauthor=A.+Santosauthor=R.+Pintoauthor=T.+Nunesauthor=P.+Soares-da-Silva&title=Effect+of+opicapone+on+levodopa+pharmacokinetics%2C+catechol-O-methyltransferase+activity+and+motor+fluctuations+in+patients+with+Parkinson%E2%80%99s+disease&doi=10.1111%2Fene.12666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease</span></div><div class="casAuthors">Ferreira J J; Rocha J-F; Falcao A; Santos A; Pinto R; Nunes T; Soares-da-Silva P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-25, e56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Opicapone (OPC) is a novel third generation catechol-O-methyltransferase (COMT) inhibitor that enhances levodopa availability.  This study investigated the effects of OPC in comparison with placebo on levodopa pharmacokinetics, tolerability and safety, COMT activity and motor response to levodopa in Parkinson's disease (PD) patients with motor fluctuations.  METHODS:  This was a randomized, multicentre, double-blind and placebo-controlled study in four parallel groups of PD patients treated with standard-release 100/25 mg levodopa/carbidopa or levodopa/benserazide and with motor fluctuations (wearing-OFF phenomenon).  Subjects were sequentially assigned to be administered, once-daily, up to 28 days (maintenance phase), placebo (n = 10) or 5 (n = 10), 15 (n = 10) and 30 mg (n = 10) OPC.  Two levodopa tests were performed, one at baseline and another following the maintenance phase.  Subjects kept a diary to record motor fluctuations (ON/OFF periods) throughout the study.  RESULTS:  In relation to placebo, levodopa exposure (AUC0-6) increased 24.7%, 53.9% and 65.6% following 5, 15 and 30 mg OPC, respectively.  Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).  The study was not designed to detect any significant differences in motor performance, but the exploratory analysis performed shows improvement in various motor outcomes, including a dose-dependent change in absolute OFF time corresponding to a percentage decrease of 4.16% (P > 0.05), 29.55% (P > 0.05) and 32.71% (P < 0.05) with 5, 15 and 30 mg OPC, respectively.  Treatments were generally well tolerated and safe.  CONCLUSIONS:  OPC is a promising new COMT inhibitor that significantly decreased COMT activity, increased systemic exposure to levodopa and improved motor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEuvMtwfdhHOQ4Pl9hzjQhfW6udTcc2ebnU3RVpkoMArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D&md5=7b33ae752bc6ace3867a38b8f9e6e9c8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fene.12666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fene.12666%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%2BJ.%26aulast%3DRocha%26aufirst%3DJ.%2BF.%26aulast%3DFalcao%26aufirst%3DA.%26aulast%3DSantos%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DR.%26aulast%3DNunes%26aufirst%3DT.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DEffect%2520of%2520opicapone%2520on%2520levodopa%2520pharmacokinetics%252C%2520catechol-O-methyltransferase%2520activity%2520and%2520motor%2520fluctuations%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2015%26volume%3D22%26spage%3D815%26epage%3D825%26doi%3D10.1111%2Fene.12666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Schapira, A. H.</span><span> </span><span class="NLM_article-title">Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.2165/11596310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.2165%2F11596310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=22133327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+Schapira&title=Monoamine+oxidase+B+inhibitors+for+the+treatment+of+Parkinson%E2%80%99s+disease%3A+a+review+of+symptomatic+and+potential+disease-modifying+effects&doi=10.2165%2F11596310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects</span></div><div class="casAuthors">Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1061-1071</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease is a disorder characterized pathol. by progressive neurodegeneration of the dopaminergic cells of the nigrostriatal pathway.  Although the resulting dopamine deficiency is the cause of the typical motor features of Parkinson's disease (bradykinesia, rigidity, tremor), addnl. non-motor symptoms appear at various timepoints and are the result of non-dopamine nerve degeneration.  Monoamine oxidase B (MAO-B) inhibitors are used in the symptomatic treatment of Parkinson's disease as they increase synaptic dopamine by blocking its degrdn.  Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson's disease and to reduce off-time in patients with more advanced Parkinson's disease and motor fluctuations related to levodopa.  A third MAO-B inhibitor (safinamide), which also combines addnl. non-dopaminergic properties of potential benefit to Parkinson's disease, is currently under development in phase III clin. trials as adjuvant therapy to either a dopamine agonist or levodopa.  MAO-B inhibitors have also been studied extensively for possible neuroprotective or disease-modifying actions.  There is considerable lab. evidence that MAO-B inhibitors do exert some neuroprotective properties, at least in the Parkinson's disease models currently available.  However, these models have significant limitations and caution is required in assuming that such results may easily be extrapolated to clin. trials.  Rasagiline 1 mg/day has been shown to provide improved motor control in terms of Unified Parkinson's Disease Rating Scale (UPDRS) score at 18 mo in those patients with early disease who began the drag 9 mo before a second group.  There are a no. of possible explanations for this effect that may include a disease-modifying action; however, the US FDA recently declined an application for the licence of rasagiline to be extended to cover disease modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AHDUDO6Ch7Vg90H21EOLACvtfcHk0lh74PyfT4Wfgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D&md5=a6c6a9380eaa9056a877fa0df9e39446</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2165%2F11596310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26atitle%3DMonoamine%2520oxidase%2520B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520of%2520symptomatic%2520and%2520potential%2520disease-modifying%2520effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071%26doi%3D10.2165%2F11596310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Huot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koprich, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piggott, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brotchie, J. M.</span><span> </span><span class="NLM_article-title">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuropharm.2014.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=24447715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=76-87&author=P.+Huotauthor=T.+H.+Johnstonauthor=K.+D.+Lewisauthor=J.+B.+Koprichauthor=M.+G.+Reyesauthor=S.+H.+Foxauthor=M.+J.+Piggottauthor=J.+M.+Brotchie&title=UWA-121%2C+a+mixed+dopamine+and+serotonin+re-uptake+inhibitor%2C+enhances+L-DOPA+anti-parkinsonian+action+without+worsening+dyskinesia+or+psychosis-like+behaviours+in+the+MPTP-lesioned+common+marmoset&doi=10.1016%2Fj.neuropharm.2014.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span></div><div class="casAuthors">Huot, Philippe; Johnston, Tom H.; Lewis, Katie D.; Koprich, James B.; Reyes, M. Gabriela; Fox, Susan H.; Piggott, Matthew J.; Brotchie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-87</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease (PD), but its long-term administration is complicated by wearing-off and dyskinesia.  UWA-101, a dual, equipotent inhibitor of dopamine (DAT) and serotonin (SERT) transporters, has previously been shown to successfully extend duration of anti-parkinsonian benefit of L-DOPA (ON-time), without exacerbating dyskinesia, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset.  However, UWA-101 is racemic and it is unclear whether one or both enantiomers contribute to its actions, and whether a better therapeutic effect might be attained by using a single antipode.  In the current study, we synthesized the two enantiomers of UWA-101, R-101 (UWA-121) and S-101 (UWA-122), characterized their pharmacol. profiles and administered them to MPTP-lesioned marmosets.  Parkinsonism, dyskinesia, psychosis-like behaviors and duration of ON-time were evaluated.  UWA-121 is a dual DAT > SERT inhibitor, with an approx. 10:1 DAT:SERT affinity ratio (inhibitory consts. (Ki) of 307 and 3830 nM, resp.).  In combination with L-DOPA, UWA-121 extended duration of ON-time when compared to L-DOPA/vehicle treatment (by 40%, P < 0.01).  UWA-121 also extended duration of ON-time without dyskinesia (by 215%, P < 0.05) and ON-time without psychosis-like behaviors when compared to L-DOPA/vehicle treatment (by 345%, P < 0.01).  UWA-121 did not worsen the severity of dyskinesia or psychosis-like behaviors (P > 0.05).  UWA-122 is a selective SERT inhibitor (Ki 120 nM, Ki at DAT > 50 μM) and, in combination with L-DOPA, had no effect on ON-time, dyskinesia or psychosis-like behaviors (P > 0.05).  These data indicate that dual DAT and SERT inhibitors effectively enhance L-DOPA anti-parkinsonian action without worsening dyskinesia and that compds. with such a pharmacol. profile represent promising agents against wearing-off in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbiBB5fc-TBrVg90H21EOLACvtfcHk0lheNhVYTMeqiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D&md5=2c88b90b665cabea18d5116c44878d9b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHuot%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DT.%2BH.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DKoprich%26aufirst%3DJ.%2BB.%26aulast%3DReyes%26aufirst%3DM.%2BG.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DPiggott%26aufirst%3DM.%2BJ.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26atitle%3DUWA-121%252C%2520a%2520mixed%2520dopamine%2520and%2520serotonin%2520re-uptake%2520inhibitor%252C%2520enhances%2520L-DOPA%2520anti-parkinsonian%2520action%2520without%2520worsening%2520dyskinesia%2520or%2520psychosis-like%2520behaviours%2520in%2520the%2520MPTP-lesioned%2520common%2520marmoset%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D76%26epage%3D87%26doi%3D10.1016%2Fj.neuropharm.2014.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H.</span><span> </span><span class="NLM_article-title">Dopamine agonists in Parkinson’s disease</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1586/14737175.8.4.671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1586%2F14737175.8.4.671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=18416667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=671-677&author=M.+Yamamotoauthor=A.+H.+Schapira&title=Dopamine+agonists+in+Parkinson%E2%80%99s+disease&doi=10.1586%2F14737175.8.4.671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists in Parkinson's disease</span></div><div class="casAuthors">Yamamoto, Mitsutoshi; Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course.  As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications.  As an adjunct to levodopa, they improve motor control and limit the need for levodopa in those patients in whom this may be considered relevant.  The non-ergot dopamine agonists in particular have a good safety profile, although as with other agonists, sedation, and cognitive and behavioral problems may be limiting in some patients.  Pramipexole has shown benefit in improving depressive symptoms in PD.  Ropinirole and pramipexole have both demonstrated a redn. in the rate of loss of nigrostriatal innervation as detd. by imaging in PD patients, when compared with levodopa.  Thus, dopamine agonists contribute to several dimensions of the management of PD and have become an integral part of the disease treatment algorithm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVM_IekUXprVg90H21EOLACvtfcHk0lheNhVYTMeqiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D&md5=9a145ab9c49de374322fb02fe543d4ad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1586%2F14737175.8.4.671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.8.4.671%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520agonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2008%26volume%3D8%26spage%3D671%26epage%3D677%26doi%3D10.1586%2F14737175.8.4.671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Henchcliffe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severt, W. L.</span><span> </span><span class="NLM_article-title">Disease modification in Parkinson’s disease</span> <span class="citation_source-journal">Drugs Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.2165/11591320-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.2165%2F11591320-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=21812497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1CltLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=605-615&author=C.+Henchcliffeauthor=W.+L.+Severt&title=Disease+modification+in+Parkinson%E2%80%99s+disease&doi=10.2165%2F11591320-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Disease modification in Parkinson's disease</span></div><div class="casAuthors">Henchcliffe, Claire; Severt, W. Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">605-615</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is an age-related, progressive, multisystem neurodegenerative disorder resulting in significant morbidity and mortality, as well as a growing social and financial burden in an aging population.  The hallmark of PD is loss of dopaminergic neurons of the substantia nigra pars compacta, leading to bradykinesia, rigidity and tremor.  Current pharmacol. treatment is therefore centered upon dopamine replacement to alleviate symptoms.  However, two major problems complicate this approach: (i) motor symptoms continue to progress, requiring increasing doses of medication, which result in both short-term adverse effects and intermediate- to long-term motor complications; (ii) dopamine replacement does little to treat non-dopaminergic motor and non-motor symptoms, which are an important source of morbidity, including dementia, sleep disturbances, depression, orthostatic hypotension, and postural instability leading to falls.  It is crit., therefore, to develop a broader and more fundamental therapeutic approach to PD, and major research efforts have focused upon developing neuroprotective interventions.  Despite many encouraging preclin. data suggesting the possibility of addressing the underlying pathophysiol. by slowing cell loss, efforts to translate this into the clin. realm have largely proved disappointing in the past.  Barriers to finding neuroprotective or disease-modifying drugs in PD include a lack of validated biomarkers of progression, which hampers clin. trial design and interpretation; difficulties sepg. symptomatic and neuroprotective effects of candidate neuroprotective therapies; and possibly fundamental flaws in some of the basic preclin. models and testing.  However, three recent clin. trials have used a novel delayed-start design in an attempt to overcome some of these roadblocks.  While not examg. markers of cell loss and function, which would det. neuroprotective effects, this trial design pragmatically tests whether earlier vs. later intervention is beneficial.  If pos. (i.e. if an earlier intervention proves more effective), this demonstrates disease modification, which could result from neuroprotection or from other mechanisms.  This strategy therefore provides a first step towards supporting neuroprotection in PD.  Of the three delayed-start design clin. trials, two have investigated early vs. later start of rasagiline, a specific irreversible monoamine oxidase B inhibitor.  Each trial has supported, although not proven, disease-modifying effects.  A third delayed-start-design clin. trial examg. potential disease-modifying effects of pramipexole has unfortunately reportedly been neg. according to preliminary presentations.  The suggestion that rasagiline is disease modifying is made all the more compelling by in vitro and PD animal-model studies in which rasagiline was shown to have neuroprotective effects.  In this review, we examine efforts to demonstrate neuroprotection in PD to date, describe ongoing neuroprotection trials, and critically discuss the results of the most recent delayed-start clin. trials that test possible disease-modifying activities of rasagiline and pramipexole in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbdflLyDbbWLVg90H21EOLACvtfcHk0lj63OsBxCfpSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1CltLfP&md5=3c3dbd364d7b2632eb1aedea1bd4b8a3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2165%2F11591320-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11591320-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DHenchcliffe%26aufirst%3DC.%26aulast%3DSevert%26aufirst%3DW.%2BL.%26atitle%3DDisease%2520modification%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%2520Aging%26date%3D2011%26volume%3D28%26spage%3D605%26epage%3D615%26doi%3D10.2165%2F11591320-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Shoulson, I.</span><span> </span><span class="NLM_article-title">DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">S160</span><span class="NLM_x">–</span> <span class="NLM_lpage">S166</span><span class="refDoi"> DOI: 10.1002/ana.410440724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1002%2Fana.410440724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1998&pages=S160-S166&author=I.+Shoulson&title=DATATOP%3A+a+decade+of+neuroprotective+inquiry.+Parkinson+Study+Group.+Deprenyl+And+Tocopherol+Antioxidative+Therapy+Of+Parkinsonism&doi=10.1002%2Fana.410440724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fana.410440724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410440724%26sid%3Dliteratum%253Aachs%26aulast%3DShoulson%26aufirst%3DI.%26atitle%3DDATATOP%253A%2520a%2520decade%2520of%2520neuroprotective%2520inquiry.%2520Parkinson%2520Study%2520Group.%2520Deprenyl%2520And%2520Tocopherol%2520Antioxidative%2520Therapy%2520Of%2520Parkinsonism%26jtitle%3DAnn.%2520Neurol.%26date%3D1998%26volume%3D44%26spage%3DS160%26epage%3DS166%26doi%3D10.1002%2Fana.410440724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Athauda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foltynie, T.</span><span> </span><span class="NLM_article-title">The ongoing pursuit of neuroprotective therapies in Parkinson disease</span> <span class="citation_source-journal">Nat. Rev. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1038/nrneurol.2014.226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1038%2Fnrneurol.2014.226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=25447485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVemsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=25-40&author=D.+Athaudaauthor=T.+Foltynie&title=The+ongoing+pursuit+of+neuroprotective+therapies+in+Parkinson+disease&doi=10.1038%2Fnrneurol.2014.226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ongoing pursuit of neuroprotective therapies in Parkinson disease</span></div><div class="casAuthors">Athauda, Dilan; Foltynie, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the lab., but none have translated to pos. results in patients with PD.  Potential neuroprotective drugs, such as ubiquinone, creatine and PYM50028, have failed to show any clin. benefits in recent high-profile clin. trials.  This 'failure to translate' is likely to be related primarily to our incomplete understanding of the pathogenic mechanisms underlying PD, and excessive reliance on data from toxin-based animal models to judge which agents should be selected for clin. trials.  Restricted resources inevitably mean that difficult compromises must be made in terms of trial design, and reliable estn. of efficacy is further hampered by the absence of validated biomarkers of disease progression.  Drug development in PD dementia has been mostly unsuccessful; however, emerging biochem., genetic and pathol. evidence suggests a link between tau and amyloid-β deposition and cognitive decline in PD, potentially opening up new possibilities for therapeutic intervention.  This Review discusses the most important 'druggable' disease mechanisms in PD, as well as the most-promising drugs that are being evaluated for their potential efficiency in treatment of motor and cognitive impairments in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo41alEY9yuaLVg90H21EOLACvtfcHk0lj63OsBxCfpSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVemsr%252FJ&md5=ee355c45e894609afff392f4b1e1a73e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2014.226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2014.226%26sid%3Dliteratum%253Aachs%26aulast%3DAthauda%26aufirst%3DD.%26aulast%3DFoltynie%26aufirst%3DT.%26atitle%3DThe%2520ongoing%2520pursuit%2520of%2520neuroprotective%2520therapies%2520in%2520Parkinson%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2015%26volume%3D11%26spage%3D25%26epage%3D40%26doi%3D10.1038%2Fnrneurol.2014.226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Dauer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Przedborski, S.</span><span> </span><span class="NLM_article-title">Parkinson’s disease: mechanisms and models</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">889</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span><span class="refDoi"> DOI: 10.1016/S0896-6273(03)00568-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2FS0896-6273%2803%2900568-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=12971891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsFait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2003&pages=889-909&author=W.+Dauerauthor=S.+Przedborski&title=Parkinson%E2%80%99s+disease%3A+mechanisms+and+models&doi=10.1016%2FS0896-6273%2803%2900568-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease: Mechanisms and models</span></div><div class="casAuthors">Dauer, William; Przedborski, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">889-909</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.  Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration.  The main obstacle to developing neuroprotective therapies is a limited understanding of the key mol. events that provoke neurodegeneration.  The discovery of PD genes has led to the hypothesis that misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis.  Previously implicated culprits in PD neurodegeneration, mitochondrial dysfunction and oxidative stress, may also act in part by causing the accumulation of misfolded proteins, in addn. to producing other deleterious events in dopaminergic neurons.  Neurotoxin-based models (particularly MPTP) have been important in elucidating the mol. cascade of cell death in dopaminergic neurons.  PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplIXMcN4C-ILVg90H21EOLACvtfcHk0lj1LK-YktRxrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsFait7o%253D&md5=70b4b771da04f6e879e9de431fce2d47</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2803%2900568-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252803%252900568-3%26sid%3Dliteratum%253Aachs%26aulast%3DDauer%26aufirst%3DW.%26aulast%3DPrzedborski%26aufirst%3DS.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%253A%2520mechanisms%2520and%2520models%26jtitle%3DNeuron%26date%3D2003%26volume%3D39%26spage%3D889%26epage%3D909%26doi%3D10.1016%2FS0896-6273%2803%2900568-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Gao, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J. S.</span><span> </span><span class="NLM_article-title">Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression</span> <span class="citation_source-journal">Trends Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1016/j.it.2008.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.it.2008.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=18599350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVCit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=357-365&author=H.+M.+Gaoauthor=J.+S.+Hong&title=Why+neurodegenerative+diseases+are+progressive%3A+uncontrolled+inflammation+drives+disease+progression&doi=10.1016%2Fj.it.2008.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression</span></div><div class="casAuthors">Gao, Hui-Ming; Hong, Jau-Shyong</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases are a group of chronic, progressive disorders characterized by the gradual loss of neurons in discrete areas of the central nervous system (CNS).  The mechanism(s) underlying their progressive nature remains unknown but a timely and well-controlled inflammatory reaction is essential for the integrity and proper function of the CNS.  Substantial evidence has documented a common inflammatory mechanism in various neurodegenerative diseases.  The authors hypothesize that in the diseased CNS, interactions between damaged neurons and dysregulated, overactivated microglia create a vicious self-propagating cycle causing uncontrolled, prolonged inflammation that drives the chronic progression of neurodegenerative diseases.  The authors further propose that dynamic modulation of this inflammatory reaction by interrupting the vicious cycle might become a disease-modifying therapeutic strategy for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGricPNjQBzPq7Vg90H21EOLACvtfcHk0lj1LK-YktRxrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVCit7w%253D&md5=b010045df3f5e1cc52e759e97773eb23</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2008.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2008.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.%2BM.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26atitle%3DWhy%2520neurodegenerative%2520diseases%2520are%2520progressive%253A%2520uncontrolled%2520inflammation%2520drives%2520disease%2520progression%26jtitle%3DTrends%2520Immunol.%26date%3D2008%26volume%3D29%26spage%3D357%26epage%3D365%26doi%3D10.1016%2Fj.it.2008.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y. P.</span><span> </span><span class="NLM_article-title">Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss</span> <span class="citation_source-journal">Brain, Behav., Immun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1016/j.bbi.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.bbi.2015.08.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=131-143&author=Z.+Liuauthor=H.+Q.+Chenauthor=Y.+Huangauthor=Y.+H.+Qiuauthor=Y.+P.+Peng&title=Transforming+growth+factor-%CE%B21+acts+via+T%CE%B2R-I+on+microglia+to+protect+against+MPP%28%2B%29-induced+dopaminergic+neuronal+loss&doi=10.1016%2Fj.bbi.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.%2BQ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DY.%2BP.%26atitle%3DTransforming%2520growth%2520factor-%25CE%25B21%2520acts%2520via%2520T%25CE%25B2R-I%2520on%2520microglia%2520to%2520protect%2520against%2520MPP%2528%252B%2529-induced%2520dopaminergic%2520neuronal%2520loss%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2016%26volume%3D51%26spage%3D131%26epage%3D143%26doi%3D10.1016%2Fj.bbi.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Van der Perren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toelen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Loor, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuypers, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gijsbers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Haute, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debyser, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baekelandt, V.</span><span> </span><span class="NLM_article-title">FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson’s disease</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1568</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2015.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neurobiolaging.2015.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=25660193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsValur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1559-1568&author=A.+Van+der+Perrenauthor=F.+Macchiauthor=J.+Toelenauthor=M.+S.+Carlonauthor=M.+Marisauthor=H.+de+Loorauthor=D.+R.+Kuypersauthor=R.+Gijsbersauthor=C.+Van+den+Hauteauthor=Z.+Debyserauthor=V.+Baekelandt&title=FK506+reduces+neuroinflammation+and+dopaminergic+neurodegeneration+in+an+%CE%B1-synuclein-based+rat+model+for+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neurobiolaging.2015.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease</span></div><div class="casAuthors">Van der Perren, Anke; Macchi, Francesca; Toelen, Jaan; Carlon, Marianne S.; Maris, Michael; de Loor, Henriette; Kuypers, Dirk R. J.; Gijsbers, Rik; Van den Haute, Chris; Debyser, Zeger; Baekelandt, Veerle</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1559-1568</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Alpha-synuclein (α-synuclein) is considered a key player in Parkinson's disease (PD), but the exact relationship between α-synuclein aggregation and dopaminergic neurodegeneration remains unresolved.  There is increasing evidence that neuroinflammatory processes are closely linked to dopaminergic cell death, but whether the inflammatory process is causally involved in PD or rather reflects secondary consequences of nigrostriatal pathway injury is still under debate.  We evaluated the therapeutic effect of the immunophilin ligand FK506 in a rAAV2/7 α-synuclein overexpression rat model.  Treatment with FK506 significantly increased the survival of dopaminergic neurons in a dose-dependent manner.  No redn. in α-synuclein aggregation was apparent in this time window, but FK506 significantly lowered the infiltration of both T helper and cytotoxic T cells and the no. and subtype of microglia and macrophages.  These data suggest that the anti-inflammatory properties of FK506 decrease neurodegeneration in this α-synuclein-based PD model, pointing to a causal role of neuroinflammation in the pathogenesis of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8mqw94W43hLVg90H21EOLACvtfcHk0lgE1ToKsoF36g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsValur4%253D&md5=cb80dcd06868a5c49165dabac76a505b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2015.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2015.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BPerren%26aufirst%3DA.%26aulast%3DMacchi%26aufirst%3DF.%26aulast%3DToelen%26aufirst%3DJ.%26aulast%3DCarlon%26aufirst%3DM.%2BS.%26aulast%3DMaris%26aufirst%3DM.%26aulast%3Dde%2BLoor%26aufirst%3DH.%26aulast%3DKuypers%26aufirst%3DD.%2BR.%26aulast%3DGijsbers%26aufirst%3DR.%26aulast%3DVan%2Bden%2BHaute%26aufirst%3DC.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DBaekelandt%26aufirst%3DV.%26atitle%3DFK506%2520reduces%2520neuroinflammation%2520and%2520dopaminergic%2520neurodegeneration%2520in%2520an%2520%25CE%25B1-synuclein-based%2520rat%2520model%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2015%26volume%3D36%26spage%3D1559%26epage%3D1568%26doi%3D10.1016%2Fj.neurobiolaging.2015.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Neuroinflammation in Parkinson’s disease and its potential as therapeutic target</span> <span class="citation_source-journal">Transl. Neurodegener.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="refDoi"> DOI: 10.1186/s40035-015-0042-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1186%2Fs40035-015-0042-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=26464797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVertLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=19&author=Q.+Wangauthor=Y.+Liuauthor=J.+Zhou&title=Neuroinflammation+in+Parkinson%E2%80%99s+disease+and+its+potential+as+therapeutic+target&doi=10.1186%2Fs40035-015-0042-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroinflammation in Parkinson's disease and its potential as therapeutic target</span></div><div class="casAuthors">Wang, Qinqin; Liu, Yingjun; Zhou, Jiawei</div><div class="citationInfo"><span class="NLM_cas:title">Translational Neurodegeneration</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19/1-19/9</span>CODEN:
                <span class="NLM_cas:coden">TNREAP</span>;
        ISSN:<span class="NLM_cas:issn">2047-9158</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD), the second most common age-assocd. neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-contg. aggregates in the substantia nigra pars compacta (SNpc).  Chronic neuroinflammation is one of the hallmarks of PD pathophysiol.  Post-mortem analyses of human PD patients and exptl. animal studies indicate that activation of glial cells and increases in pro-inflammatory factor levels are common features of the PD brain.  Chronic release of pro-inflammatory cytokines by activated astrocytes and microglia leads to the exacerbation of DA neuron degeneration in the SNpc.  Besides, peripheral immune system is also implicated in the pathogenesis of PD.  Infiltration and accumulation of immune cells from the periphery are detected in and around the affected brain regions of PD patients.  Moreover, inflammatory processes have been suggested as promising interventional targets for PD and even other neurodegenerative diseases.  A better understanding of the role of inflammation in PD will provide new insights into the pathol. processes and help to establish effective therapeutic strategies.  In this review, we will summarize recent progresses in the neuroimmune aspects of PD and highlight the potential therapeutic interventions targeting neuroinflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOtqPaQIjWM7Vg90H21EOLACvtfcHk0lgE1ToKsoF36g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVertLw%253D&md5=544927d85363f153b7469b1f59ac7069</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs40035-015-0042-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40035-015-0042-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DNeuroinflammation%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520its%2520potential%2520as%2520therapeutic%2520target%26jtitle%3DTransl.%2520Neurodegener.%26date%3D2015%26volume%3D4%26spage%3D19%26doi%3D10.1186%2Fs40035-015-0042-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Bartels, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemsen, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doorduin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dierckx, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, K. L.</span><span> </span><span class="NLM_article-title">[11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease?</span> <span class="citation_source-journal">Parkinsonism Relat. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1016/j.parkreldis.2009.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.parkreldis.2009.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=19487152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FpvFGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=57-59&author=A.+L.+Bartelsauthor=A.+T.+Willemsenauthor=J.+Doorduinauthor=E.+F.+de+Vriesauthor=R.+A.+Dierckxauthor=K.+L.+Leenders&title=%5B11C%5D-PK11195+PET%3A+quantification+of+neuroinflammation+and+a+monitor+of+anti-inflammatory+treatment+in+Parkinson%E2%80%99s+disease%3F&doi=10.1016%2Fj.parkreldis.2009.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?</span></div><div class="casAuthors">Bartels A L; Willemsen A T M; Doorduin J; de Vries E F J; Dierckx R A; Leenders K L</div><div class="citationInfo"><span class="NLM_cas:title">Parkinsonism & related disorders</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  [(11)C]-PK11195 PET has been used for in vivo brain imaging of microglia activation in Parkinson's disease (PD) patients.  COX-2 inhibition has been shown to reduce neuroinflammation and neurodegeneration in animal models of PD.  This pilot study assessed the use of [(11)C]-PK11195 PET to quantify neuroinflammation and evaluate the ability of COX-2 inhibition to reduce neuroinflammation in PD patients.  METHODS:  Fourteen PD patients and eight healthy, age matched controls underwent a [(11)C]-PK11195 PET and MRI scan.  Five PD patients were scanned before and after one month of celecoxib treatment 200 mg/day.  Arterial plasma sampling and metabolite analysis were performed to create plasma input curves.  A 2-compartment model and Logan analysis were applied and parametric DV images were compared using t-test in SPM2.  In addition a simplified reference region model (SRTM) was applied, with both the cerebellum and a reference region derived from cluster analysis.  RESULTS:  Using the cluster analysis, PD patients showed higher contralateral putamen BP and midbrain BP compared to controls, although considerable overlap was seen and differences were not statistically significant.  Unexpectedly, BP and DV after celecoxib were slightly higher.  Cerebellum as reference region resulted in lower BP values and k(3)/k(4) gave 10-fold higher BP values.  Linearization of the data did not show differences between PD patients and controls.  CONCLUSIONS:  In current practice, [(11)C]-PK11195 seems an unsuitable tracer for accurate or reliable quantification of neuroinflammation.  Refinement of [(11)C]-PK11195 uptake analysis and, more importantly, further development of better tracers is necessary to enable accurate measurement of neuroinflammation and effects of anti-inflammatory treatment in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmnhOlmzXVp8vLc4ARHEmzfW6udTcc2ebqFQoEhlukCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FpvFGgtg%253D%253D&md5=97248f02ed914ee6c1c1cae23dd6e4c0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.parkreldis.2009.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.parkreldis.2009.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBartels%26aufirst%3DA.%2BL.%26aulast%3DWillemsen%26aufirst%3DA.%2BT.%26aulast%3DDoorduin%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DDierckx%26aufirst%3DR.%2BA.%26aulast%3DLeenders%26aufirst%3DK.%2BL.%26atitle%3D%255B11C%255D-PK11195%2520PET%253A%2520quantification%2520of%2520neuroinflammation%2520and%2520a%2520monitor%2520of%2520anti-inflammatory%2520treatment%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253F%26jtitle%3DParkinsonism%2520Relat.%2520Disord.%26date%3D2010%26volume%3D16%26spage%3D57%26epage%3D59%26doi%3D10.1016%2Fj.parkreldis.2009.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Imamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hishikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, Y.</span><span> </span><span class="NLM_article-title">Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains</span> <span class="citation_source-journal">Acta Neuropathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1007/s00401-003-0766-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1007%2Fs00401-003-0766-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=14513261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Clsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2003&pages=518-526&author=K.+Imamuraauthor=N.+Hishikawaauthor=M.+Sawadaauthor=T.+Nagatsuauthor=M.+Yoshidaauthor=Y.+Hashizume&title=Distribution+of+major+histocompatibility+complex+class+II-positive+microglia+and+cytokine+profile+of+Parkinson%E2%80%99s+disease+brains&doi=10.1007%2Fs00401-003-0766-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains</span></div><div class="casAuthors">Imamura, Kazuhiro; Hishikawa, Nozomi; Sawada, Makoto; Nagatsu, Toshiharu; Yoshida, Mari; Hashizume, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">518-526</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">There are numerous observations confirming that microglia expressing major histocompatibility complex (MHC) class II mols. are assocd. with the central nervous system (CNS) in aging and pathol. conditions.  In this study, we investigated the distribution of MHC class II-pos. microglia in Parkinson's disease (PD) brains.  The no. of MHC class II-pos. microglia in the substantia nigra (SN) and putamen increased as the neuronal degeneration of the SN proceeded.  These cells were also ICAM-1 (CD54) and LFA-1 (CD11a) pos.  The no. of activated microglia not only in the SN and putamen but also in the hippocampus, transentorhinal cortex, cingulate cortex and temporal cortex in PD was significantly higher than that in the normal control.  Most activated microglia persisted regardless of the presence or absence of Lewy bodies.  They were frequently assocd. not only with α-synuclein-pos. Lewy neurites, but also with TH-16-pos. dopaminergic and WH-3-pos. serotonergic neurites, as well as MAP-2- and SMI-32-pos. neurites.  These activated microglia were also pos. for TNF-α and interleukin-6, which are known to have a neuroprotective function.  We conclude that MHC class II-pos. microglia are a sensitive index of neuropathol. change and are actively assocd. with damaged neurons and neurites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeHPMG3ileOrVg90H21EOLACvtfcHk0lim6ex33F69Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Clsrs%253D&md5=63b311e03fb741c1a2fd75274f296311</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs00401-003-0766-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-003-0766-2%26sid%3Dliteratum%253Aachs%26aulast%3DImamura%26aufirst%3DK.%26aulast%3DHishikawa%26aufirst%3DN.%26aulast%3DSawada%26aufirst%3DM.%26aulast%3DNagatsu%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DY.%26atitle%3DDistribution%2520of%2520major%2520histocompatibility%2520complex%2520class%2520II-positive%2520microglia%2520and%2520cytokine%2520profile%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DActa%2520Neuropathol.%26date%3D2003%26volume%3D106%26spage%3D518%26epage%3D526%26doi%3D10.1007%2Fs00401-003-0766-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Rees, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ives, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Shlomo, Y.</span><span> </span><span class="NLM_article-title">Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD008454</span><span class="refDoi"> DOI: 10.1002/14651858.CD008454.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1002%2F14651858.CD008454.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=CD008454&author=K.+Reesauthor=R.+Stoweauthor=S.+Patelauthor=N.+Ivesauthor=K.+Breenauthor=C.+E.+Clarkeauthor=Y.+Ben-Shlomo&title=Non-steroidal+anti-inflammatory+drugs+as+disease-modifying+agents+for+Parkinson%E2%80%99s+disease%3A+evidence+from+observational+studies&doi=10.1002%2F14651858.CD008454.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD008454.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD008454.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DK.%26aulast%3DStowe%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DIves%26aufirst%3DN.%26aulast%3DBreen%26aufirst%3DK.%26aulast%3DClarke%26aufirst%3DC.%2BE.%26aulast%3DBen-Shlomo%26aufirst%3DY.%26atitle%3DNon-steroidal%2520anti-inflammatory%2520drugs%2520as%2520disease-modifying%2520agents%2520for%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520evidence%2520from%2520observational%2520studies%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2011%26spage%3DCD008454%26doi%3D10.1002%2F14651858.CD008454.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Lindholm, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makela, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Liberto, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belluardo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saarma, M.</span><span> </span><span class="NLM_article-title">Current disease modifying approaches to treat Parkinson’s disease</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1379</span><span class="refDoi"> DOI: 10.1007/s00018-015-2101-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1007%2Fs00018-015-2101-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=26616211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFalsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=1365-1379&author=D.+Lindholmauthor=J.+Makelaauthor=V.+Di+Libertoauthor=G.+Mudoauthor=N.+Belluardoauthor=O.+Erikssonauthor=M.+Saarma&title=Current+disease+modifying+approaches+to+treat+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs00018-015-2101-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Current disease modifying approaches to treat Parkinson's disease</span></div><div class="casAuthors">Lindholm, Dan; Makela, Johanna; Di Liberto, Valentina; Mudo, Giuseppa; Belluardo, Natale; Eriksson, Ove; Saarma, Mart</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1365-1379</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a progressive neurol. disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients.  The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the mol. mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies.  Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD.  In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown pos. results in protecting and repairing dopaminergic neurons in various models of PD.  Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compds. that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation.  In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclin. or in animal models of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1OgLJZdU-abVg90H21EOLACvtfcHk0li4ib7SVg6sgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFalsL7P&md5=a66d8f4bdc0f8e91f763555789f22fcc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-2101-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-2101-1%26sid%3Dliteratum%253Aachs%26aulast%3DLindholm%26aufirst%3DD.%26aulast%3DMakela%26aufirst%3DJ.%26aulast%3DDi%2BLiberto%26aufirst%3DV.%26aulast%3DMudo%26aufirst%3DG.%26aulast%3DBelluardo%26aufirst%3DN.%26aulast%3DEriksson%26aufirst%3DO.%26aulast%3DSaarma%26aufirst%3DM.%26atitle%3DCurrent%2520disease%2520modifying%2520approaches%2520to%2520treat%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D1365%26epage%3D1379%26doi%3D10.1007%2Fs00018-015-2101-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Tatsuta, K.</span><span> </span><span class="NLM_article-title">Preparation of dihydrobenzopyrans as intermediates for sideroxylonal and physiological active substances</span>. PCT Int. Appl. JP 2000186084,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=K.+Tatsuta&title=Preparation+of+dihydrobenzopyrans+as+intermediates+for+sideroxylonal+and+physiological+active+substances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTatsuta%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520dihydrobenzopyrans%2520as%2520intermediates%2520for%2520sideroxylonal%2520and%2520physiological%2520active%2520substances%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lafon, L.</span><span> </span><span class="NLM_article-title">(2,4,6-Trimethoxyphenyl)-(3-piperidinopropyl)-ketone derivatives</span>. PCT Int. Appl. US 4705795,<span class="NLM_x"> </span><span class="NLM_year">1987</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&author=L.+Lafon&title=%282%2C4%2C6-Trimethoxyphenyl%29-%283-piperidinopropyl%29-ketone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLafon%26aufirst%3DL.%26atitle%3D%25282%252C4%252C6-Trimethoxyphenyl%2529-%25283-piperidinopropyl%2529-ketone%2520derivatives%26date%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Du, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.1021/jm301248y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301248y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=97-108&author=D.+Duauthor=J.+Yanauthor=J.+Renauthor=H.+Lvauthor=Y.+Liauthor=S.+Xuauthor=Y.+Wangauthor=S.+Maauthor=J.+Quauthor=W.+Tangauthor=Z.+Huauthor=S.+Yu&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+glycyrrhizin+derivatives+as+potent+high-mobility+group+box-1+inhibitors+with+anti-heart-failure+activity+in+vivo&doi=10.1021%2Fjm301248y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm301248y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301248y%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DS.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520glycyrrhizin%2520derivatives%2520as%2520potent%2520high-mobility%2520group%2520box-1%2520inhibitors%2520with%2520anti-heart-failure%2520activity%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D97%26epage%3D108%26doi%3D10.1021%2Fjm301248y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Dewick, P. M.</span><span> </span><span class="NLM_article-title">Benzyl p-toluenesulfonate as an <i>O</i>-benzylating agent for the protection of phenols</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span><span class="refDoi"> DOI: 10.1080/00397918108065666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1080%2F00397918108065666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADyaL38XjsVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1981&pages=853-857&author=P.+M.+Dewick&title=Benzyl+p-toluenesulfonate+as+an+O-benzylating+agent+for+the+protection+of+phenols&doi=10.1080%2F00397918108065666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Benzyl p-toluenesulfonate as an O-benzylating agent for the protection of phenols</span></div><div class="casAuthors">Dewick, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">853-7</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">Resorcinols I (R = Me, H, 4-MeOC6H4CH2; R1 = R2 = H, or one of R1 and R2 is OH and the other is H) reacted with 4-MeC6H4SO3CH2Ph (II) to yield the resp. ethers III (R3 = H, PhCH2; R4 = H, OH, OCH2Ph).  I (R = Me, R1 = R2 = H) was treated with II and K2CO3 in Me2CO to give III (R = Me, R2 = R3 = R4 = H).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp-fXmmbFcALVg90H21EOLACvtfcHk0lg6hBIF9Eml7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XjsVOhuw%253D%253D&md5=db672506f54ebab58fa4f75155b1c417</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F00397918108065666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397918108065666%26sid%3Dliteratum%253Aachs%26aulast%3DDewick%26aufirst%3DP.%2BM.%26atitle%3DBenzyl%2520p-toluenesulfonate%2520as%2520an%2520O-benzylating%2520agent%2520for%2520the%2520protection%2520of%2520phenols%26jtitle%3DSynth.%2520Commun.%26date%3D1981%26volume%3D11%26spage%3D853%26epage%3D857%26doi%3D10.1080%2F00397918108065666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kim, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, K. J.</span><span> </span><span class="NLM_article-title">Synthesis and fragmentation of furoxanaldehydes in the gas phase for nanopatterned alkyne formation on a solid surface</span> <span class="citation_source-journal">Bull. Korean Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span><span class="refDoi"> DOI: 10.5012/bkcs.2009.30.2.459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.5012%2Fbkcs.2009.30.2.459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktlansb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=459-463&author=G.+Y.+Kimauthor=J.+Kimauthor=S.+H.+Leeauthor=H.+J.+Kimauthor=K.+J.+Hwang&title=Synthesis+and+fragmentation+of+furoxanaldehydes+in+the+gas+phase+for+nanopatterned+alkyne+formation+on+a+solid+surface&doi=10.5012%2Fbkcs.2009.30.2.459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and fragmentation of furoxanaldehydes in the gas phase for nanopatterned alkyne formation on a solid surface</span></div><div class="casAuthors">Kim, Gi Young; Kim, Jucheon; Lee, Seung Hee; Kim, Hyung Jin; Hwang, Kwang-Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">459-463</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Korean Chemical Society</span>)
        </div><div class="casAbstract">Four furoxanaldehydes I (R1 = Me, Ph; R2 = OHC, 4-OHCC6H4, 4-OHCC6H4CH:CH) were designed for alkyne formation on a solid surface.  Furoxans I (R1 = Ph; R2 = OHC, 4-OHCC6H4) were prepd. via the reaction of corresponding alkenes with NaNO2 in acetic acid.  Furoxan I (R1 = Me; R2 = 4-OHCC6H4CH:CH), in which the furoxan ring is conjugated with a double bond, was prepd. from bis(bromomethyl)benzene in 5 steps using the Wittig reaction of aldehyde I (R1 = Me; R2 = OHC) as the key step.  The electron beam-mediated fragmentation of the furoxanaldehydes I in a mass spectrometer was exploited by focusing on alkyne formation on the solid surface.  The fragmentation of furoxan I (R1 = Ph; R2 = 4-OHCC6H4) afforded diarylacetylene at high efficiency, suggesting that the aryl group conjugated with the furoxan ring could facilitate alkyne formation with the evolution of NO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpndP5JHokNQrVg90H21EOLACvtfcHk0lg6hBIF9Eml7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktlansb0%253D&md5=8d262193b2a386e96b6120167fe2e210</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.5012%2Fbkcs.2009.30.2.459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5012%252Fbkcs.2009.30.2.459%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%2BY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DHwang%26aufirst%3DK.%2BJ.%26atitle%3DSynthesis%2520and%2520fragmentation%2520of%2520furoxanaldehydes%2520in%2520the%2520gas%2520phase%2520for%2520nanopatterned%2520alkyne%2520formation%2520on%2520a%2520solid%2520surface%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2009%26volume%3D30%26spage%3D459%26epage%3D463%26doi%3D10.5012%2Fbkcs.2009.30.2.459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">The role of TLR4-mediated PTEN/PI3K/AKT/NF-κB signaling pathway in neuroinflammation in hippocampal neurons</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2014.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuroscience.2014.03.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2014&pages=93-101&author=M.+Zhaoauthor=A.+Zhouauthor=L.+Xuauthor=X.+Zhang&title=The+role+of+TLR4-mediated+PTEN%2FPI3K%2FAKT%2FNF-%CE%BAB+signaling+pathway+in+neuroinflammation+in+hippocampal+neurons&doi=10.1016%2Fj.neuroscience.2014.03.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2014.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2014.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DThe%2520role%2520of%2520TLR4-mediated%2520PTEN%252FPI3K%252FAKT%252FNF-%25CE%25BAB%2520signaling%2520pathway%2520in%2520neuroinflammation%2520in%2520hippocampal%2520neurons%26jtitle%3DNeuroscience%26date%3D2014%26volume%3D269%26spage%3D93%26epage%3D101%26doi%3D10.1016%2Fj.neuroscience.2014.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Alexaki, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charalampopoulos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kampa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassalou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodoropoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stathopoilos, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzoglou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravanis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanas, E.</span><span> </span><span class="NLM_article-title">Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">1596</span><span class="refDoi"> DOI: 10.1096/fj.04-1495fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1096%2Ffj.04-1495fje" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1594-1596&author=V.+I.+Alexakiauthor=I.+Charalampopoulosauthor=M.+Kampaauthor=H.+Vassalouauthor=P.+Theodoropoulosauthor=E.+N.+Stathopoilosauthor=A.+Hatzoglouauthor=A.+Gravanisauthor=E.+Castanas&title=Estrogen+exerts+neuroprotective+effects+via+membrane+estrogen+receptors+and+rapid+Akt%2FNOS+activation&doi=10.1096%2Ffj.04-1495fje"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1096%2Ffj.04-1495fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.04-1495fje%26sid%3Dliteratum%253Aachs%26aulast%3DAlexaki%26aufirst%3DV.%2BI.%26aulast%3DCharalampopoulos%26aufirst%3DI.%26aulast%3DKampa%26aufirst%3DM.%26aulast%3DVassalou%26aufirst%3DH.%26aulast%3DTheodoropoulos%26aufirst%3DP.%26aulast%3DStathopoilos%26aufirst%3DE.%2BN.%26aulast%3DHatzoglou%26aufirst%3DA.%26aulast%3DGravanis%26aufirst%3DA.%26aulast%3DCastanas%26aufirst%3DE.%26atitle%3DEstrogen%2520exerts%2520neuroprotective%2520effects%2520via%2520membrane%2520estrogen%2520receptors%2520and%2520rapid%2520Akt%252FNOS%2520activation%26jtitle%3DFASEB%2520J.%26date%3D2004%26volume%3D18%26spage%3D1594%26epage%3D1596%26doi%3D10.1096%2Ffj.04-1495fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leak, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span> </span><span class="NLM_article-title">HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">2853</span><span class="NLM_x">–</span> <span class="NLM_lpage">2858</span><span class="refDoi"> DOI: 10.1073/pnas.1501441112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1073%2Fpnas.1501441112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=2853-2858&author=G.+Wangauthor=Y.+Shiauthor=X.+Jiangauthor=R.+K.+Leakauthor=X.+Huauthor=Y.+Wuauthor=H.+Puauthor=W.+W.+Liauthor=B.+Tangauthor=Y.+Wangauthor=Y.+Gaoauthor=P.+Zhengauthor=M.+V.+Bennettauthor=J.+Chen&title=HDAC+inhibition+prevents+white+matter+injury+by+modulating+microglia%2Fmacrophage+polarization+through+the+GSK3%CE%B2%2FPTEN%2FAkt+axis&doi=10.1073%2Fpnas.1501441112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1501441112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1501441112%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLeak%26aufirst%3DR.%2BK.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DPu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DBennett%26aufirst%3DM.%2BV.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DHDAC%2520inhibition%2520prevents%2520white%2520matter%2520injury%2520by%2520modulating%2520microglia%252Fmacrophage%2520polarization%2520through%2520the%2520GSK3%25CE%25B2%252FPTEN%252FAkt%2520axis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D2853%26epage%3D2858%26doi%3D10.1073%2Fpnas.1501441112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Fragoso, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barata, J. T.</span><span> </span><span class="NLM_article-title">Kinases, tails and more: regulation of PTEN function by phosphorylation</span> <span class="citation_source-journal">Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">77–78</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.ymeth.2014.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.ymeth.2014.10.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77%E2%80%9378&publication_year=2015&pages=75-81&author=R.+Fragosoauthor=J.+T.+Barata&title=Kinases%2C+tails+and+more%3A+regulation+of+PTEN+function+by+phosphorylation&doi=10.1016%2Fj.ymeth.2014.10.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2014.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2014.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DFragoso%26aufirst%3DR.%26aulast%3DBarata%26aufirst%3DJ.%2BT.%26atitle%3DKinases%252C%2520tails%2520and%2520more%253A%2520regulation%2520of%2520PTEN%2520function%2520by%2520phosphorylation%26jtitle%3DMethods%26date%3D2015%26volume%3D77%25E2%2580%259378%26spage%3D75%26epage%3D81%26doi%3D10.1016%2Fj.ymeth.2014.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span> </span><span class="NLM_article-title">Regulation of PTEN by Rho small GTPases</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1038/ncb1236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1038%2Fncb1236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=15793569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVakt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=399-404&author=Z.+Liauthor=X.+Dongauthor=Z.+Wangauthor=W.+Liuauthor=N.+Dengauthor=Y.+Dingauthor=L.+Tangauthor=T.+Hlaauthor=R.+Zengauthor=L.+Liauthor=D.+Wu&title=Regulation+of+PTEN+by+Rho+small+GTPases&doi=10.1038%2Fncb1236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of PTEN by Rho small GTPases</span></div><div class="casAuthors">Li, Zhong; Dong, Xiemei; Wang, Zhenglong; Liu, Wenzhong; Deng, Ning; Ding, Yu; Tang, Liuya; Hla, Tim; Zeng, Rong; Li, Lin; Wu, Dianqing</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">399-404</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">PTEN (phosphatase and tensin homolog) is a phosphatase that dephosphorylates both protein and phosphoinositide substrates.  It is mutated in a variety of human tumors and has important roles in a diverse range of biol. processes, including cell migration and chemotaxis.  PTEN's intracellular localization and presumably activity are regulated by chemoattractants in Dictyostelium and mouse neutrophils.  However, the mechanisms for its regulation remain elusive.  Here we show that RhoA and Cdc42, members of the Rho family of small GTPases, regulate the intracellular localization of PTEN in leukocytes and human transfected embryonic kidney cells.  In addn., active RhoA is able to stimulate the phospholipid phosphatase activity of PTEN in human embryonic kidney cells and leukocytes, and this regulation seems to require RhoA's downstream effector, RhoA-assocd. kinase (Rock).  Furthermore, we have identified key residues on PTEN that are required for its regulation by the small GTPase, and show that small GTPase-mediated regulation of PTEN has a significant role in the regulation of chemotaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5wzxQcMid_LVg90H21EOLACvtfcHk0liCspa-CbcZCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVakt7s%253D&md5=34f504bf42d5a9cd15c308846f9a3e80</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fncb1236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1236%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDeng%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DZeng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520PTEN%2520by%2520Rho%2520small%2520GTPases%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D399%26epage%3D404%26doi%3D10.1038%2Fncb1236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Jyothi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidyadhara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahadevan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmar, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manohari, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alladi, P. A.</span><span> </span><span class="NLM_article-title">Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3321</span><span class="NLM_x">–</span> <span class="NLM_lpage">3333</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2015.08.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neurobiolaging.2015.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=26433682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A280%3ADC%252BC283os1Sqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=3321-3333&author=H.+J.+Jyothiauthor=D.+J.+Vidyadharaauthor=A.+Mahadevanauthor=M.+Philipauthor=S.+K.+Parmarauthor=S.+G.+Manohariauthor=S.+K.+Shankarauthor=T.+R.+Rajuauthor=P.+A.+Alladi&title=Aging+causes+morphological+alterations+in+astrocytes+and+microglia+in+human+substantia+nigra+pars+compacta&doi=10.1016%2Fj.neurobiolaging.2015.08.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta</span></div><div class="casAuthors">Jyothi H J; Vidyadhara D J; Manohari S Gowri; Raju Trichur R; Mahadevan Anita; Parmar Suresh Kumar; Shankar S K; Philip Mariamma; Alladi Phalguni Anand</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of aging</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3321-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Age being a risk factor for Parkinson's disease, assessment of age-related changes in the human substantia nigra may elucidate its pathogenesis.  Increase in Marinesco bodies, α-synuclein, free radicals and so forth in the aging nigral neurons are clear indicators of neurodegeneration.  Here, we report the glial responses in aging human nigra.  The glial numbers were determined on Nissl-stained sections.  The expression of glial fibrillary acidic protein, S100β, 2', 3'-cyclic nucleotide 3' phosphodiesterase, and Iba1 was assessed on cryosections of autopsied midbrains by immunohistochemistry and densitometry.  The glial counts showed a biphasic increase, of which, the first prominent phase from fetal age to birth could be physiological gliogenesis whereas the second one after middle age may reflect mild age-related gliosis.  Astrocytic morphology was altered, but glial fibrillary acidic protein expression increased only mildly.  Presence of type-4 microglia suggests possibility of neuroinflammation.  Mild reduction in 2', 3'-cyclic nucleotide 3' phosphodiesterase-labeled area denotes subtle demyelination.  Stable age-related S100β expression indicates absence of calcium overload.  Against the expected prominent gliosis, subtle age-related morphological alterations in human nigral glia attribute them a participatory role in aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8ulipU8R-ki-bLEOO4dYpfW6udTcc2eaHRekZ72edbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283os1Sqsg%253D%253D&md5=746dd59ffca7f660bd81943052f49736</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2015.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2015.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DJyothi%26aufirst%3DH.%2BJ.%26aulast%3DVidyadhara%26aufirst%3DD.%2BJ.%26aulast%3DMahadevan%26aufirst%3DA.%26aulast%3DPhilip%26aufirst%3DM.%26aulast%3DParmar%26aufirst%3DS.%2BK.%26aulast%3DManohari%26aufirst%3DS.%2BG.%26aulast%3DShankar%26aufirst%3DS.%2BK.%26aulast%3DRaju%26aufirst%3DT.%2BR.%26aulast%3DAlladi%26aufirst%3DP.%2BA.%26atitle%3DAging%2520causes%2520morphological%2520alterations%2520in%2520astrocytes%2520and%2520microglia%2520in%2520human%2520substantia%2520nigra%2520pars%2520compacta%26jtitle%3DNeurobiol.%2520Aging%26date%3D2015%26volume%3D36%26spage%3D3321%26epage%3D3333%26doi%3D10.1016%2Fj.neurobiolaging.2015.08.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Lull, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. L.</span><span> </span><span class="NLM_article-title">Microglial activation and chronic neurodegeneration</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1016/j.nurt.2010.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.nurt.2010.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=20880500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=354-365&author=M.+E.+Lullauthor=M.+L.+Block&title=Microglial+activation+and+chronic+neurodegeneration&doi=10.1016%2Fj.nurt.2010.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial Activation and Chronic Neurodegeneration</span></div><div class="casAuthors">Lull, Melinda E.; Block, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Microglia, the resident innate immune cells in the brain, have long been implicated in the pathol. of neurodegenerative diseases.  Accumulating evidence points to activated microglia as a chronic source of multiple neurotoxic factors, including tumor necrosis factor-α, nitric oxide, interleukin-1β, and reactive oxygen species (ROS), driving progressive neuron damage.  Microglia can become chronically activated by either a single stimulus (e.g., lipopolysaccharide or neuron damage) or multiple stimuli exposures to result in cumulative neuronal loss with time.  Although the mechanisms driving these phenomena are just beginning to be understood, reactive microgliosis (the microglial response to neuron damage) and ROS have been implicated as key mechanisms of chronic and neurotoxic microglial activation, particularly in the case of Parkinson's disease.  We review the mechanisms of neurotoxicity assocd. with chronic microglial activation and discuss the role of neuronal death and microglial ROS driving the chronic and toxic microglial phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojnZw-8eRdDLVg90H21EOLACvtfcHk0lioh-yeMYTdrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLnO&md5=d12e62dba01dd76cfd2a7edf1df3d3af</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2010.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2010.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DLull%26aufirst%3DM.%2BE.%26aulast%3DBlock%26aufirst%3DM.%2BL.%26atitle%3DMicroglial%2520activation%2520and%2520chronic%2520neurodegeneration%26jtitle%3DNeurotherapeutics%26date%3D2010%26volume%3D7%26spage%3D354%26epage%3D365%26doi%3D10.1016%2Fj.nurt.2010.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Paul, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliceiri, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheresh, D. A.</span><span> </span><span class="NLM_article-title">Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1038/84675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1038%2F84675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=11175854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVyks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=222-227&author=R.+Paulauthor=Z.+G.+Zhangauthor=B.+P.+Eliceiriauthor=Q.+Jiangauthor=A.+D.+Bocciaauthor=R.+L.+Zhangauthor=M.+Choppauthor=D.+A.+Cheresh&title=Src+deficiency+or+blockade+of+Src+activity+in+mice+provides+cerebral+protection+following+stroke&doi=10.1038%2F84675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke</span></div><div class="casAuthors">Paul, Robert; Zhang, Zheng G.; Eliceiri, Brian P.; Jiang, Quan; Boccia, Antonio D.; Zhang, Rui L.; Chopp, Michael; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-227</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF), an angiogenic factor produced in response to ischemic injury, promotes vascular permeability (VP).  Evidence is provided that Src kinase regulates VEGF-mediated VP in the brain following stroke and that suppression of Src activity decreases VP thereby minimizing brain injury.  Mice lacking pp60C-SrC are resistant to VEGF-induced VP and show decreased infarct vols. after stroke whereas mice deficient in pp59C-fyn, another Src family member, have normal VEGF-mediated VP and infarct size.  Systemic application of a Src-inhibitor given up to six hours following stroke suppressed VP protecting wild-type mice from ischemia-induced brain damage without influencing VEGF expression.  This was assocd. with reduced edema, improved cerebral perfusion and decreased infarct vol. 24 h after injury as measured by magnetic resonance imaging and histol. anal.  Thus, Src represents a key intermediate and novel therapeutic target in the pathophysiol. of cerebral ischemia where it appears to regulate neuronal damage by influencing VEGF-mediated VP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh1xP-Yo2f37Vg90H21EOLACvtfcHk0lipKKZKTeo8WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVyks70%253D&md5=93f387afda4e2c301275b792072f70dd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2F84675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F84675%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DZ.%2BG.%26aulast%3DEliceiri%26aufirst%3DB.%2BP.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DBoccia%26aufirst%3DA.%2BD.%26aulast%3DZhang%26aufirst%3DR.%2BL.%26aulast%3DChopp%26aufirst%3DM.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DSrc%2520deficiency%2520or%2520blockade%2520of%2520Src%2520activity%2520in%2520mice%2520provides%2520cerebral%2520protection%2520following%2520stroke%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D222%26epage%3D227%26doi%3D10.1038%2F84675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siminovitch, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">40057</span><span class="NLM_x">–</span> <span class="NLM_lpage">40066</span><span class="refDoi"> DOI: 10.1074/jbc.M303621200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1074%2Fjbc.M303621200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=12869565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFamsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=40057-40066&author=Y.+Luauthor=Q.+Yuauthor=J.+H.+Liuauthor=J.+Zhangauthor=H.+Wangauthor=D.+Koulauthor=J.+S.+McMurrayauthor=X.+Fangauthor=W.+K.+Yungauthor=K.+A.+Siminovitchauthor=G.+B.+Mills&title=Src+family+protein-tyrosine+kinases+alter+the+function+of+PTEN+to+regulate+phosphatidylinositol+3-kinase%2FAKT+cascades&doi=10.1074%2Fjbc.M303621200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades</span></div><div class="casAuthors">Lu, Yiling; Yu, Qinghua; Liu, Jue Hui; Zhang, Jinyi; Wang, Hongwei; Koul, Dimpy; McMurray, John S.; Fang, Xianjun; Yung, W. K. Alfred; Siminovitch, Kathy A.; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">40057-40066</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Src family protein-tyrosine kinases, which play an important role in signal integration, have been implicated in tumorigenesis in multiple lineages, including breast cancer.  We demonstrate, herein, that Src kinases regulate the phosphatidylinositol 3-kinase (PI3K) signaling cascade via altering the function of the PTEN tumor suppressor.  Overexpression of activated Src protein-tyrosine kinases in PTEN-deficient breast cancer cells does not alter AKT phosphorylation, an indicator of signal transduction through the PI3K pathway.  However, in the presence of functional PTEN, Src reverses the activity of PTEN, resulting in an increase in AKT phosphorylation.  Activated Src reduces the ability of PTEN to dephosphorylate phosphatidylinositols in micelles and promotes AKT translocation to cellular plasma membranes but does not alter PTEN activity toward water-sol. phosphatidylinositols.  Thus, Src may alter the capacity of the PTEN C2 domain to bind cellular membranes rather than directly interfering with PTEN enzymic activity.  Tyrosine phosphorylation of PTEN is increased in breast cancer cells treated with pervanadate, suggesting that PTEN contains sites for tyrosine phosphorylation.  Src kinase inhibitors markedly decreased pervanadate-mediated tyrosine phosphorylation of PTEN.  Further, expression of activated Src results in marked tyrosine phosphorylation of PTEN.  SHP-1, a SH2 domain-contg. protein-tyrosine phosphatase, selectively binds and dephosphorylates PTEN in Src transfected cells.  Both Src inhibitors and SHP-1 overexpression reverse Src-induced loss of PTEN function.  Coexpression of PTEN with activated Src reduces the stability of PTEN.  Taken together, the data indicate that activated Src inhibits PTEN function leading to alterations in signaling through the PI3K/AKT pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWFNxCQ8gMqLVg90H21EOLACvtfcHk0lipKKZKTeo8WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFamsLs%253D&md5=2696aba274ab4ee0f85736f0f7b8344d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M303621200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M303621200%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKoul%26aufirst%3DD.%26aulast%3DMcMurray%26aufirst%3DJ.%2BS.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYung%26aufirst%3DW.%2BK.%26aulast%3DSiminovitch%26aufirst%3DK.%2BA.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DSrc%2520family%2520protein-tyrosine%2520kinases%2520alter%2520the%2520function%2520of%2520PTEN%2520to%2520regulate%2520phosphatidylinositol%25203-kinase%252FAKT%2520cascades%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D40057%26epage%3D40066%26doi%3D10.1074%2Fjbc.M303621200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Socodato, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portugal, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domith, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coreixas, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loiola, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paes-de-Carvalho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrosio, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Relvas, J. B.</span><span> </span><span class="NLM_article-title">c-Src function is necessary and sufficient for triggering microglial cell activation</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1002/glia.22767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1002%2Fglia.22767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=497-511&author=R.+Socodatoauthor=C.+C.+Portugalauthor=I.+Domithauthor=N.+A.+Oliveiraauthor=V.+S.+Coreixasauthor=E.+C.+Loiolaauthor=T.+Martinsauthor=A.+R.+Santiagoauthor=R.+Paes-de-Carvalhoauthor=A.+F.+Ambrosioauthor=J.+B.+Relvas&title=c-Src+function+is+necessary+and+sufficient+for+triggering+microglial+cell+activation&doi=10.1002%2Fglia.22767"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fglia.22767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.22767%26sid%3Dliteratum%253Aachs%26aulast%3DSocodato%26aufirst%3DR.%26aulast%3DPortugal%26aufirst%3DC.%2BC.%26aulast%3DDomith%26aufirst%3DI.%26aulast%3DOliveira%26aufirst%3DN.%2BA.%26aulast%3DCoreixas%26aufirst%3DV.%2BS.%26aulast%3DLoiola%26aufirst%3DE.%2BC.%26aulast%3DMartins%26aufirst%3DT.%26aulast%3DSantiago%26aufirst%3DA.%2BR.%26aulast%3DPaes-de-Carvalho%26aufirst%3DR.%26aulast%3DAmbrosio%26aufirst%3DA.%2BF.%26aulast%3DRelvas%26aufirst%3DJ.%2BB.%26atitle%3Dc-Src%2520function%2520is%2520necessary%2520and%2520sufficient%2520for%2520triggering%2520microglial%2520cell%2520activation%26jtitle%3DGlia%26date%3D2015%26volume%3D63%26spage%3D497%26epage%3D511%26doi%3D10.1002%2Fglia.22767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Tai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson’s disease models</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuropharm.2013.07.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=201-212&author=W.+Taiauthor=X.+Yeauthor=X.+Baoauthor=B.+Zhaoauthor=X.+Wangauthor=D.+Zhang&title=Inhibition+of+Src+tyrosine+kinase+activity+by+squamosamide+derivative+FLZ+attenuates+neuroinflammation+in+both+in+vivo+and+in+vitro+Parkinson%E2%80%99s+disease+models&doi=10.1016%2Fj.neuropharm.2013.07.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Src%2520tyrosine%2520kinase%2520activity%2520by%2520squamosamide%2520derivative%2520FLZ%2520attenuates%2520neuroinflammation%2520in%2520both%2520in%2520vivo%2520and%2520in%2520vitro%2520Parkinson%25E2%2580%2599s%2520disease%2520models%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D75%26spage%3D201%26epage%3D212%26doi%3D10.1016%2Fj.neuropharm.2013.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bao, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson’s disease models</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">396</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2011.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuroscience.2011.11.036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2012&pages=396-40&author=X.+Q.+Baoauthor=X.+C.+Kongauthor=C.+Qianauthor=D.+Zhang&title=FLZ+protects+dopaminergic+neuron+through+activating+protein+kinase+B%2Fmammalian+target+of+rapamycin+pathway+and+inhibiting+RTP801+expression+in+Parkinson%E2%80%99s+disease+models&doi=10.1016%2Fj.neuroscience.2011.11.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2011.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2011.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DX.%2BQ.%26aulast%3DKong%26aufirst%3DX.%2BC.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DFLZ%2520protects%2520dopaminergic%2520neuron%2520through%2520activating%2520protein%2520kinase%2520B%252Fmammalian%2520target%2520of%2520rapamycin%2520pathway%2520and%2520inhibiting%2520RTP801%2520expression%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520models%26jtitle%3DNeuroscience%26date%3D2012%26volume%3D202%26spage%3D396%26epage%3D40%26doi%3D10.1016%2Fj.neuroscience.2011.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Diogo Carregosa, Rafael Carecho, Inês Figueira, <span class="NLM_string-name hlFld-ContribAuthor">Cláudia N Santos</span>. </span><span class="cited-content_cbyCitation_article-title">Low-Molecular Weight Metabolites from Polyphenols as Effectors for Attenuating Neuroinflammation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (7)
                                     , 1790-1807. <a href="https://doi.org/10.1021/acs.jafc.9b02155" title="DOI URL">https://doi.org/10.1021/acs.jafc.9b02155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.9b02155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.9b02155%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DLow-Molecular%252BWeight%252BMetabolites%252Bfrom%252BPolyphenols%252Bas%252BEffectors%252Bfor%252BAttenuating%252BNeuroinflammation%26aulast%3DCarregosa%26aufirst%3DDiogo%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D05042019%26date%3D26062019%26date%3D24062019%26date%3D24072019%26date%3D26062019%26volume%3D68%26issue%3D7%26spage%3D1790%26epage%3D1807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">María
Goretti Arvizu-Espinosa, Gilsane Lino von Poser, Amelia Teresinha Henriques, Aniceto Mendoza-Ruiz, Anaberta Cardador-Martínez, Reinier Gesto-Borroto, Pablo Noé Núñez-Aragón, María Luisa Villarreal-Ortega, Ashutosh Sharma, <span class="NLM_string-name hlFld-ContribAuthor">Alexandre Cardoso-Taketa</span>. </span><span class="cited-content_cbyCitation_article-title">Bioactive Dimeric Acylphloroglucinols from the Mexican Fern Elaphoglossum paleaceum. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2019,</strong> <em>82 </em>
                                    (4)
                                     , 785-791. <a href="https://doi.org/10.1021/acs.jnatprod.8b00677" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.8b00677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.8b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.8b00677%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DBioactive%252BDimeric%252BAcylphloroglucinols%252Bfrom%252Bthe%252BMexican%252BFern%252BElaphoglossum%252Bpaleaceum%26aulast%3DArvizu-Espinosa%26aufirst%3DMar%25C3%25ADa%2BGoretti%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D11082018%26date%3D28032019%26volume%3D82%26issue%3D4%26spage%3D785%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longping  Yao</span>, <span class="hlFld-ContribAuthor ">Jiayu  Wu</span>, <span class="hlFld-ContribAuthor ">Sumeyye  Koc</span>, <span class="hlFld-ContribAuthor ">Guohui  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.655819" title="DOI URL">https://doi.org/10.3389/fcell.2021.655819</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.655819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.655819%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DGenetic%252BImaging%252Bof%252BNeuroinflammation%252Bin%252BParkinson%2525E2%252580%252599s%252BDisease%25253A%252BRecent%252BAdvancements%26aulast%3DYao%26aufirst%3DLongping%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanyu  Yang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Caixia  Zang</span>, <span class="hlFld-ContribAuthor ">Xu  Yang</span>, <span class="hlFld-ContribAuthor ">Xiuqi  Bao</span>, <span class="hlFld-ContribAuthor ">Junmei  Shang</span>, <span class="hlFld-ContribAuthor ">Zihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Cheng  Ju</span>, <span class="hlFld-ContribAuthor ">Fangyuan  Li</span>, <span class="hlFld-ContribAuthor ">Fangyu  Yuan</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Squamosamide Derivative FLZ Diminishes Aberrant Mitochondrial Fission by Inhibiting Dynamin-Related Protein 1. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.588003" title="DOI URL">https://doi.org/10.3389/fphar.2021.588003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.588003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.588003%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DSquamosamide%252BDerivative%252BFLZ%252BDiminishes%252BAberrant%252BMitochondrial%252BFission%252Bby%252BInhibiting%252BDynamin-Related%252BProtein%252B1%26aulast%3DYang%26aufirst%3DHanyu%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qianqian  Ma</span>, <span class="hlFld-ContribAuthor ">Li  Ye</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Shengxi  Lin</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zhao</span>, <span class="hlFld-ContribAuthor ">Chenghua  Jin</span>, <span class="hlFld-ContribAuthor ">Guancheng  Liu</span>, <span class="hlFld-ContribAuthor ">Huan  Liu</span>, <span class="hlFld-ContribAuthor ">Yunpeng  Sun</span>, <span class="hlFld-ContribAuthor ">Haidan  Yuan</span>, <span class="hlFld-ContribAuthor ">Guangchun  Piao</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitory Effects of Twenty-Nine Compounds From Potentilla longifolia on Lipid Accumulation and Their Mechanisms in 3T3-L1 Cells. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.555715" title="DOI URL">https://doi.org/10.3389/fphar.2020.555715</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.555715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.555715%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DInhibitory%252BEffects%252Bof%252BTwenty-Nine%252BCompounds%252BFrom%252BPotentilla%252Blongifolia%252Bon%252BLipid%252BAccumulation%252Band%252BTheir%252BMechanisms%252Bin%252B3T3-L1%252BCells%26aulast%3DMa%26aufirst%3DQianqian%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiu-qi  Bao</span>, <span class="hlFld-ContribAuthor ">Zihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Fangyuan  Li</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel phloroglucinol derivative Compound 21 protects experimental autoimmune encephalomyelitis rats via inhibiting Th1/Th17 cell infiltration. </span><span class="cited-content_cbyCitation_journal-name">Brain, Behavior, and Immunity</span><span> <strong>2020,</strong> <em>87 </em>, 751-764. <a href="https://doi.org/10.1016/j.bbi.2020.03.009" title="DOI URL">https://doi.org/10.1016/j.bbi.2020.03.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbi.2020.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbi.2020.03.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBrain%252C%2520Behavior%252C%2520and%2520Immunity%26atitle%3DNovel%252Bphloroglucinol%252Bderivative%252BCompound%252B21%252Bprotects%252Bexperimental%252Bautoimmune%252Bencephalomyelitis%252Brats%252Bvia%252Binhibiting%252BTh1%25252FTh17%252Bcell%252Binfiltration%26aulast%3DZhao%26aufirst%3DZhe%26date%3D2020%26volume%3D87%26spage%3D751%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiu-qi  Bao</span>, <span class="hlFld-ContribAuthor ">Zihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Phloroglucinol derivative compound 21 attenuates cuprizone-induced multiple sclerosis mice through promoting remyelination and inhibiting neuroinflammation. </span><span class="cited-content_cbyCitation_journal-name">Science China Life Sciences</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 905-914. <a href="https://doi.org/10.1007/s11427-019-9821-2" title="DOI URL">https://doi.org/10.1007/s11427-019-9821-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11427-019-9821-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11427-019-9821-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520China%2520Life%2520Sciences%26atitle%3DPhloroglucinol%252Bderivative%252Bcompound%252B21%252Battenuates%252Bcuprizone-induced%252Bmultiple%252Bsclerosis%252Bmice%252Bthrough%252Bpromoting%252Bremyelination%252Band%252Binhibiting%252Bneuroinflammation%26aulast%3DZhao%26aufirst%3DZhe%26date%3D2020%26date%3D2019%26volume%3D63%26issue%3D6%26spage%3D905%26epage%3D914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanyu  Yang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Caixia  Zang</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Junmei  Shang</span>, <span class="hlFld-ContribAuthor ">Zihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Xiuqi  Bao</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson’s Disease Models. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neuroscience</span><span> <strong>2020,</strong> <em>14 </em><a href="https://doi.org/10.3389/fnins.2020.00045" title="DOI URL">https://doi.org/10.3389/fnins.2020.00045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnins.2020.00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnins.2020.00045%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neuroscience%26atitle%3DSrc%252BInhibition%252BAttenuates%252BNeuroinflammation%252Band%252BProtects%252BDopaminergic%252BNeurons%252Bin%252BParkinson%2525E2%252580%252599s%252BDisease%252BModels%26aulast%3DYang%26aufirst%3DHanyu%26date%3D2020%26date%3D2020%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Chavarria</span>, <span class="hlFld-ContribAuthor ">Carlos  Fernandes</span>, <span class="hlFld-ContribAuthor ">Vera  Silva</span>, <span class="hlFld-ContribAuthor ">Catia  Silva</span>, <span class="hlFld-ContribAuthor ">Eva  Gil-Martins</span>, <span class="hlFld-ContribAuthor ">Pedro  Soares</span>, <span class="hlFld-ContribAuthor ">Tiago  Silva</span>, <span class="hlFld-ContribAuthor ">Renata  Silva</span>, <span class="hlFld-ContribAuthor ">Fernando  Remião</span>, <span class="hlFld-ContribAuthor ">Paulo J.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>. </span><span class="cited-content_cbyCitation_article-title">Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111770. <a href="https://doi.org/10.1016/j.ejmech.2019.111770" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111770%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Bnovel%252Bmonoamine%252Boxidase-B%252Binhibitors%252Bbased%252Bon%252Bpiperine%252Bscaffold%25253A%252BStructure-activity-toxicity%25252C%252Bdrug-likeness%252Band%252Befflux%252Btransport%252Bstudies%26aulast%3DChavarria%26aufirst%3DDaniel%26date%3D2020%26volume%3D185%26spage%3D111770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deng  Tao</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Xiu-Qi  Bao</span>, <span class="hlFld-ContribAuthor ">Bei-Bei  Yang</span>, <span class="hlFld-ContribAuthor ">Fan  Gao</span>, <span class="hlFld-ContribAuthor ">Lin  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>173 </em>, 203-212. <a href="https://doi.org/10.1016/j.ejmech.2019.04.016" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bcoumarin%252BMannich%252Bbase%252Bderivatives%252Bas%252Bmultifunctional%252Bagents%252Bagainst%252Bmonoamine%252Boxidase%252BB%252Band%252Bneuroinflammation%252Bfor%252Bthe%252Btreatment%252Bof%252BParkinson%252527s%252Bdisease%26aulast%3DTao%26aufirst%3DDeng%26date%3D2019%26volume%3D173%26spage%3D203%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marianna  Tosato</span>, <span class="hlFld-ContribAuthor ">Valerio  Di Marco</span>. </span><span class="cited-content_cbyCitation_article-title">Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (7)
                                     , 269. <a href="https://doi.org/10.3390/biom9070269" title="DOI URL">https://doi.org/10.3390/biom9070269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9070269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9070269%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DMetal%252BChelation%252BTherapy%252Band%252BParkinson%2525E2%252580%252599s%252BDisease%25253A%252BA%252BCritical%252BReview%252Bon%252Bthe%252BThermodynamics%252Bof%252BComplex%252BFormation%252Bbetween%252BRelevant%252BMetal%252BIons%252Band%252BPromising%252Bor%252BEstablished%252BDrugs%26aulast%3DTosato%26aufirst%3DMarianna%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caixia  Zang</span>, <span class="hlFld-ContribAuthor ">Hanyu  Yang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Xiuqi  Bao</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel Synthetic Derivative of Phloroglucinol Inhibits Neuroinflammatory Responses Through Attenuating Kalirin Signaling Pathway in Murine BV2 Microglial Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Neurobiology</span><span> <strong>2019,</strong> <em>56 </em>
                                    (4)
                                     , 2870-2880. <a href="https://doi.org/10.1007/s12035-018-1233-3" title="DOI URL">https://doi.org/10.1007/s12035-018-1233-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12035-018-1233-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12035-018-1233-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Neurobiology%26atitle%3DA%252BNovel%252BSynthetic%252BDerivative%252Bof%252BPhloroglucinol%252BInhibits%252BNeuroinflammatory%252BResponses%252BThrough%252BAttenuating%252BKalirin%252BSignaling%252BPathway%252Bin%252BMurine%252BBV2%252BMicroglial%252BCells%26aulast%3DZang%26aufirst%3DCaixia%26date%3D2019%26date%3D2018%26volume%3D56%26issue%3D4%26spage%3D2870%26epage%3D2880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula A. Q.  Videira</span>, <span class="hlFld-ContribAuthor ">Margarida  Castro-Caldas</span>. </span><span class="cited-content_cbyCitation_article-title">Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neuroscience</span><span> <strong>2018,</strong> <em>12 </em><a href="https://doi.org/10.3389/fnins.2018.00381" title="DOI URL">https://doi.org/10.3389/fnins.2018.00381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnins.2018.00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnins.2018.00381%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neuroscience%26atitle%3DLinking%252BGlycation%252Band%252BGlycosylation%252BWith%252BInflammation%252Band%252BMitochondrial%252BDysfunction%252Bin%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DVideira%26aufirst%3DPaula%2BA.%2BQ.%26date%3D2018%26date%3D2018%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ester  Gangoso</span>, <span class="hlFld-ContribAuthor ">Rocío  Talaverón</span>, <span class="hlFld-ContribAuthor ">Myriam  Jaraíz-Rodríguez</span>, <span class="hlFld-ContribAuthor ">Marta  Domínguez-Prieto</span>, <span class="hlFld-ContribAuthor ">Pascal  Ezan</span>, <span class="hlFld-ContribAuthor ">Annette  Koulakoff</span>, <span class="hlFld-ContribAuthor ">José M.  Medina</span>, <span class="hlFld-ContribAuthor ">Christian  Giaume</span>, <span class="hlFld-ContribAuthor ">Arantxa  Tabernero</span>. </span><span class="cited-content_cbyCitation_article-title">A c-Src Inhibitor Peptide Based on Connexin43 Exerts Neuroprotective Effects through the Inhibition of Glial Hemichannel Activity. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Neuroscience</span><span> <strong>2017,</strong> <em>10 </em><a href="https://doi.org/10.3389/fnmol.2017.00418" title="DOI URL">https://doi.org/10.3389/fnmol.2017.00418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnmol.2017.00418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnmol.2017.00418%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Neuroscience%26atitle%3DA%252Bc-Src%252BInhibitor%252BPeptide%252BBased%252Bon%252BConnexin43%252BExerts%252BNeuroprotective%252BEffects%252Bthrough%252Bthe%252BInhibition%252Bof%252BGlial%252BHemichannel%252BActivity%26aulast%3DGangoso%26aufirst%3DEster%26date%3D2017%26date%3D2017%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debleena  Guin</span>, <span class="hlFld-ContribAuthor ">Manish Kumar  Mishra</span>, <span class="hlFld-ContribAuthor ">Puneet  Talwar</span>, <span class="hlFld-ContribAuthor ">Chitra  Rawat</span>, <span class="hlFld-ContribAuthor ">Suman S.  Kushwaha</span>, <span class="hlFld-ContribAuthor ">Shrikant  Kukreti</span>, <span class="hlFld-ContribAuthor ">Ritushree  Kukreti</span>. </span><span class="cited-content_cbyCitation_article-title">A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson’s disease. </span><span class="cited-content_cbyCitation_journal-name">BMC Medical Genomics</span><span> <strong>2017,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12920-017-0291-0" title="DOI URL">https://doi.org/10.1186/s12920-017-0291-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12920-017-0291-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12920-017-0291-0%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Medical%2520Genomics%26atitle%3DA%252Bsystematic%252Breview%252Band%252Bintegrative%252Bapproach%252Bto%252Bdecode%252Bthe%252Bcommon%252Bmolecular%252Blink%252Bbetween%252Blevodopa%252Bresponse%252Band%252BParkinson%2525E2%252580%252599s%252Bdisease%26aulast%3DGuin%26aufirst%3DDebleena%26date%3D2017%26date%3D2017%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0001.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the hit compound.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>3</sub>OCH<sub>2</sub>Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (b) Me<sub>2</sub>SO<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 5 h; (c) 2 N HCl, reflux, 1 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>3</b>–<b>8</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isovaleryl chloride, BF<sub>3</sub>-Et<sub>2</sub>O, 80 °C, 2 h; (b) valeryl chloride, BF<sub>3</sub>-Et<sub>2</sub>O, 80 °C, 2 h; (c) acetyl chloride, BF<sub>3</sub>-Et<sub>2</sub>O, 80 °C, 2 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>9</b> and <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) oxalyl chloride, DMSO, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h; (b) isopropylamine, THF, rt, 1 h; (c) butylamine, THF, rt, 1 h.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>11</b>–<b>14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) chloroacetonitrile, HCl gas, PhCl, rt, 6 h; (b) H<sub>2</sub>O, reflux, 1 h; (c) piperidine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h; (d) morpholine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h; (e) 1-methylpiperazine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h; (f) 1-ethylpiperazine, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 24 h.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>15</b>–<b>17</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) piperidine, K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, rt, 20 h; (b) <i>N</i>-methylcyclohexanamine, K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, rt, 20 h; (c) 1-(3-chlorophenyl)piperazine, K<sub>2</sub>CO<sub>3</sub>, NaI, acetonitrile, rt, 20 h; (d) (i) phloroglucinol, HCl gas, PhNO<sub>2</sub>, rt, 12 h, (ii) H<sub>2</sub>O, reflux, 1 h.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>18</b>–<b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isopropylamine, NaBH<sub>3</sub>CN, MeOH, HOAc, argon, rt, 3 h; (b) <span class="smallcaps smallerCapital">l</span>-GlyOEt-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (c) <span class="smallcaps smallerCapital">l</span>-AlaOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (d) <span class="smallcaps smallerCapital">l</span>-SerOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (e) <span class="smallcaps smallerCapital">l</span>-Asp(OMe)<sub>2</sub>-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (f) <span class="smallcaps smallerCapital">l</span>-Glu(OMe)<sub>2</sub>-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (g) <span class="smallcaps smallerCapital">l</span>-PheOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (h) <span class="smallcaps smallerCapital">l</span>-HisOMe-HCl, NaBH<sub>3</sub>CN, MeOH, argon, rt, 3 h; (i) KOH, EtOH-H<sub>2</sub>O (1:1), rt, 2 h, Amberlite 120 H<sup>+</sup> resin.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0013.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>26</b>–<b>31</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) benzyl <i>p</i>-toluenesulfonate, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 3 h; (b) 2-(chloromethyl)oxirane, NaH, DMF, N<sub>2</sub>, 90 °C, 2 h; (c) (i) isopropylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (d) (i) <i>tert</i>-butylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (e) H<sub>2</sub>, 3 atm, Pd-C, MeOH, HCl, rt, 12 h.</p></p></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0014.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>32</b>–<b>43</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, NaH, DMF, N<sub>2</sub>, 90 °C, 24 h; (b) (<i>R</i>)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane, NaH, DMF, N<sub>2</sub>, 90 °C, 24 h; (c) 4% H<sub>2</sub>SO<sub>4</sub>, THF, rt, 8 h; (d) TsCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 48 h; (e) (i) isopropylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (f) (i) <i>tert</i>-butylamine, 70 °C, 3 h, (ii) ethereal HCl, 10 min; (g) H<sub>2</sub>, 3 atm, Pd-C, MeOH, HCl, rt, 12 h.</p></p></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compound <b>44</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaNO<sub>2</sub>, HOAc, H<sub>2</sub>O, rt, 24 h; (b) SOCl<sub>2</sub>, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h; (c) K<sub>2</sub>CO<sub>3</sub>, KI, acetone, reflux, 5 h; (d) 2 N HCl, reflux, 1 h.</p></p></figure><figure data-id="fig2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0002.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of compounds <b>2</b>, <b>21</b>, <b>23</b>, and <b>44</b> on neuroinflammation and TH expression in primary mixed midbrain neuronal/glial cultures stimulated with LPS. Control group: primary mixed mesencephalic neuronal/glial cultures with no treatment. LPS group: primary mixed neuronal/glial cultures stimulated with LPS (100 ng/mL). Other groups: 10 μM of <b>2</b>, <b>21</b>, <b>23</b>, and <b>44</b> incubated with cells for 1 h before LPS challenge and then incubated for 5 h to detect cytokines, 24 h to measure Iba-1 expression, and 7 days to measure TH expression. (A) Effects of the indicated compounds on Iba-1 expression in microglia (<i>n</i> = 4). A representative image is shown. Inhibitory effects of the indicated compounds on (B) IL-1β and (C) TNF-α production in medium measured by ELISA assay (<i>n</i> = 6). (D) Effects of the indicated compounds on TH expression measured by Western blot (<i>n</i> = 4). A representative immunoblot image is shown. Data are the mean ± standard deviation (SD), *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control cells; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus LPS-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0003.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of compound <b>21</b> on the MPTP-induced subacute PD mouse model. Control group: mice were treated with 0.5% sodium carboxymethylcellulose (CMC-Na). MPTP group: mice were injected with MPTP hydrochloride (30 mg/kg, ip) for 5 consecutive days. Other groups: mice were administered different doses of compound <b>21</b> (5, 10, 15 mg/kg) and L-DOPA (20 mg/kg) 30 min before each MPTP injection and continued administering for the next 7 days. Compound <b>21</b> improved motor behavior of mice, as measured by (A) rotarod test and (B) pole test (<i>n</i> = 15). (C) Effect of compound <b>21</b> on dopamine level (<i>n</i> = 8). (D) Effect of compound <b>21</b> on the TH-positive staining neurons. Representative sections of substantia nigra from five mice are shown. Inhibitory effect of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in the mouse midbrain measured by ELISA assay on the 12th day after the administration of compound <b>21</b> (<i>n</i> = 6). Data are the mean ± SD; *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control mice; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus MPTP injected mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0004.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compound <b>21</b> on the MPTP/prob-induced chronic PD mouse model. Control group: mice were treated with 0.5% CMC-Na. MPTP/prob group: mice were administered 10 doses of MPTP hydrochloride (25 mg/kg, subcutaneously, sc) in combination with probenecid (250 mg/kg, ip) on a 5-week schedule. Other groups: mice showing behavioral dysfunction after the last MPTP/prob injection were administered different doses of compound <b>21</b> (5, 10, 15 mg/kg) and L-DOPA (20 mg/kg) once a day for 7 weeks. Compound <b>21</b> improved motor behavior of mice, as measured by (A) rotarod test and (B) pole test (<i>n</i> = 15). (C) Effect of compound <b>21</b> on dopamine level (<i>n</i> = 8). (D) Effect of compound <b>21</b> on the TH-positive staining neurons. Representative sections of substantia nigra from five mice are shown. Inhibitory effect of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in the mouse midbrain measured by ELISA assay (<i>n</i> = 6). Data are the mean ± SD; *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control mice; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus MPTP/prob-treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0005.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>21</b> on α-syn transgenic mice. WT group: mice were treated with 0.5% CMC-Na. α-Syn group: α-Syn (A53T) transgenic mice. Other groups: mice were administered different doses of compound <b>21</b> (5, 10, 15 mg/kg) and L-DOPA (20 mg/kg) once a day for 12 weeks. Compound <b>21</b> improved motor behavior of mice, as measured by (A) rotarod test and (B) pole test (<i>n</i> = 15). (C) Effect of compound <b>21</b> on dopamine level (<i>n</i> = 8). (D) Effect of compound <b>21</b> on the TH-positive staining neurons. Representative sections of substantia nigra from five mice are shown. Inhibitory effect of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in the mouse midbrain measured by ELISA assay (<i>n</i> = 6). Data are the mean ± SD; *<i>P</i> < 0.05 and **<i>P</i> < 0.01 versus control mice; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus α-syn transgenic mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/medium/jm-2016-00976a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0006.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>21</b> suppressed neuroinflammation by inhibiting Src signaling. Control group: primary microglia with no treatment. LPS group: primary microglia stimulated with LPS (100 ng/mL). LPS <i>+</i><b>21</b> group: the microglia was incubated with compound <b>21</b> (10 μM) for 1 h followed by LPS challenge. Negative control group: primary microglia or mixed mesencephalic neuronal/glial cultures were tranfected with empty vector. Negative control + LPS group: primary microglia or mixed mesencephalic neuronal/glial cultures were tranfected with empty vector followed by LPS challenge. Src siRNA group: microglia or mixed mesencephalic neuronal/glial cultures were tranfected with Src siRNA. Src siRNA <i>+</i> LPS/MPP<sup>+</sup>/α-Syn group: primary microglia or mixed mesencephalic neuronal/glial cultures were tranfected with Src siRNA, LPS (100 ng/mL), MPP<sup>+</sup> (30 μM), or α-syn (250 nM) was added 4 h later. Src siRNA + LPS/MPP<sup>+</sup>/α-Syn + <b>21</b> group: primary microglia or mixed neuronal/glial cultures were tranfected with Src siRNA, compound <b>21</b> (10 μM) was added 1 h before LPS, MPP<sup>+</sup> or α-Syn challenge. Effects of compound <b>21</b> on (A) p-PTEN, (B) p-Akt, and (C) p-Src expression in primary microglia cultures. (D) Regulation of Src on PTEN and Akt in primary microglia cultures (<i>n</i> = 4). Effects of compound <b>21</b> on (E) IL-1β and (F) TNF-α production in LPS-stimulated primary microglia cultures (<i>n</i> = 6). Effects of compound <b>21</b> on TH expression in (G) LPS-, (H) MPP<sup>+</sup>-, and (I) α-syn-stimulated primary mixed mesencephalic neuronal/glial cultures (<i>n</i> = 4). Representative immunoblot images are shown. The results are shown as the mean ± SD; **<i>P</i> < 0.01 versus control cells; <sup>#</sup><i>P</i> < 0.05 and <sup>##</sup><i>P</i> < 0.01 versus LPS-, MPP<sup>+</sup>- or α-syn-treated cells; Δ<i>P</i> < 0.05 versus Src siRNA-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00976/20161007/images/large/jm-2016-00976a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00976&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lozano, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostrovsky, J. O.</span><span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson’s disease and in its treatment</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span><span class="refDoi"> DOI: 10.1016/S0959-4388(98)80122-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2FS0959-4388%2898%2980122-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%E2%80%99s+disease+and+in+its+treatment&doi=10.1016%2FS0959-4388%2898%2980122-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0959-4388%2898%2980122-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-4388%252898%252980122-0%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790%26doi%3D10.1016%2FS0959-4388%2898%2980122-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ferreira, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocha, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares-da-Silva, P.</span><span> </span><span class="NLM_article-title">Effect of opicapone on levodopa pharmacokinetics, catechol-<i>O</i>-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease</span> <span class="citation_source-journal">Eur. J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">825</span><span class="refDoi"> DOI: 10.1111/ene.12666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1111%2Fene.12666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=25649051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=815-825&author=J.+J.+Ferreiraauthor=J.+F.+Rochaauthor=A.+Falcaoauthor=A.+Santosauthor=R.+Pintoauthor=T.+Nunesauthor=P.+Soares-da-Silva&title=Effect+of+opicapone+on+levodopa+pharmacokinetics%2C+catechol-O-methyltransferase+activity+and+motor+fluctuations+in+patients+with+Parkinson%E2%80%99s+disease&doi=10.1111%2Fene.12666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease</span></div><div class="casAuthors">Ferreira J J; Rocha J-F; Falcao A; Santos A; Pinto R; Nunes T; Soares-da-Silva P</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-25, e56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Opicapone (OPC) is a novel third generation catechol-O-methyltransferase (COMT) inhibitor that enhances levodopa availability.  This study investigated the effects of OPC in comparison with placebo on levodopa pharmacokinetics, tolerability and safety, COMT activity and motor response to levodopa in Parkinson's disease (PD) patients with motor fluctuations.  METHODS:  This was a randomized, multicentre, double-blind and placebo-controlled study in four parallel groups of PD patients treated with standard-release 100/25 mg levodopa/carbidopa or levodopa/benserazide and with motor fluctuations (wearing-OFF phenomenon).  Subjects were sequentially assigned to be administered, once-daily, up to 28 days (maintenance phase), placebo (n = 10) or 5 (n = 10), 15 (n = 10) and 30 mg (n = 10) OPC.  Two levodopa tests were performed, one at baseline and another following the maintenance phase.  Subjects kept a diary to record motor fluctuations (ON/OFF periods) throughout the study.  RESULTS:  In relation to placebo, levodopa exposure (AUC0-6) increased 24.7%, 53.9% and 65.6% following 5, 15 and 30 mg OPC, respectively.  Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).  The study was not designed to detect any significant differences in motor performance, but the exploratory analysis performed shows improvement in various motor outcomes, including a dose-dependent change in absolute OFF time corresponding to a percentage decrease of 4.16% (P > 0.05), 29.55% (P > 0.05) and 32.71% (P < 0.05) with 5, 15 and 30 mg OPC, respectively.  Treatments were generally well tolerated and safe.  CONCLUSIONS:  OPC is a promising new COMT inhibitor that significantly decreased COMT activity, increased systemic exposure to levodopa and improved motor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEuvMtwfdhHOQ4Pl9hzjQhfW6udTcc2eYPPu-W4VI877ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MritlCqsA%253D%253D&md5=7b33ae752bc6ace3867a38b8f9e6e9c8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fene.12666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fene.12666%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%2BJ.%26aulast%3DRocha%26aufirst%3DJ.%2BF.%26aulast%3DFalcao%26aufirst%3DA.%26aulast%3DSantos%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DR.%26aulast%3DNunes%26aufirst%3DT.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DEffect%2520of%2520opicapone%2520on%2520levodopa%2520pharmacokinetics%252C%2520catechol-O-methyltransferase%2520activity%2520and%2520motor%2520fluctuations%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2015%26volume%3D22%26spage%3D815%26epage%3D825%26doi%3D10.1111%2Fene.12666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Schapira, A. H.</span><span> </span><span class="NLM_article-title">Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.2165/11596310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.2165%2F11596310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=22133327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+Schapira&title=Monoamine+oxidase+B+inhibitors+for+the+treatment+of+Parkinson%E2%80%99s+disease%3A+a+review+of+symptomatic+and+potential+disease-modifying+effects&doi=10.2165%2F11596310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects</span></div><div class="casAuthors">Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1061-1071</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease is a disorder characterized pathol. by progressive neurodegeneration of the dopaminergic cells of the nigrostriatal pathway.  Although the resulting dopamine deficiency is the cause of the typical motor features of Parkinson's disease (bradykinesia, rigidity, tremor), addnl. non-motor symptoms appear at various timepoints and are the result of non-dopamine nerve degeneration.  Monoamine oxidase B (MAO-B) inhibitors are used in the symptomatic treatment of Parkinson's disease as they increase synaptic dopamine by blocking its degrdn.  Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson's disease and to reduce off-time in patients with more advanced Parkinson's disease and motor fluctuations related to levodopa.  A third MAO-B inhibitor (safinamide), which also combines addnl. non-dopaminergic properties of potential benefit to Parkinson's disease, is currently under development in phase III clin. trials as adjuvant therapy to either a dopamine agonist or levodopa.  MAO-B inhibitors have also been studied extensively for possible neuroprotective or disease-modifying actions.  There is considerable lab. evidence that MAO-B inhibitors do exert some neuroprotective properties, at least in the Parkinson's disease models currently available.  However, these models have significant limitations and caution is required in assuming that such results may easily be extrapolated to clin. trials.  Rasagiline 1 mg/day has been shown to provide improved motor control in terms of Unified Parkinson's Disease Rating Scale (UPDRS) score at 18 mo in those patients with early disease who began the drag 9 mo before a second group.  There are a no. of possible explanations for this effect that may include a disease-modifying action; however, the US FDA recently declined an application for the licence of rasagiline to be extended to cover disease modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AHDUDO6Ch7Vg90H21EOLACvtfcHk0lhXVZJTHOjgGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D&md5=a6c6a9380eaa9056a877fa0df9e39446</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2165%2F11596310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26atitle%3DMonoamine%2520oxidase%2520B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520of%2520symptomatic%2520and%2520potential%2520disease-modifying%2520effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071%26doi%3D10.2165%2F11596310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Huot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koprich, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piggott, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brotchie, J. M.</span><span> </span><span class="NLM_article-title">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuropharm.2014.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=24447715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=76-87&author=P.+Huotauthor=T.+H.+Johnstonauthor=K.+D.+Lewisauthor=J.+B.+Koprichauthor=M.+G.+Reyesauthor=S.+H.+Foxauthor=M.+J.+Piggottauthor=J.+M.+Brotchie&title=UWA-121%2C+a+mixed+dopamine+and+serotonin+re-uptake+inhibitor%2C+enhances+L-DOPA+anti-parkinsonian+action+without+worsening+dyskinesia+or+psychosis-like+behaviours+in+the+MPTP-lesioned+common+marmoset&doi=10.1016%2Fj.neuropharm.2014.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset</span></div><div class="casAuthors">Huot, Philippe; Johnston, Tom H.; Lewis, Katie D.; Koprich, James B.; Reyes, M. Gabriela; Fox, Susan H.; Piggott, Matthew J.; Brotchie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-87</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease (PD), but its long-term administration is complicated by wearing-off and dyskinesia.  UWA-101, a dual, equipotent inhibitor of dopamine (DAT) and serotonin (SERT) transporters, has previously been shown to successfully extend duration of anti-parkinsonian benefit of L-DOPA (ON-time), without exacerbating dyskinesia, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset.  However, UWA-101 is racemic and it is unclear whether one or both enantiomers contribute to its actions, and whether a better therapeutic effect might be attained by using a single antipode.  In the current study, we synthesized the two enantiomers of UWA-101, R-101 (UWA-121) and S-101 (UWA-122), characterized their pharmacol. profiles and administered them to MPTP-lesioned marmosets.  Parkinsonism, dyskinesia, psychosis-like behaviors and duration of ON-time were evaluated.  UWA-121 is a dual DAT > SERT inhibitor, with an approx. 10:1 DAT:SERT affinity ratio (inhibitory consts. (Ki) of 307 and 3830 nM, resp.).  In combination with L-DOPA, UWA-121 extended duration of ON-time when compared to L-DOPA/vehicle treatment (by 40%, P < 0.01).  UWA-121 also extended duration of ON-time without dyskinesia (by 215%, P < 0.05) and ON-time without psychosis-like behaviors when compared to L-DOPA/vehicle treatment (by 345%, P < 0.01).  UWA-121 did not worsen the severity of dyskinesia or psychosis-like behaviors (P > 0.05).  UWA-122 is a selective SERT inhibitor (Ki 120 nM, Ki at DAT > 50 μM) and, in combination with L-DOPA, had no effect on ON-time, dyskinesia or psychosis-like behaviors (P > 0.05).  These data indicate that dual DAT and SERT inhibitors effectively enhance L-DOPA anti-parkinsonian action without worsening dyskinesia and that compds. with such a pharmacol. profile represent promising agents against wearing-off in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbiBB5fc-TBrVg90H21EOLACvtfcHk0lhXVZJTHOjgGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFynt7o%253D&md5=2c88b90b665cabea18d5116c44878d9b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHuot%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DT.%2BH.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DKoprich%26aufirst%3DJ.%2BB.%26aulast%3DReyes%26aufirst%3DM.%2BG.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DPiggott%26aufirst%3DM.%2BJ.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26atitle%3DUWA-121%252C%2520a%2520mixed%2520dopamine%2520and%2520serotonin%2520re-uptake%2520inhibitor%252C%2520enhances%2520L-DOPA%2520anti-parkinsonian%2520action%2520without%2520worsening%2520dyskinesia%2520or%2520psychosis-like%2520behaviours%2520in%2520the%2520MPTP-lesioned%2520common%2520marmoset%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D76%26epage%3D87%26doi%3D10.1016%2Fj.neuropharm.2014.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H.</span><span> </span><span class="NLM_article-title">Dopamine agonists in Parkinson’s disease</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1586/14737175.8.4.671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1586%2F14737175.8.4.671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=18416667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=671-677&author=M.+Yamamotoauthor=A.+H.+Schapira&title=Dopamine+agonists+in+Parkinson%E2%80%99s+disease&doi=10.1586%2F14737175.8.4.671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists in Parkinson's disease</span></div><div class="casAuthors">Yamamoto, Mitsutoshi; Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course.  As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications.  As an adjunct to levodopa, they improve motor control and limit the need for levodopa in those patients in whom this may be considered relevant.  The non-ergot dopamine agonists in particular have a good safety profile, although as with other agonists, sedation, and cognitive and behavioral problems may be limiting in some patients.  Pramipexole has shown benefit in improving depressive symptoms in PD.  Ropinirole and pramipexole have both demonstrated a redn. in the rate of loss of nigrostriatal innervation as detd. by imaging in PD patients, when compared with levodopa.  Thus, dopamine agonists contribute to several dimensions of the management of PD and have become an integral part of the disease treatment algorithm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVM_IekUXprVg90H21EOLACvtfcHk0lhrAz7f57Qopw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D&md5=9a145ab9c49de374322fb02fe543d4ad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1586%2F14737175.8.4.671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.8.4.671%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520agonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2008%26volume%3D8%26spage%3D671%26epage%3D677%26doi%3D10.1586%2F14737175.8.4.671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Henchcliffe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severt, W. L.</span><span> </span><span class="NLM_article-title">Disease modification in Parkinson’s disease</span> <span class="citation_source-journal">Drugs Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.2165/11591320-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.2165%2F11591320-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=21812497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1CltLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=605-615&author=C.+Henchcliffeauthor=W.+L.+Severt&title=Disease+modification+in+Parkinson%E2%80%99s+disease&doi=10.2165%2F11591320-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Disease modification in Parkinson's disease</span></div><div class="casAuthors">Henchcliffe, Claire; Severt, W. Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">605-615</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is an age-related, progressive, multisystem neurodegenerative disorder resulting in significant morbidity and mortality, as well as a growing social and financial burden in an aging population.  The hallmark of PD is loss of dopaminergic neurons of the substantia nigra pars compacta, leading to bradykinesia, rigidity and tremor.  Current pharmacol. treatment is therefore centered upon dopamine replacement to alleviate symptoms.  However, two major problems complicate this approach: (i) motor symptoms continue to progress, requiring increasing doses of medication, which result in both short-term adverse effects and intermediate- to long-term motor complications; (ii) dopamine replacement does little to treat non-dopaminergic motor and non-motor symptoms, which are an important source of morbidity, including dementia, sleep disturbances, depression, orthostatic hypotension, and postural instability leading to falls.  It is crit., therefore, to develop a broader and more fundamental therapeutic approach to PD, and major research efforts have focused upon developing neuroprotective interventions.  Despite many encouraging preclin. data suggesting the possibility of addressing the underlying pathophysiol. by slowing cell loss, efforts to translate this into the clin. realm have largely proved disappointing in the past.  Barriers to finding neuroprotective or disease-modifying drugs in PD include a lack of validated biomarkers of progression, which hampers clin. trial design and interpretation; difficulties sepg. symptomatic and neuroprotective effects of candidate neuroprotective therapies; and possibly fundamental flaws in some of the basic preclin. models and testing.  However, three recent clin. trials have used a novel delayed-start design in an attempt to overcome some of these roadblocks.  While not examg. markers of cell loss and function, which would det. neuroprotective effects, this trial design pragmatically tests whether earlier vs. later intervention is beneficial.  If pos. (i.e. if an earlier intervention proves more effective), this demonstrates disease modification, which could result from neuroprotection or from other mechanisms.  This strategy therefore provides a first step towards supporting neuroprotection in PD.  Of the three delayed-start design clin. trials, two have investigated early vs. later start of rasagiline, a specific irreversible monoamine oxidase B inhibitor.  Each trial has supported, although not proven, disease-modifying effects.  A third delayed-start-design clin. trial examg. potential disease-modifying effects of pramipexole has unfortunately reportedly been neg. according to preliminary presentations.  The suggestion that rasagiline is disease modifying is made all the more compelling by in vitro and PD animal-model studies in which rasagiline was shown to have neuroprotective effects.  In this review, we examine efforts to demonstrate neuroprotection in PD to date, describe ongoing neuroprotection trials, and critically discuss the results of the most recent delayed-start clin. trials that test possible disease-modifying activities of rasagiline and pramipexole in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbdflLyDbbWLVg90H21EOLACvtfcHk0lhrAz7f57Qopw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1CltLfP&md5=3c3dbd364d7b2632eb1aedea1bd4b8a3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2165%2F11591320-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11591320-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DHenchcliffe%26aufirst%3DC.%26aulast%3DSevert%26aufirst%3DW.%2BL.%26atitle%3DDisease%2520modification%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%2520Aging%26date%3D2011%26volume%3D28%26spage%3D605%26epage%3D615%26doi%3D10.2165%2F11591320-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Shoulson, I.</span><span> </span><span class="NLM_article-title">DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">S160</span><span class="NLM_x">–</span> <span class="NLM_lpage">S166</span><span class="refDoi"> DOI: 10.1002/ana.410440724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1002%2Fana.410440724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1998&pages=S160-S166&author=I.+Shoulson&title=DATATOP%3A+a+decade+of+neuroprotective+inquiry.+Parkinson+Study+Group.+Deprenyl+And+Tocopherol+Antioxidative+Therapy+Of+Parkinsonism&doi=10.1002%2Fana.410440724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fana.410440724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410440724%26sid%3Dliteratum%253Aachs%26aulast%3DShoulson%26aufirst%3DI.%26atitle%3DDATATOP%253A%2520a%2520decade%2520of%2520neuroprotective%2520inquiry.%2520Parkinson%2520Study%2520Group.%2520Deprenyl%2520And%2520Tocopherol%2520Antioxidative%2520Therapy%2520Of%2520Parkinsonism%26jtitle%3DAnn.%2520Neurol.%26date%3D1998%26volume%3D44%26spage%3DS160%26epage%3DS166%26doi%3D10.1002%2Fana.410440724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Athauda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foltynie, T.</span><span> </span><span class="NLM_article-title">The ongoing pursuit of neuroprotective therapies in Parkinson disease</span> <span class="citation_source-journal">Nat. Rev. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1038/nrneurol.2014.226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1038%2Fnrneurol.2014.226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=25447485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVemsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=25-40&author=D.+Athaudaauthor=T.+Foltynie&title=The+ongoing+pursuit+of+neuroprotective+therapies+in+Parkinson+disease&doi=10.1038%2Fnrneurol.2014.226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ongoing pursuit of neuroprotective therapies in Parkinson disease</span></div><div class="casAuthors">Athauda, Dilan; Foltynie, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the lab., but none have translated to pos. results in patients with PD.  Potential neuroprotective drugs, such as ubiquinone, creatine and PYM50028, have failed to show any clin. benefits in recent high-profile clin. trials.  This 'failure to translate' is likely to be related primarily to our incomplete understanding of the pathogenic mechanisms underlying PD, and excessive reliance on data from toxin-based animal models to judge which agents should be selected for clin. trials.  Restricted resources inevitably mean that difficult compromises must be made in terms of trial design, and reliable estn. of efficacy is further hampered by the absence of validated biomarkers of disease progression.  Drug development in PD dementia has been mostly unsuccessful; however, emerging biochem., genetic and pathol. evidence suggests a link between tau and amyloid-β deposition and cognitive decline in PD, potentially opening up new possibilities for therapeutic intervention.  This Review discusses the most important 'druggable' disease mechanisms in PD, as well as the most-promising drugs that are being evaluated for their potential efficiency in treatment of motor and cognitive impairments in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo41alEY9yuaLVg90H21EOLACvtfcHk0li-qmxU0fHwUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVemsr%252FJ&md5=ee355c45e894609afff392f4b1e1a73e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2014.226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2014.226%26sid%3Dliteratum%253Aachs%26aulast%3DAthauda%26aufirst%3DD.%26aulast%3DFoltynie%26aufirst%3DT.%26atitle%3DThe%2520ongoing%2520pursuit%2520of%2520neuroprotective%2520therapies%2520in%2520Parkinson%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2015%26volume%3D11%26spage%3D25%26epage%3D40%26doi%3D10.1038%2Fnrneurol.2014.226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Dauer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Przedborski, S.</span><span> </span><span class="NLM_article-title">Parkinson’s disease: mechanisms and models</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">889</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span><span class="refDoi"> DOI: 10.1016/S0896-6273(03)00568-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2FS0896-6273%2803%2900568-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=12971891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsFait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2003&pages=889-909&author=W.+Dauerauthor=S.+Przedborski&title=Parkinson%E2%80%99s+disease%3A+mechanisms+and+models&doi=10.1016%2FS0896-6273%2803%2900568-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease: Mechanisms and models</span></div><div class="casAuthors">Dauer, William; Przedborski, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">889-909</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.  Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration.  The main obstacle to developing neuroprotective therapies is a limited understanding of the key mol. events that provoke neurodegeneration.  The discovery of PD genes has led to the hypothesis that misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis.  Previously implicated culprits in PD neurodegeneration, mitochondrial dysfunction and oxidative stress, may also act in part by causing the accumulation of misfolded proteins, in addn. to producing other deleterious events in dopaminergic neurons.  Neurotoxin-based models (particularly MPTP) have been important in elucidating the mol. cascade of cell death in dopaminergic neurons.  PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplIXMcN4C-ILVg90H21EOLACvtfcHk0li-qmxU0fHwUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsFait7o%253D&md5=70b4b771da04f6e879e9de431fce2d47</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2803%2900568-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252803%252900568-3%26sid%3Dliteratum%253Aachs%26aulast%3DDauer%26aufirst%3DW.%26aulast%3DPrzedborski%26aufirst%3DS.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%253A%2520mechanisms%2520and%2520models%26jtitle%3DNeuron%26date%3D2003%26volume%3D39%26spage%3D889%26epage%3D909%26doi%3D10.1016%2FS0896-6273%2803%2900568-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Gao, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J. S.</span><span> </span><span class="NLM_article-title">Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression</span> <span class="citation_source-journal">Trends Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1016/j.it.2008.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.it.2008.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=18599350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVCit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=357-365&author=H.+M.+Gaoauthor=J.+S.+Hong&title=Why+neurodegenerative+diseases+are+progressive%3A+uncontrolled+inflammation+drives+disease+progression&doi=10.1016%2Fj.it.2008.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression</span></div><div class="casAuthors">Gao, Hui-Ming; Hong, Jau-Shyong</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases are a group of chronic, progressive disorders characterized by the gradual loss of neurons in discrete areas of the central nervous system (CNS).  The mechanism(s) underlying their progressive nature remains unknown but a timely and well-controlled inflammatory reaction is essential for the integrity and proper function of the CNS.  Substantial evidence has documented a common inflammatory mechanism in various neurodegenerative diseases.  The authors hypothesize that in the diseased CNS, interactions between damaged neurons and dysregulated, overactivated microglia create a vicious self-propagating cycle causing uncontrolled, prolonged inflammation that drives the chronic progression of neurodegenerative diseases.  The authors further propose that dynamic modulation of this inflammatory reaction by interrupting the vicious cycle might become a disease-modifying therapeutic strategy for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGricPNjQBzPq7Vg90H21EOLACvtfcHk0li-qmxU0fHwUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVCit7w%253D&md5=b010045df3f5e1cc52e759e97773eb23</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2008.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2008.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.%2BM.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26atitle%3DWhy%2520neurodegenerative%2520diseases%2520are%2520progressive%253A%2520uncontrolled%2520inflammation%2520drives%2520disease%2520progression%26jtitle%3DTrends%2520Immunol.%26date%3D2008%26volume%3D29%26spage%3D357%26epage%3D365%26doi%3D10.1016%2Fj.it.2008.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y. P.</span><span> </span><span class="NLM_article-title">Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss</span> <span class="citation_source-journal">Brain, Behav., Immun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1016/j.bbi.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.bbi.2015.08.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=131-143&author=Z.+Liuauthor=H.+Q.+Chenauthor=Y.+Huangauthor=Y.+H.+Qiuauthor=Y.+P.+Peng&title=Transforming+growth+factor-%CE%B21+acts+via+T%CE%B2R-I+on+microglia+to+protect+against+MPP%28%2B%29-induced+dopaminergic+neuronal+loss&doi=10.1016%2Fj.bbi.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.%2BQ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DY.%2BP.%26atitle%3DTransforming%2520growth%2520factor-%25CE%25B21%2520acts%2520via%2520T%25CE%25B2R-I%2520on%2520microglia%2520to%2520protect%2520against%2520MPP%2528%252B%2529-induced%2520dopaminergic%2520neuronal%2520loss%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2016%26volume%3D51%26spage%3D131%26epage%3D143%26doi%3D10.1016%2Fj.bbi.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Van der Perren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toelen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Loor, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuypers, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gijsbers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Haute, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debyser, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baekelandt, V.</span><span> </span><span class="NLM_article-title">FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson’s disease</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1568</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2015.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neurobiolaging.2015.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=25660193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsValur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1559-1568&author=A.+Van+der+Perrenauthor=F.+Macchiauthor=J.+Toelenauthor=M.+S.+Carlonauthor=M.+Marisauthor=H.+de+Loorauthor=D.+R.+Kuypersauthor=R.+Gijsbersauthor=C.+Van+den+Hauteauthor=Z.+Debyserauthor=V.+Baekelandt&title=FK506+reduces+neuroinflammation+and+dopaminergic+neurodegeneration+in+an+%CE%B1-synuclein-based+rat+model+for+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neurobiolaging.2015.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease</span></div><div class="casAuthors">Van der Perren, Anke; Macchi, Francesca; Toelen, Jaan; Carlon, Marianne S.; Maris, Michael; de Loor, Henriette; Kuypers, Dirk R. J.; Gijsbers, Rik; Van den Haute, Chris; Debyser, Zeger; Baekelandt, Veerle</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1559-1568</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Alpha-synuclein (α-synuclein) is considered a key player in Parkinson's disease (PD), but the exact relationship between α-synuclein aggregation and dopaminergic neurodegeneration remains unresolved.  There is increasing evidence that neuroinflammatory processes are closely linked to dopaminergic cell death, but whether the inflammatory process is causally involved in PD or rather reflects secondary consequences of nigrostriatal pathway injury is still under debate.  We evaluated the therapeutic effect of the immunophilin ligand FK506 in a rAAV2/7 α-synuclein overexpression rat model.  Treatment with FK506 significantly increased the survival of dopaminergic neurons in a dose-dependent manner.  No redn. in α-synuclein aggregation was apparent in this time window, but FK506 significantly lowered the infiltration of both T helper and cytotoxic T cells and the no. and subtype of microglia and macrophages.  These data suggest that the anti-inflammatory properties of FK506 decrease neurodegeneration in this α-synuclein-based PD model, pointing to a causal role of neuroinflammation in the pathogenesis of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8mqw94W43hLVg90H21EOLACvtfcHk0lic9zx40-pWdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsValur4%253D&md5=cb80dcd06868a5c49165dabac76a505b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2015.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2015.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BPerren%26aufirst%3DA.%26aulast%3DMacchi%26aufirst%3DF.%26aulast%3DToelen%26aufirst%3DJ.%26aulast%3DCarlon%26aufirst%3DM.%2BS.%26aulast%3DMaris%26aufirst%3DM.%26aulast%3Dde%2BLoor%26aufirst%3DH.%26aulast%3DKuypers%26aufirst%3DD.%2BR.%26aulast%3DGijsbers%26aufirst%3DR.%26aulast%3DVan%2Bden%2BHaute%26aufirst%3DC.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DBaekelandt%26aufirst%3DV.%26atitle%3DFK506%2520reduces%2520neuroinflammation%2520and%2520dopaminergic%2520neurodegeneration%2520in%2520an%2520%25CE%25B1-synuclein-based%2520rat%2520model%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2015%26volume%3D36%26spage%3D1559%26epage%3D1568%26doi%3D10.1016%2Fj.neurobiolaging.2015.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Neuroinflammation in Parkinson’s disease and its potential as therapeutic target</span> <span class="citation_source-journal">Transl. Neurodegener.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="refDoi"> DOI: 10.1186/s40035-015-0042-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1186%2Fs40035-015-0042-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=26464797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVertLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=19&author=Q.+Wangauthor=Y.+Liuauthor=J.+Zhou&title=Neuroinflammation+in+Parkinson%E2%80%99s+disease+and+its+potential+as+therapeutic+target&doi=10.1186%2Fs40035-015-0042-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroinflammation in Parkinson's disease and its potential as therapeutic target</span></div><div class="casAuthors">Wang, Qinqin; Liu, Yingjun; Zhou, Jiawei</div><div class="citationInfo"><span class="NLM_cas:title">Translational Neurodegeneration</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19/1-19/9</span>CODEN:
                <span class="NLM_cas:coden">TNREAP</span>;
        ISSN:<span class="NLM_cas:issn">2047-9158</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD), the second most common age-assocd. neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-contg. aggregates in the substantia nigra pars compacta (SNpc).  Chronic neuroinflammation is one of the hallmarks of PD pathophysiol.  Post-mortem analyses of human PD patients and exptl. animal studies indicate that activation of glial cells and increases in pro-inflammatory factor levels are common features of the PD brain.  Chronic release of pro-inflammatory cytokines by activated astrocytes and microglia leads to the exacerbation of DA neuron degeneration in the SNpc.  Besides, peripheral immune system is also implicated in the pathogenesis of PD.  Infiltration and accumulation of immune cells from the periphery are detected in and around the affected brain regions of PD patients.  Moreover, inflammatory processes have been suggested as promising interventional targets for PD and even other neurodegenerative diseases.  A better understanding of the role of inflammation in PD will provide new insights into the pathol. processes and help to establish effective therapeutic strategies.  In this review, we will summarize recent progresses in the neuroimmune aspects of PD and highlight the potential therapeutic interventions targeting neuroinflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOtqPaQIjWM7Vg90H21EOLACvtfcHk0lic9zx40-pWdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVertLw%253D&md5=544927d85363f153b7469b1f59ac7069</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs40035-015-0042-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40035-015-0042-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DNeuroinflammation%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520its%2520potential%2520as%2520therapeutic%2520target%26jtitle%3DTransl.%2520Neurodegener.%26date%3D2015%26volume%3D4%26spage%3D19%26doi%3D10.1186%2Fs40035-015-0042-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Bartels, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemsen, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doorduin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dierckx, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, K. L.</span><span> </span><span class="NLM_article-title">[11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease?</span> <span class="citation_source-journal">Parkinsonism Relat. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1016/j.parkreldis.2009.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.parkreldis.2009.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=19487152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FpvFGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=57-59&author=A.+L.+Bartelsauthor=A.+T.+Willemsenauthor=J.+Doorduinauthor=E.+F.+de+Vriesauthor=R.+A.+Dierckxauthor=K.+L.+Leenders&title=%5B11C%5D-PK11195+PET%3A+quantification+of+neuroinflammation+and+a+monitor+of+anti-inflammatory+treatment+in+Parkinson%E2%80%99s+disease%3F&doi=10.1016%2Fj.parkreldis.2009.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?</span></div><div class="casAuthors">Bartels A L; Willemsen A T M; Doorduin J; de Vries E F J; Dierckx R A; Leenders K L</div><div class="citationInfo"><span class="NLM_cas:title">Parkinsonism & related disorders</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  [(11)C]-PK11195 PET has been used for in vivo brain imaging of microglia activation in Parkinson's disease (PD) patients.  COX-2 inhibition has been shown to reduce neuroinflammation and neurodegeneration in animal models of PD.  This pilot study assessed the use of [(11)C]-PK11195 PET to quantify neuroinflammation and evaluate the ability of COX-2 inhibition to reduce neuroinflammation in PD patients.  METHODS:  Fourteen PD patients and eight healthy, age matched controls underwent a [(11)C]-PK11195 PET and MRI scan.  Five PD patients were scanned before and after one month of celecoxib treatment 200 mg/day.  Arterial plasma sampling and metabolite analysis were performed to create plasma input curves.  A 2-compartment model and Logan analysis were applied and parametric DV images were compared using t-test in SPM2.  In addition a simplified reference region model (SRTM) was applied, with both the cerebellum and a reference region derived from cluster analysis.  RESULTS:  Using the cluster analysis, PD patients showed higher contralateral putamen BP and midbrain BP compared to controls, although considerable overlap was seen and differences were not statistically significant.  Unexpectedly, BP and DV after celecoxib were slightly higher.  Cerebellum as reference region resulted in lower BP values and k(3)/k(4) gave 10-fold higher BP values.  Linearization of the data did not show differences between PD patients and controls.  CONCLUSIONS:  In current practice, [(11)C]-PK11195 seems an unsuitable tracer for accurate or reliable quantification of neuroinflammation.  Refinement of [(11)C]-PK11195 uptake analysis and, more importantly, further development of better tracers is necessary to enable accurate measurement of neuroinflammation and effects of anti-inflammatory treatment in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmnhOlmzXVp8vLc4ARHEmzfW6udTcc2eYcZiBqb-gQcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FpvFGgtg%253D%253D&md5=97248f02ed914ee6c1c1cae23dd6e4c0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.parkreldis.2009.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.parkreldis.2009.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBartels%26aufirst%3DA.%2BL.%26aulast%3DWillemsen%26aufirst%3DA.%2BT.%26aulast%3DDoorduin%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DDierckx%26aufirst%3DR.%2BA.%26aulast%3DLeenders%26aufirst%3DK.%2BL.%26atitle%3D%255B11C%255D-PK11195%2520PET%253A%2520quantification%2520of%2520neuroinflammation%2520and%2520a%2520monitor%2520of%2520anti-inflammatory%2520treatment%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253F%26jtitle%3DParkinsonism%2520Relat.%2520Disord.%26date%3D2010%26volume%3D16%26spage%3D57%26epage%3D59%26doi%3D10.1016%2Fj.parkreldis.2009.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Imamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hishikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, Y.</span><span> </span><span class="NLM_article-title">Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains</span> <span class="citation_source-journal">Acta Neuropathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1007/s00401-003-0766-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1007%2Fs00401-003-0766-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=14513261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Clsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2003&pages=518-526&author=K.+Imamuraauthor=N.+Hishikawaauthor=M.+Sawadaauthor=T.+Nagatsuauthor=M.+Yoshidaauthor=Y.+Hashizume&title=Distribution+of+major+histocompatibility+complex+class+II-positive+microglia+and+cytokine+profile+of+Parkinson%E2%80%99s+disease+brains&doi=10.1007%2Fs00401-003-0766-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains</span></div><div class="casAuthors">Imamura, Kazuhiro; Hishikawa, Nozomi; Sawada, Makoto; Nagatsu, Toshiharu; Yoshida, Mari; Hashizume, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">518-526</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">There are numerous observations confirming that microglia expressing major histocompatibility complex (MHC) class II mols. are assocd. with the central nervous system (CNS) in aging and pathol. conditions.  In this study, we investigated the distribution of MHC class II-pos. microglia in Parkinson's disease (PD) brains.  The no. of MHC class II-pos. microglia in the substantia nigra (SN) and putamen increased as the neuronal degeneration of the SN proceeded.  These cells were also ICAM-1 (CD54) and LFA-1 (CD11a) pos.  The no. of activated microglia not only in the SN and putamen but also in the hippocampus, transentorhinal cortex, cingulate cortex and temporal cortex in PD was significantly higher than that in the normal control.  Most activated microglia persisted regardless of the presence or absence of Lewy bodies.  They were frequently assocd. not only with α-synuclein-pos. Lewy neurites, but also with TH-16-pos. dopaminergic and WH-3-pos. serotonergic neurites, as well as MAP-2- and SMI-32-pos. neurites.  These activated microglia were also pos. for TNF-α and interleukin-6, which are known to have a neuroprotective function.  We conclude that MHC class II-pos. microglia are a sensitive index of neuropathol. change and are actively assocd. with damaged neurons and neurites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeHPMG3ileOrVg90H21EOLACvtfcHk0lhkW-AE1RVxwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Clsrs%253D&md5=63b311e03fb741c1a2fd75274f296311</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs00401-003-0766-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-003-0766-2%26sid%3Dliteratum%253Aachs%26aulast%3DImamura%26aufirst%3DK.%26aulast%3DHishikawa%26aufirst%3DN.%26aulast%3DSawada%26aufirst%3DM.%26aulast%3DNagatsu%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DY.%26atitle%3DDistribution%2520of%2520major%2520histocompatibility%2520complex%2520class%2520II-positive%2520microglia%2520and%2520cytokine%2520profile%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DActa%2520Neuropathol.%26date%3D2003%26volume%3D106%26spage%3D518%26epage%3D526%26doi%3D10.1007%2Fs00401-003-0766-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Rees, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ives, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Shlomo, Y.</span><span> </span><span class="NLM_article-title">Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD008454</span><span class="refDoi"> DOI: 10.1002/14651858.CD008454.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1002%2F14651858.CD008454.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=CD008454&author=K.+Reesauthor=R.+Stoweauthor=S.+Patelauthor=N.+Ivesauthor=K.+Breenauthor=C.+E.+Clarkeauthor=Y.+Ben-Shlomo&title=Non-steroidal+anti-inflammatory+drugs+as+disease-modifying+agents+for+Parkinson%E2%80%99s+disease%3A+evidence+from+observational+studies&doi=10.1002%2F14651858.CD008454.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD008454.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD008454.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DK.%26aulast%3DStowe%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DIves%26aufirst%3DN.%26aulast%3DBreen%26aufirst%3DK.%26aulast%3DClarke%26aufirst%3DC.%2BE.%26aulast%3DBen-Shlomo%26aufirst%3DY.%26atitle%3DNon-steroidal%2520anti-inflammatory%2520drugs%2520as%2520disease-modifying%2520agents%2520for%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520evidence%2520from%2520observational%2520studies%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2011%26spage%3DCD008454%26doi%3D10.1002%2F14651858.CD008454.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Lindholm, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makela, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Liberto, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belluardo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saarma, M.</span><span> </span><span class="NLM_article-title">Current disease modifying approaches to treat Parkinson’s disease</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1379</span><span class="refDoi"> DOI: 10.1007/s00018-015-2101-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1007%2Fs00018-015-2101-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=26616211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFalsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=1365-1379&author=D.+Lindholmauthor=J.+Makelaauthor=V.+Di+Libertoauthor=G.+Mudoauthor=N.+Belluardoauthor=O.+Erikssonauthor=M.+Saarma&title=Current+disease+modifying+approaches+to+treat+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs00018-015-2101-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Current disease modifying approaches to treat Parkinson's disease</span></div><div class="casAuthors">Lindholm, Dan; Makela, Johanna; Di Liberto, Valentina; Mudo, Giuseppa; Belluardo, Natale; Eriksson, Ove; Saarma, Mart</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1365-1379</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a progressive neurol. disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients.  The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the mol. mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies.  Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD.  In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown pos. results in protecting and repairing dopaminergic neurons in various models of PD.  Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compds. that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation.  In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclin. or in animal models of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1OgLJZdU-abVg90H21EOLACvtfcHk0lhkW-AE1RVxwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFalsL7P&md5=a66d8f4bdc0f8e91f763555789f22fcc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-2101-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-2101-1%26sid%3Dliteratum%253Aachs%26aulast%3DLindholm%26aufirst%3DD.%26aulast%3DMakela%26aufirst%3DJ.%26aulast%3DDi%2BLiberto%26aufirst%3DV.%26aulast%3DMudo%26aufirst%3DG.%26aulast%3DBelluardo%26aufirst%3DN.%26aulast%3DEriksson%26aufirst%3DO.%26aulast%3DSaarma%26aufirst%3DM.%26atitle%3DCurrent%2520disease%2520modifying%2520approaches%2520to%2520treat%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D1365%26epage%3D1379%26doi%3D10.1007%2Fs00018-015-2101-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Tatsuta, K.</span><span> </span><span class="NLM_article-title">Preparation of dihydrobenzopyrans as intermediates for sideroxylonal and physiological active substances</span>. PCT Int. Appl. JP 2000186084,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=K.+Tatsuta&title=Preparation+of+dihydrobenzopyrans+as+intermediates+for+sideroxylonal+and+physiological+active+substances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTatsuta%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520dihydrobenzopyrans%2520as%2520intermediates%2520for%2520sideroxylonal%2520and%2520physiological%2520active%2520substances%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lafon, L.</span><span> </span><span class="NLM_article-title">(2,4,6-Trimethoxyphenyl)-(3-piperidinopropyl)-ketone derivatives</span>. PCT Int. Appl. US 4705795,<span class="NLM_x"> </span><span class="NLM_year">1987</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&author=L.+Lafon&title=%282%2C4%2C6-Trimethoxyphenyl%29-%283-piperidinopropyl%29-ketone+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLafon%26aufirst%3DL.%26atitle%3D%25282%252C4%252C6-Trimethoxyphenyl%2529-%25283-piperidinopropyl%2529-ketone%2520derivatives%26date%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Du, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.1021/jm301248y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301248y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=97-108&author=D.+Duauthor=J.+Yanauthor=J.+Renauthor=H.+Lvauthor=Y.+Liauthor=S.+Xuauthor=Y.+Wangauthor=S.+Maauthor=J.+Quauthor=W.+Tangauthor=Z.+Huauthor=S.+Yu&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+glycyrrhizin+derivatives+as+potent+high-mobility+group+box-1+inhibitors+with+anti-heart-failure+activity+in+vivo&doi=10.1021%2Fjm301248y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm301248y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301248y%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DS.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520glycyrrhizin%2520derivatives%2520as%2520potent%2520high-mobility%2520group%2520box-1%2520inhibitors%2520with%2520anti-heart-failure%2520activity%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D97%26epage%3D108%26doi%3D10.1021%2Fjm301248y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Dewick, P. M.</span><span> </span><span class="NLM_article-title">Benzyl p-toluenesulfonate as an <i>O</i>-benzylating agent for the protection of phenols</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span><span class="refDoi"> DOI: 10.1080/00397918108065666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1080%2F00397918108065666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADyaL38XjsVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1981&pages=853-857&author=P.+M.+Dewick&title=Benzyl+p-toluenesulfonate+as+an+O-benzylating+agent+for+the+protection+of+phenols&doi=10.1080%2F00397918108065666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Benzyl p-toluenesulfonate as an O-benzylating agent for the protection of phenols</span></div><div class="casAuthors">Dewick, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">853-7</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">Resorcinols I (R = Me, H, 4-MeOC6H4CH2; R1 = R2 = H, or one of R1 and R2 is OH and the other is H) reacted with 4-MeC6H4SO3CH2Ph (II) to yield the resp. ethers III (R3 = H, PhCH2; R4 = H, OH, OCH2Ph).  I (R = Me, R1 = R2 = H) was treated with II and K2CO3 in Me2CO to give III (R = Me, R2 = R3 = R4 = H).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp-fXmmbFcALVg90H21EOLACvtfcHk0lja9qc1FgPBPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XjsVOhuw%253D%253D&md5=db672506f54ebab58fa4f75155b1c417</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F00397918108065666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397918108065666%26sid%3Dliteratum%253Aachs%26aulast%3DDewick%26aufirst%3DP.%2BM.%26atitle%3DBenzyl%2520p-toluenesulfonate%2520as%2520an%2520O-benzylating%2520agent%2520for%2520the%2520protection%2520of%2520phenols%26jtitle%3DSynth.%2520Commun.%26date%3D1981%26volume%3D11%26spage%3D853%26epage%3D857%26doi%3D10.1080%2F00397918108065666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kim, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, K. J.</span><span> </span><span class="NLM_article-title">Synthesis and fragmentation of furoxanaldehydes in the gas phase for nanopatterned alkyne formation on a solid surface</span> <span class="citation_source-journal">Bull. Korean Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span><span class="refDoi"> DOI: 10.5012/bkcs.2009.30.2.459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.5012%2Fbkcs.2009.30.2.459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktlansb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=459-463&author=G.+Y.+Kimauthor=J.+Kimauthor=S.+H.+Leeauthor=H.+J.+Kimauthor=K.+J.+Hwang&title=Synthesis+and+fragmentation+of+furoxanaldehydes+in+the+gas+phase+for+nanopatterned+alkyne+formation+on+a+solid+surface&doi=10.5012%2Fbkcs.2009.30.2.459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and fragmentation of furoxanaldehydes in the gas phase for nanopatterned alkyne formation on a solid surface</span></div><div class="casAuthors">Kim, Gi Young; Kim, Jucheon; Lee, Seung Hee; Kim, Hyung Jin; Hwang, Kwang-Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Korean Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">459-463</span>CODEN:
                <span class="NLM_cas:coden">BKCSDE</span>;
        ISSN:<span class="NLM_cas:issn">0253-2964</span>.
    
            (<span class="NLM_cas:orgname">Korean Chemical Society</span>)
        </div><div class="casAbstract">Four furoxanaldehydes I (R1 = Me, Ph; R2 = OHC, 4-OHCC6H4, 4-OHCC6H4CH:CH) were designed for alkyne formation on a solid surface.  Furoxans I (R1 = Ph; R2 = OHC, 4-OHCC6H4) were prepd. via the reaction of corresponding alkenes with NaNO2 in acetic acid.  Furoxan I (R1 = Me; R2 = 4-OHCC6H4CH:CH), in which the furoxan ring is conjugated with a double bond, was prepd. from bis(bromomethyl)benzene in 5 steps using the Wittig reaction of aldehyde I (R1 = Me; R2 = OHC) as the key step.  The electron beam-mediated fragmentation of the furoxanaldehydes I in a mass spectrometer was exploited by focusing on alkyne formation on the solid surface.  The fragmentation of furoxan I (R1 = Ph; R2 = 4-OHCC6H4) afforded diarylacetylene at high efficiency, suggesting that the aryl group conjugated with the furoxan ring could facilitate alkyne formation with the evolution of NO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpndP5JHokNQrVg90H21EOLACvtfcHk0lja9qc1FgPBPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktlansb0%253D&md5=8d262193b2a386e96b6120167fe2e210</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.5012%2Fbkcs.2009.30.2.459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5012%252Fbkcs.2009.30.2.459%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%2BY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DHwang%26aufirst%3DK.%2BJ.%26atitle%3DSynthesis%2520and%2520fragmentation%2520of%2520furoxanaldehydes%2520in%2520the%2520gas%2520phase%2520for%2520nanopatterned%2520alkyne%2520formation%2520on%2520a%2520solid%2520surface%26jtitle%3DBull.%2520Korean%2520Chem.%2520Soc.%26date%3D2009%26volume%3D30%26spage%3D459%26epage%3D463%26doi%3D10.5012%2Fbkcs.2009.30.2.459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">The role of TLR4-mediated PTEN/PI3K/AKT/NF-κB signaling pathway in neuroinflammation in hippocampal neurons</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2014.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuroscience.2014.03.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2014&pages=93-101&author=M.+Zhaoauthor=A.+Zhouauthor=L.+Xuauthor=X.+Zhang&title=The+role+of+TLR4-mediated+PTEN%2FPI3K%2FAKT%2FNF-%CE%BAB+signaling+pathway+in+neuroinflammation+in+hippocampal+neurons&doi=10.1016%2Fj.neuroscience.2014.03.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2014.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2014.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DThe%2520role%2520of%2520TLR4-mediated%2520PTEN%252FPI3K%252FAKT%252FNF-%25CE%25BAB%2520signaling%2520pathway%2520in%2520neuroinflammation%2520in%2520hippocampal%2520neurons%26jtitle%3DNeuroscience%26date%3D2014%26volume%3D269%26spage%3D93%26epage%3D101%26doi%3D10.1016%2Fj.neuroscience.2014.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Alexaki, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charalampopoulos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kampa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassalou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodoropoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stathopoilos, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzoglou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravanis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanas, E.</span><span> </span><span class="NLM_article-title">Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">1596</span><span class="refDoi"> DOI: 10.1096/fj.04-1495fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1096%2Ffj.04-1495fje" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1594-1596&author=V.+I.+Alexakiauthor=I.+Charalampopoulosauthor=M.+Kampaauthor=H.+Vassalouauthor=P.+Theodoropoulosauthor=E.+N.+Stathopoilosauthor=A.+Hatzoglouauthor=A.+Gravanisauthor=E.+Castanas&title=Estrogen+exerts+neuroprotective+effects+via+membrane+estrogen+receptors+and+rapid+Akt%2FNOS+activation&doi=10.1096%2Ffj.04-1495fje"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1096%2Ffj.04-1495fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.04-1495fje%26sid%3Dliteratum%253Aachs%26aulast%3DAlexaki%26aufirst%3DV.%2BI.%26aulast%3DCharalampopoulos%26aufirst%3DI.%26aulast%3DKampa%26aufirst%3DM.%26aulast%3DVassalou%26aufirst%3DH.%26aulast%3DTheodoropoulos%26aufirst%3DP.%26aulast%3DStathopoilos%26aufirst%3DE.%2BN.%26aulast%3DHatzoglou%26aufirst%3DA.%26aulast%3DGravanis%26aufirst%3DA.%26aulast%3DCastanas%26aufirst%3DE.%26atitle%3DEstrogen%2520exerts%2520neuroprotective%2520effects%2520via%2520membrane%2520estrogen%2520receptors%2520and%2520rapid%2520Akt%252FNOS%2520activation%26jtitle%3DFASEB%2520J.%26date%3D2004%26volume%3D18%26spage%3D1594%26epage%3D1596%26doi%3D10.1096%2Ffj.04-1495fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leak, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span> </span><span class="NLM_article-title">HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">2853</span><span class="NLM_x">–</span> <span class="NLM_lpage">2858</span><span class="refDoi"> DOI: 10.1073/pnas.1501441112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1073%2Fpnas.1501441112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=2853-2858&author=G.+Wangauthor=Y.+Shiauthor=X.+Jiangauthor=R.+K.+Leakauthor=X.+Huauthor=Y.+Wuauthor=H.+Puauthor=W.+W.+Liauthor=B.+Tangauthor=Y.+Wangauthor=Y.+Gaoauthor=P.+Zhengauthor=M.+V.+Bennettauthor=J.+Chen&title=HDAC+inhibition+prevents+white+matter+injury+by+modulating+microglia%2Fmacrophage+polarization+through+the+GSK3%CE%B2%2FPTEN%2FAkt+axis&doi=10.1073%2Fpnas.1501441112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1501441112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1501441112%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLeak%26aufirst%3DR.%2BK.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DPu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DBennett%26aufirst%3DM.%2BV.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DHDAC%2520inhibition%2520prevents%2520white%2520matter%2520injury%2520by%2520modulating%2520microglia%252Fmacrophage%2520polarization%2520through%2520the%2520GSK3%25CE%25B2%252FPTEN%252FAkt%2520axis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D2853%26epage%3D2858%26doi%3D10.1073%2Fpnas.1501441112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Fragoso, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barata, J. T.</span><span> </span><span class="NLM_article-title">Kinases, tails and more: regulation of PTEN function by phosphorylation</span> <span class="citation_source-journal">Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">77–78</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.ymeth.2014.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.ymeth.2014.10.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77%E2%80%9378&publication_year=2015&pages=75-81&author=R.+Fragosoauthor=J.+T.+Barata&title=Kinases%2C+tails+and+more%3A+regulation+of+PTEN+function+by+phosphorylation&doi=10.1016%2Fj.ymeth.2014.10.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2014.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2014.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DFragoso%26aufirst%3DR.%26aulast%3DBarata%26aufirst%3DJ.%2BT.%26atitle%3DKinases%252C%2520tails%2520and%2520more%253A%2520regulation%2520of%2520PTEN%2520function%2520by%2520phosphorylation%26jtitle%3DMethods%26date%3D2015%26volume%3D77%25E2%2580%259378%26spage%3D75%26epage%3D81%26doi%3D10.1016%2Fj.ymeth.2014.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span> </span><span class="NLM_article-title">Regulation of PTEN by Rho small GTPases</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1038/ncb1236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1038%2Fncb1236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=15793569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVakt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=399-404&author=Z.+Liauthor=X.+Dongauthor=Z.+Wangauthor=W.+Liuauthor=N.+Dengauthor=Y.+Dingauthor=L.+Tangauthor=T.+Hlaauthor=R.+Zengauthor=L.+Liauthor=D.+Wu&title=Regulation+of+PTEN+by+Rho+small+GTPases&doi=10.1038%2Fncb1236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of PTEN by Rho small GTPases</span></div><div class="casAuthors">Li, Zhong; Dong, Xiemei; Wang, Zhenglong; Liu, Wenzhong; Deng, Ning; Ding, Yu; Tang, Liuya; Hla, Tim; Zeng, Rong; Li, Lin; Wu, Dianqing</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">399-404</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">PTEN (phosphatase and tensin homolog) is a phosphatase that dephosphorylates both protein and phosphoinositide substrates.  It is mutated in a variety of human tumors and has important roles in a diverse range of biol. processes, including cell migration and chemotaxis.  PTEN's intracellular localization and presumably activity are regulated by chemoattractants in Dictyostelium and mouse neutrophils.  However, the mechanisms for its regulation remain elusive.  Here we show that RhoA and Cdc42, members of the Rho family of small GTPases, regulate the intracellular localization of PTEN in leukocytes and human transfected embryonic kidney cells.  In addn., active RhoA is able to stimulate the phospholipid phosphatase activity of PTEN in human embryonic kidney cells and leukocytes, and this regulation seems to require RhoA's downstream effector, RhoA-assocd. kinase (Rock).  Furthermore, we have identified key residues on PTEN that are required for its regulation by the small GTPase, and show that small GTPase-mediated regulation of PTEN has a significant role in the regulation of chemotaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5wzxQcMid_LVg90H21EOLACvtfcHk0lhUoXYajzyCCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVakt7s%253D&md5=34f504bf42d5a9cd15c308846f9a3e80</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fncb1236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1236%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDeng%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DZeng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520PTEN%2520by%2520Rho%2520small%2520GTPases%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D399%26epage%3D404%26doi%3D10.1038%2Fncb1236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Jyothi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidyadhara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahadevan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmar, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manohari, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alladi, P. A.</span><span> </span><span class="NLM_article-title">Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3321</span><span class="NLM_x">–</span> <span class="NLM_lpage">3333</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2015.08.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neurobiolaging.2015.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=26433682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A280%3ADC%252BC283os1Sqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=3321-3333&author=H.+J.+Jyothiauthor=D.+J.+Vidyadharaauthor=A.+Mahadevanauthor=M.+Philipauthor=S.+K.+Parmarauthor=S.+G.+Manohariauthor=S.+K.+Shankarauthor=T.+R.+Rajuauthor=P.+A.+Alladi&title=Aging+causes+morphological+alterations+in+astrocytes+and+microglia+in+human+substantia+nigra+pars+compacta&doi=10.1016%2Fj.neurobiolaging.2015.08.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta</span></div><div class="casAuthors">Jyothi H J; Vidyadhara D J; Manohari S Gowri; Raju Trichur R; Mahadevan Anita; Parmar Suresh Kumar; Shankar S K; Philip Mariamma; Alladi Phalguni Anand</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of aging</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3321-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Age being a risk factor for Parkinson's disease, assessment of age-related changes in the human substantia nigra may elucidate its pathogenesis.  Increase in Marinesco bodies, α-synuclein, free radicals and so forth in the aging nigral neurons are clear indicators of neurodegeneration.  Here, we report the glial responses in aging human nigra.  The glial numbers were determined on Nissl-stained sections.  The expression of glial fibrillary acidic protein, S100β, 2', 3'-cyclic nucleotide 3' phosphodiesterase, and Iba1 was assessed on cryosections of autopsied midbrains by immunohistochemistry and densitometry.  The glial counts showed a biphasic increase, of which, the first prominent phase from fetal age to birth could be physiological gliogenesis whereas the second one after middle age may reflect mild age-related gliosis.  Astrocytic morphology was altered, but glial fibrillary acidic protein expression increased only mildly.  Presence of type-4 microglia suggests possibility of neuroinflammation.  Mild reduction in 2', 3'-cyclic nucleotide 3' phosphodiesterase-labeled area denotes subtle demyelination.  Stable age-related S100β expression indicates absence of calcium overload.  Against the expected prominent gliosis, subtle age-related morphological alterations in human nigral glia attribute them a participatory role in aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8ulipU8R-ki-bLEOO4dYpfW6udTcc2ebu50qYRZ8D67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283os1Sqsg%253D%253D&md5=746dd59ffca7f660bd81943052f49736</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2015.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2015.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DJyothi%26aufirst%3DH.%2BJ.%26aulast%3DVidyadhara%26aufirst%3DD.%2BJ.%26aulast%3DMahadevan%26aufirst%3DA.%26aulast%3DPhilip%26aufirst%3DM.%26aulast%3DParmar%26aufirst%3DS.%2BK.%26aulast%3DManohari%26aufirst%3DS.%2BG.%26aulast%3DShankar%26aufirst%3DS.%2BK.%26aulast%3DRaju%26aufirst%3DT.%2BR.%26aulast%3DAlladi%26aufirst%3DP.%2BA.%26atitle%3DAging%2520causes%2520morphological%2520alterations%2520in%2520astrocytes%2520and%2520microglia%2520in%2520human%2520substantia%2520nigra%2520pars%2520compacta%26jtitle%3DNeurobiol.%2520Aging%26date%3D2015%26volume%3D36%26spage%3D3321%26epage%3D3333%26doi%3D10.1016%2Fj.neurobiolaging.2015.08.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Lull, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. L.</span><span> </span><span class="NLM_article-title">Microglial activation and chronic neurodegeneration</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1016/j.nurt.2010.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.nurt.2010.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=20880500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=354-365&author=M.+E.+Lullauthor=M.+L.+Block&title=Microglial+activation+and+chronic+neurodegeneration&doi=10.1016%2Fj.nurt.2010.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial Activation and Chronic Neurodegeneration</span></div><div class="casAuthors">Lull, Melinda E.; Block, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Microglia, the resident innate immune cells in the brain, have long been implicated in the pathol. of neurodegenerative diseases.  Accumulating evidence points to activated microglia as a chronic source of multiple neurotoxic factors, including tumor necrosis factor-α, nitric oxide, interleukin-1β, and reactive oxygen species (ROS), driving progressive neuron damage.  Microglia can become chronically activated by either a single stimulus (e.g., lipopolysaccharide or neuron damage) or multiple stimuli exposures to result in cumulative neuronal loss with time.  Although the mechanisms driving these phenomena are just beginning to be understood, reactive microgliosis (the microglial response to neuron damage) and ROS have been implicated as key mechanisms of chronic and neurotoxic microglial activation, particularly in the case of Parkinson's disease.  We review the mechanisms of neurotoxicity assocd. with chronic microglial activation and discuss the role of neuronal death and microglial ROS driving the chronic and toxic microglial phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojnZw-8eRdDLVg90H21EOLACvtfcHk0lhbhPH-SEkDeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLnO&md5=d12e62dba01dd76cfd2a7edf1df3d3af</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2010.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2010.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DLull%26aufirst%3DM.%2BE.%26aulast%3DBlock%26aufirst%3DM.%2BL.%26atitle%3DMicroglial%2520activation%2520and%2520chronic%2520neurodegeneration%26jtitle%3DNeurotherapeutics%26date%3D2010%26volume%3D7%26spage%3D354%26epage%3D365%26doi%3D10.1016%2Fj.nurt.2010.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Paul, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliceiri, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheresh, D. A.</span><span> </span><span class="NLM_article-title">Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1038/84675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1038%2F84675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=11175854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVyks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=222-227&author=R.+Paulauthor=Z.+G.+Zhangauthor=B.+P.+Eliceiriauthor=Q.+Jiangauthor=A.+D.+Bocciaauthor=R.+L.+Zhangauthor=M.+Choppauthor=D.+A.+Cheresh&title=Src+deficiency+or+blockade+of+Src+activity+in+mice+provides+cerebral+protection+following+stroke&doi=10.1038%2F84675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke</span></div><div class="casAuthors">Paul, Robert; Zhang, Zheng G.; Eliceiri, Brian P.; Jiang, Quan; Boccia, Antonio D.; Zhang, Rui L.; Chopp, Michael; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-227</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF), an angiogenic factor produced in response to ischemic injury, promotes vascular permeability (VP).  Evidence is provided that Src kinase regulates VEGF-mediated VP in the brain following stroke and that suppression of Src activity decreases VP thereby minimizing brain injury.  Mice lacking pp60C-SrC are resistant to VEGF-induced VP and show decreased infarct vols. after stroke whereas mice deficient in pp59C-fyn, another Src family member, have normal VEGF-mediated VP and infarct size.  Systemic application of a Src-inhibitor given up to six hours following stroke suppressed VP protecting wild-type mice from ischemia-induced brain damage without influencing VEGF expression.  This was assocd. with reduced edema, improved cerebral perfusion and decreased infarct vol. 24 h after injury as measured by magnetic resonance imaging and histol. anal.  Thus, Src represents a key intermediate and novel therapeutic target in the pathophysiol. of cerebral ischemia where it appears to regulate neuronal damage by influencing VEGF-mediated VP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh1xP-Yo2f37Vg90H21EOLACvtfcHk0lhbhPH-SEkDeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVyks70%253D&md5=93f387afda4e2c301275b792072f70dd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2F84675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F84675%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DZ.%2BG.%26aulast%3DEliceiri%26aufirst%3DB.%2BP.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DBoccia%26aufirst%3DA.%2BD.%26aulast%3DZhang%26aufirst%3DR.%2BL.%26aulast%3DChopp%26aufirst%3DM.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DSrc%2520deficiency%2520or%2520blockade%2520of%2520Src%2520activity%2520in%2520mice%2520provides%2520cerebral%2520protection%2520following%2520stroke%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D222%26epage%3D227%26doi%3D10.1038%2F84675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siminovitch, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">40057</span><span class="NLM_x">–</span> <span class="NLM_lpage">40066</span><span class="refDoi"> DOI: 10.1074/jbc.M303621200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1074%2Fjbc.M303621200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=12869565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFamsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=40057-40066&author=Y.+Luauthor=Q.+Yuauthor=J.+H.+Liuauthor=J.+Zhangauthor=H.+Wangauthor=D.+Koulauthor=J.+S.+McMurrayauthor=X.+Fangauthor=W.+K.+Yungauthor=K.+A.+Siminovitchauthor=G.+B.+Mills&title=Src+family+protein-tyrosine+kinases+alter+the+function+of+PTEN+to+regulate+phosphatidylinositol+3-kinase%2FAKT+cascades&doi=10.1074%2Fjbc.M303621200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades</span></div><div class="casAuthors">Lu, Yiling; Yu, Qinghua; Liu, Jue Hui; Zhang, Jinyi; Wang, Hongwei; Koul, Dimpy; McMurray, John S.; Fang, Xianjun; Yung, W. K. Alfred; Siminovitch, Kathy A.; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">40057-40066</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Src family protein-tyrosine kinases, which play an important role in signal integration, have been implicated in tumorigenesis in multiple lineages, including breast cancer.  We demonstrate, herein, that Src kinases regulate the phosphatidylinositol 3-kinase (PI3K) signaling cascade via altering the function of the PTEN tumor suppressor.  Overexpression of activated Src protein-tyrosine kinases in PTEN-deficient breast cancer cells does not alter AKT phosphorylation, an indicator of signal transduction through the PI3K pathway.  However, in the presence of functional PTEN, Src reverses the activity of PTEN, resulting in an increase in AKT phosphorylation.  Activated Src reduces the ability of PTEN to dephosphorylate phosphatidylinositols in micelles and promotes AKT translocation to cellular plasma membranes but does not alter PTEN activity toward water-sol. phosphatidylinositols.  Thus, Src may alter the capacity of the PTEN C2 domain to bind cellular membranes rather than directly interfering with PTEN enzymic activity.  Tyrosine phosphorylation of PTEN is increased in breast cancer cells treated with pervanadate, suggesting that PTEN contains sites for tyrosine phosphorylation.  Src kinase inhibitors markedly decreased pervanadate-mediated tyrosine phosphorylation of PTEN.  Further, expression of activated Src results in marked tyrosine phosphorylation of PTEN.  SHP-1, a SH2 domain-contg. protein-tyrosine phosphatase, selectively binds and dephosphorylates PTEN in Src transfected cells.  Both Src inhibitors and SHP-1 overexpression reverse Src-induced loss of PTEN function.  Coexpression of PTEN with activated Src reduces the stability of PTEN.  Taken together, the data indicate that activated Src inhibits PTEN function leading to alterations in signaling through the PI3K/AKT pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWFNxCQ8gMqLVg90H21EOLACvtfcHk0lgZI302rOGEWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFamsLs%253D&md5=2696aba274ab4ee0f85736f0f7b8344d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M303621200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M303621200%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKoul%26aufirst%3DD.%26aulast%3DMcMurray%26aufirst%3DJ.%2BS.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYung%26aufirst%3DW.%2BK.%26aulast%3DSiminovitch%26aufirst%3DK.%2BA.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DSrc%2520family%2520protein-tyrosine%2520kinases%2520alter%2520the%2520function%2520of%2520PTEN%2520to%2520regulate%2520phosphatidylinositol%25203-kinase%252FAKT%2520cascades%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D40057%26epage%3D40066%26doi%3D10.1074%2Fjbc.M303621200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Socodato, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portugal, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domith, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coreixas, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loiola, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paes-de-Carvalho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrosio, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Relvas, J. B.</span><span> </span><span class="NLM_article-title">c-Src function is necessary and sufficient for triggering microglial cell activation</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1002/glia.22767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1002%2Fglia.22767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=497-511&author=R.+Socodatoauthor=C.+C.+Portugalauthor=I.+Domithauthor=N.+A.+Oliveiraauthor=V.+S.+Coreixasauthor=E.+C.+Loiolaauthor=T.+Martinsauthor=A.+R.+Santiagoauthor=R.+Paes-de-Carvalhoauthor=A.+F.+Ambrosioauthor=J.+B.+Relvas&title=c-Src+function+is+necessary+and+sufficient+for+triggering+microglial+cell+activation&doi=10.1002%2Fglia.22767"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fglia.22767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.22767%26sid%3Dliteratum%253Aachs%26aulast%3DSocodato%26aufirst%3DR.%26aulast%3DPortugal%26aufirst%3DC.%2BC.%26aulast%3DDomith%26aufirst%3DI.%26aulast%3DOliveira%26aufirst%3DN.%2BA.%26aulast%3DCoreixas%26aufirst%3DV.%2BS.%26aulast%3DLoiola%26aufirst%3DE.%2BC.%26aulast%3DMartins%26aufirst%3DT.%26aulast%3DSantiago%26aufirst%3DA.%2BR.%26aulast%3DPaes-de-Carvalho%26aufirst%3DR.%26aulast%3DAmbrosio%26aufirst%3DA.%2BF.%26aulast%3DRelvas%26aufirst%3DJ.%2BB.%26atitle%3Dc-Src%2520function%2520is%2520necessary%2520and%2520sufficient%2520for%2520triggering%2520microglial%2520cell%2520activation%26jtitle%3DGlia%26date%3D2015%26volume%3D63%26spage%3D497%26epage%3D511%26doi%3D10.1002%2Fglia.22767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Tai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson’s disease models</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuropharm.2013.07.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=201-212&author=W.+Taiauthor=X.+Yeauthor=X.+Baoauthor=B.+Zhaoauthor=X.+Wangauthor=D.+Zhang&title=Inhibition+of+Src+tyrosine+kinase+activity+by+squamosamide+derivative+FLZ+attenuates+neuroinflammation+in+both+in+vivo+and+in+vitro+Parkinson%E2%80%99s+disease+models&doi=10.1016%2Fj.neuropharm.2013.07.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Src%2520tyrosine%2520kinase%2520activity%2520by%2520squamosamide%2520derivative%2520FLZ%2520attenuates%2520neuroinflammation%2520in%2520both%2520in%2520vivo%2520and%2520in%2520vitro%2520Parkinson%25E2%2580%2599s%2520disease%2520models%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D75%26spage%3D201%26epage%3D212%26doi%3D10.1016%2Fj.neuropharm.2013.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bao, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson’s disease models</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">396</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2011.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;key=10.1016%2Fj.neuroscience.2011.11.036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2012&pages=396-40&author=X.+Q.+Baoauthor=X.+C.+Kongauthor=C.+Qianauthor=D.+Zhang&title=FLZ+protects+dopaminergic+neuron+through+activating+protein+kinase+B%2Fmammalian+target+of+rapamycin+pathway+and+inhibiting+RTP801+expression+in+Parkinson%E2%80%99s+disease+models&doi=10.1016%2Fj.neuroscience.2011.11.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2011.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2011.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DX.%2BQ.%26aulast%3DKong%26aufirst%3DX.%2BC.%26aulast%3DQian%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DFLZ%2520protects%2520dopaminergic%2520neuron%2520through%2520activating%2520protein%2520kinase%2520B%252Fmammalian%2520target%2520of%2520rapamycin%2520pathway%2520and%2520inhibiting%2520RTP801%2520expression%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520models%26jtitle%3DNeuroscience%26date%3D2012%26volume%3D202%26spage%3D396%26epage%3D40%26doi%3D10.1016%2Fj.neuroscience.2011.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i89"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00976">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_02182"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00976">10.1021/acs.jmedchem.6b00976</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR (<sup>1</sup>H and <sup>13</sup>C) spectra of all target compounds, HPLC analysis of compounds, proteomics studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Proteomics data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_002.xlsx">XLSX</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_001.pdf">jm6b00976_si_001.pdf (1.89 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_002.xlsx">jm6b00976_si_002.xlsx (521.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00976/suppl_file/jm6b00976_si_003.csv">jm6b00976_si_003.csv (5.27 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00976&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00976%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00976" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c772c4acb03d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
